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I 
 
Abstract 
 
Cytomegalovirus (CMV) infection is the most frequent and significant opportunistic infection 
in kidney transplant recipients. It is associated with direct (CMV disease) and indirect 
(rejection, poor graft survival) effects with resultant increases in morbidity and mortality. The 
mechanisms responsible for the indirect effects of CMV infection remain unclear. 
In this thesis, the indirect effects of cytomegalovirus infection in kidney transplantation are 
studied. Firstly, the mechanism of CMV infection is investigated. Secondly, the mechanism of 
CMV associated kidney transplant damage is explored. Thirdly, an assessment for the role of 
CMV in causing immunosenescence within the kidney transplantation cohort is undertaken.  
 
This thesis provides previously undescribed and direct evidence of immune hypo- 
responsiveness to latent CMV. I have shown CD4+CD27-CD28null cells are pathognomonic of 
prior CMV exposure and have a role in glomerular endothelial cell damage, an effect which 
may be mediated by NKG2D. Higher CD4+CD27-CD28null cell counts at 12 months post-
transplantation predict a steeper decline in kidney allograft function thereafter. I provide 
novel insight into the ‘indirect’ effect of CMV in the pathogenesis of CD8+CD28null cells. My 
study is the first to demonstrate a temporal association between elevated CD8+CD28null cell 
frequencies and subsequent development of clinically relevant episodes of infection.  
 
The findings from this thesis set the scene for future interventional research and therapeutic 
strategies. 
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1.1 Introduction 
 
Kidney transplantation is the gold standard treatment for end stage kidney disease (ESKD), 
offering improved quality of life and life expectancy compared with maintenance dialysis [1, 
2]. Figure 1.1 demonstrates the large survival advantage kidney transplantation holds over 
maintenance dialysis.  
 
 
Figure 1.1: Kaplan–Meier survival curves for three groups of renal replacement 
therapy (RRT) patients: those transplanted with a living‐related kidney donor (LD), those 
transplanted with a cadaveric kidney, and those remaining on dialysis. Follow‐up for 10 years [184].   
 
Potent long-term immunosuppression is used to avoid acute rejection and extend graft 
survival. The two main complications associated with chronic immunosuppression are 
opportunistic infections and cancer [3].   
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Cytomegalovirus (CMV) infection is the most frequent and significant opportunistic infection 
in kidney transplant recipients [3, 4].  Cytomegalovirus is a ubiquitous β-herpesvirus which is 
seemingly harmless in healthy individuals. In kidney transplantation, CMV infection is 
associated with significantly reduced patient and graft survival (Figure 1.2) [5]. CMV induces 
a strong cellular immune response and has developed strategies to evade immune 
surveillance [6]. The mechanism behind CMV driven damage remains unclear. 
 
 
 
Figure 1.2: Patient and graft survival in patients with and without CMV 
CMV infection following kidney transplantation significantly reduced long-term patient and graft 
survival (p = 0.008) [5]. 
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 CMV infection is associated with direct (CMV disease) and indirect (rejection, poor graft 
survival) effects [7, 8]. CMV causes direct effects by viral inclusion in the cells of various tissues 
with resultant cytopathic effects. CMV inclusions are seen in glomerular endothelial cells 
(Figure 1.3), peritubular capillaries, and tubular epithelial cells, resulting in an immunotactoid 
glomerulopathy and interstitial nephritis [9]. 
 
 
 
 
Figure 1.3 CMV in glomerular endothelial cell 
Cytomegalovirus (arrow) in a glomerular endocapillary nucleus, shown by immunoperoxidase staining. 
Courtesy of Alexander J Howie, University College London. 
 
The indirect effects of CMV result from an interaction between CMV and the host immune 
system [10].  Primary CMV infection produces a robust and specific adaptive immune 
response involving CMV-specific CD4+ T cells, CD8+ T cells, and IgG, which persist lifelong [11]. 
Latent CMV infection is associated with expansion of circulating, late-differentiated CMV-
specific CD8+ T cells [12]. As these cells play a central role in the control of CMV, it has been 
proposed to monitor these cells before and after transplantation to guide optimal use of anti-
CMV prophylaxis and therapy [13]. Expansion of an unusual and rare subset of CD4+ T cells 
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has been reported in CMV seropositive patients with ESKD or autoimmune conditions [14]. 
These cells are characterised by the absence of the co-stimulatory molecule CD28 
(CD4+CD28null); they are unusual in that they are cytotoxic [14]. In patients with autoimmune 
conditions, these CD4+CD28null cells have be shown to be CMV specific and are associated 
with poor patient outcomes [15, 16].  CD4+CD28null cells have been reported in a study of 
lung transplant recipients with associated increased risk of allograft rejection [17, 18]. 
Furthermore, one study demonstrated emergence of CD4+CD28null cells in four kidney 
transplant recipients following primary CMV infection [19], although evaluation of these cells’ 
reactivity to alloantigen has not yet been studied. 
 
Indirect effects of CMV are associated with poor patient and graft survival, acute rejection, 
chronic allograft dysfunction (interstitial fibrosis/tubular atrophy), new-onset diabetes after 
transplantation (NODAT) and an increased cardiovascular risk [20]. 
 
 The direct cytopathic effects of cytomegalovirus on the renal allograft are now uncommon 
in clinical practice due to effective antiviral therapies. Unfortunately, far less is known about 
the efficacy of antiviral therapy in managing the indirect effects of cytomegalovirus [21].  
Widespread and prolonged use of antiviral drugs has changed the natural course of CMV 
disease by delaying its onset and causing drug resistance.  
 
An increasing number of immunological, clinical and epidemiological studies suggest that 
persistent CMV infection is associated with accelerated ageing of the immune system and 
with several age-related diseases. However, current evidence on whether and how CMV 
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infection is implicated in immunosenescence and in age-related diseases remains incomplete 
and many aspects of CMV involvement in immune ageing remain controversial [22]. 
 
1.2 Cytomegalovirus 
1.2.1 Epidemiology 
 
CMV affects 60% to 90% of healthy individuals worldwide and is closely linked with 
socioeconomic status [23]. Seroprevalence in communities has a large impact on the risk of 
developing CMV disease following transplantation and the methodologies used to reduce this 
risk [24]. 
 
CMV is present in a number of bodily secretions, such as saliva, urine and breast milk. In early 
childhood, transmission of CMV results from both vertical and horizontal transmission 
following shedding of virus in urine and respiratory secretions [6]. Sexual transmission is one 
of the major modes of transmission in adults. In solid-organ transplant recipients, CMV can 
be transmitted through the donor organ. 
 
 1.2.2 Genomics 
 
Cytomegalovirus has a 236Kb double-stranded DNA genome, the largest of the human herpes 
virus species [25]. The virion is 150-200nm in diameter and icosahedral (Figure 1.4) [6]. CMV-
DNA is surrounded by three layers: a tegument, a capsid with 162 protein capsomeres, and 
an outer envelope. Capsid encloses the tegument consisting of three phosphoproteins: 
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pp150, pp65, and pp71. The envelope contains lipoproteins and at least 33 structural 
proteins, some of which are glycosylated. These glycoproteins determine the CMV strain and 
consist of three distinct families of glycoprotein complexes, gcI (also known as gB), gcII, and 
gcIII, which are used for viral cellular entry and form the target for neutralizing antibodies [6]. 
The principal reservoirs of CMV are fibroblasts, myeloid cells and endothelial cells.  
 
Six strains of human CMV have been sequenced, two laboratory (AD169 and Towne) and four 
clinical [26].  Our understanding of CMV pathogenesis has been aided by determination of the 
complete DNA sequence for AD169 by Chee and colleagues at Cambridge in 1990 [27] and 
subsequent further data on the additional genes carried by the clinical strains [26, 28, 29].  
 
1.2.3 CMV cell entry 
 
CMV infects a number of different cell types such as epithelial, smooth muscle, endothelial, 
macrophage and dendritic cells. Viral entry is mediated through engagement (tethering) 
between key surface viral glycoproteins and heparan sulphate-bearing polysaccharides 
(HSPGs) on the cell surface (Figure 1.5) [30]. This results in delivery of viral DNA (capsid), viral 
proteins and virion mRNA transcripts into the cytoplasm of the infected cell [31]. CMV can 
also enter cells by engaging (docking) with receptors such as the epidermal growth factor 
receptor (EGFR), integrins and Toll-Like receptor 2 (TLR-2) with resultant intracellular signal 
transduction and subsequent replication [32].  
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Figure 1.4 Human Cytomegalovirus [33] 
 
 
 
 
Figure 1.5 Cytomegalovirus entry into cells [30] 
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 1.2.4 The lytic cycle 
 
Figure 1.6 displays the CMV lytic life cycle. Following cell entry, CMV mRNA transcripts 
undergo translation in the cytoplasm.  Viral DNA and certain viral proteins are transported to 
the nucleus, viral DNA is replicated through gene expression. Gene expression takes place in 
three steps:  
 
• immediate-early (IE) gene expression – synthesis of proteins (IE 72, IE86) necessary 
for viral replication, cellular survival and escape from the host’s immune 
surveillance. Occurs during the first 4 hours of infection.  
• early (E) gene expression – synthesis of proteins key for viral replication  
• late (L) gene synthesis -  provides proteins that will be used to construct the new 
virions, within 6 to 24 hours after DNA synthesis. 
This lytic cycle of replication produces at least 165 unique proteins [29]. Three key enzymes; 
DNA polymerase, CMV protease and Terminase are responsible for CMV replication, assembly 
and packaging of the capsid respectively [34, 35]. The infectious viral particle is then released 
from the cell. 
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Figure 1.6  CMV lytic life cycle [31] 
 
1.2.5 Latency 
 
All herpesviruses, including CMV have the ability to escape immunological clearance and 
persist life-long in the infected host. This is known as latency. CMV latency has been described 
in both bone marrow progenitor cells and monocytes, although other cell types may also be 
important as a latent reservoir (e.g., endothelial cells) [36, 37]. 
The frequency of latently infected cells in blood appears to be very low.  It is believed that 
CMV is continually reactivating and being supressed by the immune system. This suggests 
that even in healthy individuals the natural history of CMV replication is highly dynamic, which 
in turn has implications for patients when they are immunosuppressed [38]. In this context, 
there has been a focus on identifying the factors that may be important for triggering latent 
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CMV infection into an active infection. Triggers for reactivation in the healthy individual may 
be very different to those that are present in other settings. For example, in the case of organ 
transplantation, there is increasing evidence that the cytokine TNF-alpha mediates 
stimulation of the IE promoter in both human CMV and in murine models [39, 40]. Tissue 
damage at the time of organ harvesting and during transplantation surgery produces 
inflammation and a significant increase in pro-inflammatory cytokines, including TNF-alpha. 
Interestingly, CMV-specific CD8 T cells are also known to secrete large amounts of TNF-alpha, 
and CMV infection itself upregulates TNF-alpha production [41]. Consequently, in this 
scenario, a positive feedback loop may exist that leads to high-level CMV replication and a 
subsequent development of CMV disease. 
 
1.3 Immune responses to Cytomegalovirus 
 
Both the innate and adaptive immune system plays an important role in the defence against 
cytomegalovirus infection. In contrast to the level of response seen to other acute and 
persistent viruses, a substantial proportion of the immune systems efforts are devoted to the 
control of CMV [42].  
 
1.3.1 Innate Immunity 
 
The innate immune system is important in both the defence against CMV and in priming the 
adaptive immune response to CMV [33]. Evidence from murine [43, 44] and human models 
[32, 45, 46] of CMV demonstrates the important role Toll-like receptors (TLRs) play in the 
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innate sensing of CMV. The interaction of CMV with TLRs results in activation of signal 
transduction pathways, secretion of inflammatory cytokines (interferon alpha/beta) by 
dendritic cells and macrophages (Figure 1.6) and the subsequent activation of natural killer 
(NK) cells.  
 
The role of NK cells in the immune defence against CMV has been determined from murine 
models of CMV infection (MCMV). Experimental studies have shown NK cells to be involved 
in the clearance of experimental MCMV infection [47, 48]; depletion of NK cells increased 
susceptibility to MCMV [49], whereas adoptive transfer of NK cells resulted in protection from 
MCMV [50]. There is paucity of data on the role of NK cells in the immune defence against 
human CMV (HCMV). In renal transplant patients, increased NK activity during primary and 
recurrent CMV infection has been demonstrated [51]. CMV disease and suboptimal recovery 
from CMV infection has been reported in patients with NK cell deficiency [52, 53].   
 
1.3.2 Adaptive Immunity 
 
Long-lasting immunity to CMV is vital in preventing uncontrolled viral replication and severe 
CMV disease. T-cell mediated immune responses are predominately responsible for 
controlling and restricting viral replication during primary latent infection (Figure 1.7) [33]. 
Although the role of B cells in the control of CMV replication has been debated, there is 
evidence to support their role in restricting viral dissemination and limiting severity of disease 
(Figure 1.6) [54, 55]. 
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1.3.2.1 T-cell mediated immune responses 
 
The role of T-cell immunity to CMV is supported by data from murine and human models of 
CMV. Figure 1.6 shows the role of T cells in the acute and latent phase of CMV infection.  
 
 
 
Figure 1.7 Immune control of CMV by innate and adaptive immunity [33] 
 
1.3.2.2 Role of CD8+ T cells 
 
CD8+ T cells play a pivotal role in the immune control of CMV [48]. In murine models, depletion 
of CMV-specific CD8+ T cells resulted in an increase in reactivation and dissemination of CMV 
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infection, whereas adoptive transfer of CMV-specific CD8+ T cells provided protection from 
the infection [56, 57]. In humans, fetal CD8+ T cells have been shown to expand in response 
to a primary CMV infection [58]. In immunocompromised patients, CMV-specific CD8+ T cells 
are largely responsible for the control of CMV. This has been supported by data from studies 
of patients with AIDS [59], bone marrow transplants [60-62], and solid organ transplants [63, 
64] . A dominant CD8+ T-cell response to both primary and latent CMV has been shown in 
kidney transplant recipients [65-67].  
 
A substantial proportion of the CD8+ T-cell pool is committed to the anti-CMV response. In 
healthy virus carriers, 4-10% of peripheral blood CD8+ T cells can be specific for CMV antigens 
[68-71]. In healthy elderly CMV seropositive donors, up to 40% of the CD8+ T-cell pool can be 
CMV specific [70]. The impact this immune dominance has on the response to other 
pathogens/antigens remains unclear [33].  
 
Studies in healthy CMV-seropositive donors have revealed CMV-specific CD8+  T cells are 
directed towards a hierarchy of virus-encoded proteins, with UL123 (IE-1), UL122 (IE-2), and 
UL83 (pp65) as immunodominant antigens [71, 72].  
 
Figure 1.8 demonstrates the phenotypic changes of CMV-specific T cells from acute infection 
to latent state [73].  During acute CMV infection, CD8 effector T cells have a CD45RA- CD45RO+ 
CD27+ CD28+/- CCR7- phenotype [33]. In chronic CMV infection (latent state), CMV-specific T 
cells are either effector memory (CD45RA- CD45R0+ CD27-CD28- CCR7-) or terminally 
differentiated effector T cells re-expressing CD45RA (TEMRA) (CD45RA+ CD45R0- CD27- CD28- 
CCR7-) [74]. These highly differentiated effector memory T cells undergo oligoclonal 
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expansion (memory inflation) with resultant reduction in the naïve T-cell pool [75].  The 
expansion of these cells is driven by persistence of antigen, and do not require IL-7, unlike 
memory cells found after infection with cleared viruses. 
 
 
Figure 1.8 Phenotypic changes of CMV-specific T cells from acute infection to 
latent state [73]    
 
1.3.2.3 Role of CD4+ T cells  
 
The role of CD4+ T cells in the control of CMV infection is becoming increasingly evident [76, 
77]. In murine models of CMV infection, CD4+ T cells have been shown to contribute to both 
the control of primary and recurrent MCMV infection [48, 78]. Deficiency of CD4+ T-cell 
immunity to cytomegalovirus in immunocompetent children is associated with prolonged 
viral urinary and salivary shedding [79]. In studies of HIV-infected patients, CMV-specific CD4+ 
T cells have been shown to be crucial for a functional CMV-specific CD8+ T-cell response [80-
82]. These observations have direct relevance for the control of CMV replication post-
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transplantation, especially as the immunosuppressant drugs utilised to prevent organ 
rejection have a significant impact on CD4 T-cell function. In a study of allo-stem cell 
transplant patients, a single infusion of predominately CMV-specific CD4+ T cells resulted in 
the clearing of CMV viraemia in five out of seven patients [76]. Following kidney 
transplantation, levels of CMV-specific CD4+ T cells have been shown to correlate with 
cytomegalovirus control and may be useful to predict CMV disease [83]. A further study 
involving kidney transplant patients demonstrated the importance of CMV-specific effector-
memory CD4+ T cells for recovery of infection [11].  
 
In healthy CMV seropositive individuals, a substantial proportion of circulating CD4+ T cells is 
committed to anti-CMV immunity. A median frequency of 9.1% [71], and up to 40% in some 
donors occurs, with no overt compromise to the remaining protective immunity [84].  
 
In latent CMV infections, the role of CD4+ T cells in providing indirect help for maintaining 
virus-specific antibody responses [85] and expanding the CD8+ T-cell population [61] is well 
established. However, CMV-specific CD4+ T cells also have a direct role in controlling infection 
by killing virus-infected cells [86, 87].  The cytolytic activity of CMV-specific CD4+ T cells is 
associated with a terminally differentiated phenotype (Figure 1.8, CD4+CD27-CD28null) [88].  
These cells are cytotoxic in that they express perforin and granzyme B in response to CMV 
[89].  
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1.3.2.4 Humoral immunity  
 
The importance of antibodies in the effective immune response against CMV is supported by 
various animal and human studies [90-94]. In the guinea pig model, passive immunization 
with guinea pig cytomegalovirus antibodies did not prevent infection, but the antibodies 
increased the survival of pups [90]. In humans, the transfer of antibodies from a CMV-
seropositive mother to a new-born infant was shown to be protective against CMV infection 
from seropositive blood transfusions [91]. It is now well established that women with 
preconception immunity to CMV transmit infection to the foetus at a lower frequency than 
women with primary infections [91]. 
 
1.4 Immune Evasion by Cytomegalovirus 
 
Cytomegaloviruses have developed a number of strategies to subvert host immune 
surveillance and defence, allowing them to co-exist with their host despite an anti-CMV 
immune response. These include:  
• Downregulation of MHC class I: results in inhibition of direct present of CMV 
antigens to CD8+ T cells [95] 
• Downregulation of MHC class II: results in inhibition of indirect presentation of CMV 
antigens to CD4+ T cells [96, 97] 
• Inhibition of NK cell activation: CMV activates NKG2A inhibitory receptor [98] and 
blocks NKG2D activating receptor [99] 
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The control of CMV replication in the immunocompromised host has been studied using class 
I HLA tetramers together with intracellular cytokine assays. This has revealed that patients 
who fail to control CMV replication have poorly functional CD4 and CD8 T-cell responses (ref). 
The functional ability of CD8+ and CD4+ T cells to produce interferon-gamma (IFN-gamma) and 
IL-2 in response to CMV peptides has been shown to be essential for limiting high-level 
replication in both renal and liver transplant recipients [100, 101]. Other markers that are 
associated with periods of active replication include PD-1 and perforin. However, there is 
paucity of data on prognostic immune markers for future CMV disease.  
 
1.5 CMV pathogenesis after solid organ transplantation 
 
Figure 1.9 A model for CMV pathogenesis after solid organ transplantation [24] 
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Figure 1.9 shows a model for CMV pathogenesis after solid organ transplantation [24]. The 
donor organ harbours a small number of cells with latent infection (red dots). The 
physiological stress associated with transplantation surgery results in the release of 
inflammatory cytokines such tumour necrosis factor (TNF). TNF-alpha appears to be an 
important driver for re-activation of latent CMV in the transplanted organ and there is 
increasing evidence that CMV replication begins very early after the transplant surgery is 
complete [102]. Subsequent organ-specific replication ensues over the next 7 days, with the 
production of new virions. These new virions may then spread through the blood to infect 
other target organs, which contributes to the overall level of CMV DNAemia. In the absence 
of CMV prophylaxis, virus detection in the blood usually occurs between 20 and 30 days post-
transplant. If left untreated, these high levels of replication will be associated with the direct 
effects of CMV infection. In addition, early graft infection may contribute to acute transplant 
dysfunction, occurrence of other opportunistic infections and affect long-term graft and 
patient survival (indirect effects) [24].  
 
Figure 1.10 shows the possible mechanisms responsible for graft damage during an infection 
[103]. Microorganisms can have direct cytopathic effects, with resultant release of damage-
associated molecular patterns (DAMPs), microbial or donor antigens (alloantigens) and 
possibly autoantigens (Figure 1.10a). Recipient antigen-presenting cells (APCs) or endothelial 
cells in the graft take up and cross-present exogenous microbial antigens to recipient T cells 
(Figure 1.10b). Activated APCs and/or T cells secrete cytokines that are damaging to the graft 
or that injure endothelial cells, thereby reducing vascular supply to the graft. Infections can 
induce the maturation of recipient APCs or activate endothelial cells that have taken up donor 
antigens (blue triangles). This results in the indirect activation of alloreactive T cells and in 
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graft injury mediated by pro-inflammatory cytokines and toxic soluble factors that injure 
blood vessels (Figure 1.10c). Similarly, infections can augment the direct activation of 
alloreactive T cells by enhancing the maturation of donor APCs or graft parenchymal cells, 
resulting in graft damage (Figure 1.10d). Cellular graft damage may release cryptic antigens 
(autoantigens) and DAMPs that then activate autoreactive T cells (Figure 2e). After re-
encountering these antigens on cross-presenting recipient APCs or endothelial cells, these 
autoreactive T cells may contribute to graft damage in a phenomenon analogous to epitope 
spreading.  
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Figure 1.10 Potential causes of graft damage during microbial infections [103] 
 
Figure 1.11 shows a possible mechanism for CMV induced endothelial damage. Latent CMV 
infection produces a large pool of terminally differentiated CD8+, and to a lesser extent, CD4+ 
effector T cells [104, 105].  These CD8+CD27-CD28null and CD4+CD27-CD28null cells have the 
potential to produce IFNγ and are armed with cytotoxic granules (perforin, granzyme B), 
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ready to become active as soon as viral replication occurs [106]. CD8+CD27-CD28null and 
CD4+CD27-CD28null cells have a potential role in vascular damage.  CMV infection induces a 
systemic Th1 response with increased serum levels of IFNγ and TNFα [106] [107]. These 
cytokines have been shown to induce an upregulation of fractalkine on endothelial cells (EC) 
in vitro, and CMV specific effector T cells were shown to bind to these fractalkine-expressing 
endothelial cells. This was followed by migration of these cells to activated EC in vitro, 
followed by damage and apoptosis of these endothelial cells [108] and [109].  
 
 
Figure 1.11 Immunopathology caused by cytomegalovirus [106] 
Figure 1.11 illustrates how CMV can influence cell adhesion. 
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1.6 Definitions 
 
Individuals who have no prior exposure to CMV are defined as ‘CMV seronegative’. Following 
infection with CMV, individuals become ‘CMV seropositive’ lifelong due to the formation of 
antibodies directed against CMV and the ability of the virus to establish latency. In the context 
of transplantation, the organ/cell donor can be CMV seronegative (D-) or CMV seropositive 
(D+) and likewise, the recipient is either CMV seronegative (R-) or CMV seropositive (R+). 
 
1.6.1 Primary CMV infection 
 
Primary CMV infection in an immunocompetent host is defined as CMV infection in a 
previously seronegative individual.  
In the immunocompromised host; such as a transplant recipient, primary CMV infection 
occurs when latently infected cells from a CMV seropositive donor are transferred to the 
seronegative recipient [21]. In the vast majority of cases, these latently infected cells are 
within the allograft; however, transfusion of viable leukocytes from seropositive blood donors 
can also transmit CMV [21]. 
 
1.6.2 CMV infection 
 
CMV infection is defined as detectable viral replication in any body fluid/tissue specimen, or 
a significant rise in CMV-specific antibodies [6]. CMV infection can be asymptomatic, or give 
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rise to CMV syndrome or disease. British Transplant Society Guidelines for the diagnosis of 
CMV syndrome and disease in solid organ transplantation are as follows:  
 
CMV Syndrome 
 
CMV disease 
 
1. CMV viraemia  
2. One or more of: 
• fever 
• new onset severe malaise  
• leukopenia 
• atypical lymphocytosis  
• thrombocytopenia 
• hepatitis (ALT or AST >2 upper 
limit of normal) 
 
In addition to criteria for CMV syndrome, 
evidence of organ involvement (supported 
by histological evidence where possible): 
• BM suppression 
• Hepatitis 
• Pneumonitis 
• Nephritis 
• Gastrointestinal tract 
• CNS 
• Retinitis 
• Myocarditis 
• Pancreatitis 
 
 
1.6.3 Latent infection 
 
Following primary infection, CMV establishes lifelong persistence within the host. Latency is 
defined as carriership of CMV genome without active replication [6]. Latent CMV has the 
ability to reactivate under specific stimuli.   
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1.6.4CMV Reactivation 
 
CMV reactivation is new detection of CMV infection in a seropositive individual. It occurs as a 
result of reactivation of host’s latent CMV. In the context of transplantation, this is the result 
of reactivation of the seropositive transplant recipient’s endogenous latent CMV strain. 
 
1.6.5 CMV Superinfection/Re-infection 
 
CMV superinfection/re-infection occurs when both the transplant donor and recipient are 
seropositive (D+/R+).  It occurs as a result of reactivation of exogenous latent CMV (donor 
origin) [21]. 
 
1.6.6 CMV disease 
 
CMV disease is the clinical expression of active infection [6]. 
 
1.7 Clinical presentation 
 
In transplantation, the incidence and severity of CMV disease is determined by the pre-
transplant CMV serostatus of the donor (D) and recipient (R) [110, 111]. The three risk groups 
as defined by the donor and recipient CMV serostatus are: 
1. High risk (D+/R-)  
2. Intermediate risk (D-/R+, D+/R+) 
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3. Low risk (D-/R-)  
The British Transplant Society guidelines (2011) recommend CMV prophylaxis or pre-emptive 
therapy for the high risk (D+/R-) group and for transplant recipients treated with T-cell 
depleting antibodies.  
 
The effects of CMV infection in immunocompromised hosts can be divided into direct and 
indirect effects. In immunocompetent hosts, primary CMV infection is usually asymptomatic 
but can produce an infectious mononucleosis-like syndrome with fever, myalgia, pharyngitis, 
cervical lymphadenopathy, mild hepatitis, and splenic enlargement [6, 112]. However, 
primary CMV infection may take a much more aggressive course in immunocompromised 
individuals. Resultant tissue-invasive disease may present as pneumonitis, carditis, 
gastrointestinal disease, hepatitis, nephritis or retinitis [113]. Direct effects of CMV are 
related to viral burden, with high viral loads intimately involved in the pathogenesis of CMV 
infection [38]. 
 
1.7.1 Indirect effects of CMV infection 
 
CMV associated adverse outcomes, not directly related to viral invasion of tissues are outlined 
below. These indirect effects of CMV infection are mediated by cellular and humoral immune 
responses [114].  
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1.7.1.1 Acute and chronic allograft rejection 
 
Data from clinical studies [7, 8, 115], and animal models [116, 117], supports an association 
between CMV infection, rejection and graft loss.  
 
The mechanism for CMV-driven rejection in not fully understood. However, an in-vitro study 
of a rat heart transplantation model suggests CMV infection of vascular endothelium and 
smooth muscle cells plays a key role in the pathogenesis of chronic rejection [116]. CMV 
infection up-regulates endothelial cell adhesion molecules [118-120] and enhances 
production of inflammatory cytokines (IL-10, TNF-alpha) and chemokines [39, 41, 43]. These 
cytokines and chemokines can also be produced due to allograft rejection. Therefore, CMV 
has the potential to both trigger and exacerbate a rejection episode.  
 
CMV infection and disease significantly increased the risk for acute rejection in a study of 477 
kidney transplant recipients not receiving CMV prophylaxis [115]. In a separate series of 259 
kidney transplant patients, Sola et al identified CMV disease as an independent risk factor for 
chronic allograft nephropathy (p<0.02) [121]. Helantera and colleagues have shown 
persistent CMV infection in kidney allografts is associated with reduced kidney allograft 
function (p=0.007) and survival (p=0.04) [8]. In a separate study, CMV DNA was localised to 
renal tubular epithelial cells and associated with poor long-term kidney allograft function 
[102].  
 
Complementing these human studies is a large body of evidence from the rat CMV model. 
These animal studies show CMV infection accelerates progression to poor graft function 
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(chronic allograft nephropathy) and graft loss [84].  In rat models, CMV can induce tubular 
apoptosis via the TNF-alpha/TNF-alpha receptor-1 pathway [117]. Importantly, treatment of 
these animals with ganciclovir reduced intimal thickness to levels seen in uninfected rats 
[122]. 
 
The immune response against CMV is extensive. Migration of CMV-specific lymphocytes into 
an organ to kill CMV-infected cells may be mistaken for acute rejection in the absence of 
evidence showing that CMV is present. This suggests CMV prophylaxis in the early post-
transplant period may minimize the effects of CMV as a causative or exacerbating agent for 
acute rejection [123].  
 
1.7.1.2 Accelerated coronary artery disease 
 
In the general population CMV has been implicated in the pathogenesis of atherosclerosis as 
early as the 1970s [124]; with a number of clinical studies demonstrating it as an independent 
risk factor for restenosis after coronary angioplasty [125, 126]. A high incidence of CMV DNA 
has been demonstrated in both coronary atherectomy specimens and re-stenotic lesions 
[127, 128]. High antibody titres against CMV are associated with coronary artery disease and 
may predict restenosis risk following coronary angioplasty [129]. 
 
Although the mechanism of injury remains unclear, rat models have shown CMV infection to 
cause endothelial injury, increase leukocyte adhesion, and precipitate the accumulation of 
lipids in vascular endothelium [120]. In vitro studies indicate that CMV infects endothelial 
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cells, smooth muscle cells, monocytes, and macrophages, all of which have been implicated 
in atherosclerosis [130, 131].  
 
In kidney transplantation, CMV infection has been shown to be an independent risk factor for 
atherosclerotic events; with increased incidence of arrhythmias, congestive heart failure, and 
vessel occlusion [131-133]. 
 
1.7.1.3 Increased incidence of opportunistic infections 
 
CMV infections increase the susceptibility of transplant patients for other opportunistic 
infections (bacterial, fungal and protozoal) [134-136]. CMV interferes with the recognition of 
infected cells by altering the function of dendritic cells and preventing the delivery of signals 
required for T-cell activation [137]. CMV has been linked to an increased risk of Epstein-Barr 
virus (EBV) related post-transplant lymphoproliferative disease (PTLD) [138, 139]. High levels 
of IL-10 have been observed in the serum of patients with PTLD [140] and it has been 
suggested that the CMV IL-10 virokine could mediate this increased risk [141]. 
 
1.7.1.4 New-onset diabetes after transplantation (NODAT) 
 
New-onset diabetes after transplantation (NODAT) is common, with a reported incidence 
ranging between 2% and 53% [142]. Data from clinical [143] and animal studies [144] suggest 
that CMV infection may be a predisposing factor for NODAT.  A fivefold increased risk of 
NODAT has been reported in kidney transplant patients with asymptomatic CMV infection 
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compared with patients who remained free of CMV infection (figure 1.12) [143]. It has been 
suggested that CMV may damage the beta cells of the pancreas in a variety of ways, including 
direct infection and immune-mediated destruction [143]. 
 
 
Figure 1.12 Relative proportions of patients with varying degrees of glucose 
tolerance according to CMV status 
A significantly higher proportion of patients with CMV infection developed NODAT (p=0.003) and 
Impaired Glucose Tolerance (p=0.008) compared with controls. 
CMV infection (n=61), patients without CMV infection (controls, n=63). White: Normal Glucose 
Tolerance, Grey: Impaired Glucose Tolerance, Black:  Post-Transplant Diabetes Mellitus [143]. 
 
1.8 Role of CMV in immunosenescence 
 
Aging of the immune system (‘immunosenescence’) is characterised by the following immune 
risk profile (IRP):  
1.  Accumulation of memory T cells, especially CD8+CD28null cells and EMRA cells [145, 
146] . 
2. Inverted CD4:CD8 ratio.  
3. Increased memory: naïve cell ratio within the CD8 compartment [145-147]. 
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These markers of immunosenescence have clinical correlates in the general population, and 
specifically are associated with increased risk for infection and mortality, and a reduced 
vaccine response [147-151]. 
 
It has been suggested and increasingly accepted, that CMV infection is a major driver of the 
immune phenotype characteristic of immunosenescence [152-155]. The link between CMV 
and the immunosenescence phenotype is not clearly established in transplantation, although 
a recent study demonstrated expansion of CD8+CD28null cells in 11 kidney transplant 
recipients experiencing primary CMV infection [156].  Increased frequencies of CD8 EMRA and 
CD8+CD28null cells at the time of transplantation have been associated with freedom from 
early biopsy-proven acute rejection [157, 158]; CD8 EMRA frequencies were also associated 
with (a trend towards) increased risk of graft dysfunction over the long term in prevalent 
patients [159]. In a cross sectional ‘extended phenotype’ study, CD8+CD28null cell frequencies 
were higher in patients with histological lesions of ‘chronic rejection’ in comparison to those 
with drug-free operational tolerance [160]. Surprisingly only one (very recent) study 
addressed infection as an endpoint, with no association found between CD8+CD28null cell 
frequencies or CD4:CD8 ratio and episodes of infection [161]. These studies of transplant 
cohorts understandably addressed the ‘transplant-specific’ end measures as described; the 
potential role of CMV in driving the studied markers of immunosenescence was not a focus 
in most of these particular studies.  
 
Finally, an increasingly recognised phenomenon is immunosenescence of the innate immune 
system, in particular abnormalities of neutrophils which represent the most abundant 
circulating immune cell and a first line of defence against pathogens [162, 163]. Yet far less 
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work has been undertaken in this area compared with T-cell immunosenescence, and is 
lacking in the field of transplantation. Overviews of this subject in transplantation to date 
have necessarily extrapolated data from non-transplant settings [164-166].  
 
1.9 Monitoring of CMV-specific T-cell responses 
 
 
 
 
Figure 1.13 Ex vivo monitoring of CMV-specific T-cell responses [33] 
 
The diagnosis of CMV disease is guided by clinical symptoms and signs, and supported by 
detection of CMV in the blood and involved tissue(s) [33, 167]. In transplantation, 
Quantitative PCR methods (Figure 2.3c) are routinely used for determining CMV loads and 
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monitoring viral DNAemia [33]. However, patients with a detectable viral load do not 
necessarily develop CMV disease but may receive treatment with toxic anti-viral medication 
regardless [33, 168].   
 
The development of ex-vivo T-cell assays (MHC-peptide tetramers: Figure 1.13a, ELISPOT: 
Figure 1.13b, intra-cellular cytokine analysis by flow cytometry: Figure 1.13a) have facilitated 
the identification and functional analysis of CMV-specific T cells [64, 68, 169].  
  
In transplantation, various cross-sectional studies have focused on the diagnostic and clinical 
utility of measuring the cell-mediated immune (CMI) response to CMV [33, 64, 83]. Although 
the results are somewhat conflicting, nonetheless, these studies have provided preliminary 
evidence that the frequency of IFN-γ-secreting CMV-specific CD4+ and CD8+ T cells may be 
clinically relevant and could be an effective tool for monitoring disease activity [64, 83]. A 
recent prospective study identified an association between pre-transplant CMI to CMV and 
post-transplant viral replication in 55 kidney or lung transplant recipients undergoing either 
antiviral prophylaxis or pre-emptive therapy [13]. Further prospective studies under 
contemporary immunosuppression are required to further evaluate the diagnostic utility of 
these ex-vivo T-cell assays. 
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1.10 Aims and Outline of the Thesis 
 
With this background, evidently, there are significant gaps in the current literature 
pertaining to the indirect effects of cytomegalovirus infection following kidney 
transplantation. The studies presented in this thesis aim to explore both the mechanism of 
CMV infection following kidney transplantation and CMV-driven kidney transplant damage. 
  
 
 
35 
 
Chapter 2: Impaired Direct CD8 Priming to Donor-Derived Cytomegalovirus Following Kidney 
Transplantation 
 
Chapter 2 investigates the associations between donor CMV serostatus on CMV disease risk 
in seropositive recipients and explores mechanism of CMV infection in D+/R+ 
transplantation.  Also, utility of pre-transplant cellular immunity assays in predicting CMV 
infection are evaluated.  
 
In D+/R- transplantation, high rates of primary CMV infection are well recognised and 
requirement for antiviral prophylaxis largely uncontested. CMV disease is also seen in 
seropositive recipients (R+), often grouped together as ‘intermediate risk’ irrespective of 
donor serostatus. However, both historical and recent evidence suggest higher infection rates 
in D+R+ transplantation compared with D-R+ transplantation [110, 170-172]. The latter studies 
focussed on CMV infection rather than symptomatic disease, and used either antiviral 
prophylaxis or pre-emptive therapy of CMV infection. It therefore remains unclear whether 
disease rates differ between D+R+ and D-R+ transplantation, particularly under contemporary 
immunosuppression without antiviral prophylaxis. The mechanism behind CMV infection in 
D+R+ transplantation is incompletely understood [170, 173]. Donor-derived infection and lack 
of protective immunity to newly infecting strains may be important (Ishibashi). An additional 
possible mechanism is human leucocyte antigen (HLA) mismatch between donor and 
recipient. However, data is conflicting with suggestion of both increased [174, 175] and 
reduced [176, 177] CMV disease rates with increased HLA Class II mismatch. HLA Class I 
mismatch has been identified as a risk factor for CMV disease in a historical study by Pouteil-
Noble C [175]. 
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 The primary aims of this chapter were to evaluate the impact of donor CMV serostatus on 
disease risk in seropositive recipients and explore the mechanism of infection by use of HLA 
class I tetramers. The secondary aim was to study the utility of pre-transplant cellular 
immunity assays in predicting CMV infection in D+/R- and D+/R+ transplantation.  
 
The findings will be of considerable interest in further understanding the mechanism of viral 
infection in solid organ transplantation and aid the clinical management of CMV infection.  
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Chapter 3: CMV-associated CD4+CD28null cells in NKG2D-dependent glomerular endothelial 
injury and kidney allograft dysfunction 
 
Chapter 3 focuses on the temporal association between CMV serostatus, CMV infection and 
CD4+CD28null cells. It explores mechanisms of kidney allograft damage by CD4+CD28null cells 
and their impact on kidney transplant outcomes.  
 
Latent CMV infection in patients with end-stage kidney disease (ESKD) is associated with 
expansion of circulating, late-differentiated, cytotoxic CD4+ T cells which have lost expression 
of the costimulatory molecule CD28 (“CD4+CD28null”) [14].  In 2004, a study by Van Leeuwen 
demonstrated emergence of CD4+CD28null cells in four kidney transplant recipients following 
primary CMV infection [19]. In studies involving subjects with autoimmune conditions, 
expansion of CD4+CD28null cells occurs in response to CMV antigens rather than candidate 
autoantigens [15, 16].  In kidney transplantation, reactivity of these cells to alloantigen has 
not yet been studied. In lung transplantation, expansion of CD4+CD28null cells has been 
associated with allograft rejection [17, 18]. CD4+CD28null cells express the cytotoxic mediators’ 
perforin and granzyme B [19] .  They express natural killer-like receptors such as NKG2D [178]. 
In vitro studies suggest a pathogenic role for CD4+CD28null cells, with endothelial cell injury via 
an NKG2D-dependant mechanism [179]. However, these studies involved human umbilical 
vein endothelial cells (HUVEC). At present, there is no data on the pathogenic role of 
CD4+CD28nulls cells in kidney transplantation or their impact on kidney transplant outcomes. 
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The purpose of this study was to evaluate the temporal relationship of CMV serostatus, CMV 
infection and CD4+CD28null cell frequencies during the first post-transplantation year. In vitro 
responses to CMV-derived and HLA-derived antigens were examined. The pathogenic role of 
CD4+CD28null cells was evaluated using in vitro assays of glomerular endothelial cells. Finally, 
the relationship between CD4+CD28null cell frequency and kidney transplant outcome was 
studied. 
 
The findings will help provide potential novel strategies to interfere with CD4+CD28null cell 
toxicity and may result in further improvements in allograft outcome. 
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Chapter 4: Immunosenescence in kidney transplantation: relationship with CMV, infection, 
and neutrophil dysfunction 
 
Chapter 4 evaluates the relationship between CMV infection and immunosenescence, and 
explores whether immunosenescence predicts episodes of other infections. The mechanisms 
responsible for increased rates of infection are studied using in-vitro neutrophil assays. 
 
Immunosenescence is defined by an immune risk profile (IRP). The immune parameters that 
characterise the IRP are: CMV seropositivity, clonal expansion of CMV–specific CD8+ T cells, 
an increase in CD8+CD28null cells, low CD4+ T-cell, low  B cells,  and an inverted CD4: CD8 ratio 
[145]. These findings are based on studies of healthy Scandinavian octo- and nonagenarians 
[147, 180]. In these studies, the IRP has been associated with adverse clinical sequelae 
(reduced vaccine response, increased infection and mortality). As described in the earlier 
chapter, CMV elicits a particularly profound CD8 immune response termed ‘memory inflation’ 
and is characterised by accumulation of late-differentiated CD8+CD28null and CD8+ EMRA 
subsets [152]. It is therefore suggested that CMV represents a major driver towards 
immunosenescence.  Studies in kidney transplantation have focused on the association 
between increased frequencies of CD8+CD28null and CD8+ EMRA cells and transplant specific 
outcomes (biopsy-proven acute rejection, chronic rejection and chronic allograft dysfunction) 
[157, 159, 160]. There are no studies to date in clinical transplantation addressing the 
potential role of CMV in driving immunosenescence.  
 
In this prospective, longitudinal study of kidney transplant recipients I define the most 
informative single cell-phenotype marker of immunosenescence.  I establish the link of CMV 
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latency and infection with immunosenescence, and then the relationship between 
immunosenescence and subsequent episodes of infection. Finally, I describe the association 
between immunosenescence and impaired neutrophil function in vitro.  
 
The findings of this study will provide novel insights into the indirect effects of CMV infection 
in kidney transplantation, with resultant impact on our approach to this important virus.  
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Chapter 5: Transitional B lymphocytes are associated with protection from kidney allograft 
rejection: a prospective study. 
 
Chapter 5 tracks the temporal relationship between CMV, B cells and clinical events in 
kidney transplantation. 
 
Retrospective, cross-sectional studies report regulatory protective role for a B-cell subset in 
kidney transplant outcomes [181, 182]. This transitional (regulatory) B-cell subset is defined 
by the phenotype CD19+CD24hiCD38hi. However, these studies focused on antibody-
mediated rejection and were conducted as case control studies many years after 
transplantation. Interestingly, an association between CD19+CD24hiCD38hi cells and 
immunosenescence has been reported in a recent study of healthy older donors [183]. 
 
The is the first prospective study to track the evolution of transitional B cells following 
kidney transplantation, and evaluate the temporal relationship between cell counts, CMV, 
rejection, and graft function from the time of transplantation.  
 
The findings of this study will further clarify the role of CD19+CD24hiCD38hi cells in clinical 
transplantation, either as biomarkers of rejection risk, or in potential cell-based therapies. 
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Chapter 6: General Discussion 
 
Chapter 6 addresses the major findings from the thesis, discussing the strengths and 
limitations of the aforementioned studies, the clinical implications and directions for future 
research. 
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Chapter 7: Appendices 
 
Chapter 7 includes confirmation of ethical approval, and the standard operating protocols 
for the laboratory work undertaken. 
 
1.11 Study Design and Patient Selection in this Thesis 
 
The studies presented in chapters 2 to 5 are prospective, longitudinal and single-centre.  
Patients admitted to the Queen Elizabeth Hospital Birmingham (United Kingdom) for a 
kidney transplant were approached. In total, 100 unselected kidney transplant recipients 
were enrolled between February 2009 and October 2010. The flow diagram in figure 1.14 
summarises the patient selection and clinical outcomes for the study cohort.  
 
All study patients received standard immunosuppression, with Basiliximab for induction 
followed by maintenance tacrolimus (Prograf; pre-dose level 5-8ng/ml), mycophenolate 
mofetil (Cellcept; 2g daily) and prednisolone (20mg daily; reducing to 5mg by 3 months post 
transplantation). Valganciclovir prophylaxis (100 days) was administered to CMV 
seronegative recipients of seropositive donors; co-trimoxazole prophylaxis was administered 
to all for 12 months and isoniazid prophylaxis for 12 months to those of South-Asian ethnicity 
or previous tuberculosis.  
 
Serial clinical, immunological and biochemical information was collected over 48 +/- 6 months 
of study follow up. Regular and frequent sampling for CMV PCR, anti-HLA antibodies and 
detailed phenotyping of patients’ peripheral blood mononuclear cells (PBMCs) by multicolour 
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flow cytometry add to the strengths of this prospective, longitudinal study (outlined by figure 
below). 
 
 
Table 1.1 provides a summary of the study plan over the first 12 months. Kidney transplant 
outcome data continued to be collected thereafter at three monthly intervals until end of the 
study. 
 
1.12 Ethical Approval of Research Studies presented in this Thesis 
 
The studies presented in chapters 2 to 5 in this thesis were approved by the Staffordshire 
Research Ethics Committee, with Research Ethics Committee reference number of 
(08/H1204/103), confirmation of favourable ethical opinion can be found under Appendices. 
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Figure 1.14 Overview of the study cohort 
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Table 1.1 Summary of study plan 
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2.1 ABSTRACT 
 
This study aimed to clarify the risk of clinically significant CMV disease in “D+R+” 
transplantation under contemporary immunosuppression, and to examine recipients’ cellular 
immune responses to CMV antigens primed directly by donor cells. In a retrospective cohort 
of 569 patients administered standardised basiliximab-tacrolimus-mycophenolate-
corticosteroid immunosuppression, increased CMV disease rates were seen with D+R+ 
serostatus pairings compared with D-R+ (HR:2.61[95%CI:1.36,5.01]; p=0.004). Increased 
donor-recipient HLA mismatch was associated with increased disease rates in D+R+ 
transplantation (HR [per class 1 mismatch]:1.43[95%CI:1.12-1.82]; p=0.02). Implantation 
histology demonstrated CMV antigen expression in all seropositive donor organs examined 
(n=10). Cellular immunity to CMV presented exclusively by donor-restricted HLA within donor 
tissue was examined using HLA Class I-peptide tetramers. Transplant procedures whereby the 
donor expressed a HLA Class I allele not expressed by the recipient, and where the recipient 
expressed a HLA Class I allele not expressed by the donor, were prospectively followed from 
the time of transplantation (all donors seropositive;8 recipients seropositive;3 recipients 
seronegative). During the first-year post-transplantation, 4/8 seropositive recipients and 1/3 
seronegative recipients displayed peripheral blood CD8+ T-cell responses to CMV presented 
by recipient-specific HLA. Very interestingly, no recipients mounted responses to CMV 
presented by donor-specific HLA, suggesting the allograft of seropositive donors may 
represent a “reservoir” inaccessible to CD8+ T-cell responses. Finally, pre-transplant assays of 
anti-CMV cellular immunity predicted post-transplant CMV replication less accurately in D+R+ 
compared to D-R+ pairings, possibly reflecting specificity of in-vitro assays for recipient (rather 
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than donor) HLA. These findings have important implications for clinical management and 
immunological understanding of donor-transmitted viral infection. 
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2.2 INTRODUCTION 
 
Cytomegalovirus (CMV) infection remains an important complication of kidney 
transplantation, being associated with increased graft failure rates, morbidity and mortality. 
Although the cellular immune response to CMV, especially the CD8+ T-cell response, is of 
primary importance in controlling infection [1-3], the CMV-specific antibody serostatus of 
donor (D) and recipient (R) is a useful surrogate to aid risk stratification, as it identifies 
individuals with latent CMV infection which may subsequently reactivate. High disease rates 
in primary infection (D+R- transplantation) are well recognised, and requirement for antiviral 
prophylaxis in this context largely uncontested.  CMV disease is also seen in seropositive 
recipients (R+), and may occur irrespective of donor serostatus. Seropositive recipients are 
often grouped together as ‘intermediate risk’, irrespective of donor serostatus. However 
historical evidence suggests D+R+ transplantation is associated with increased disease rates 
compared to D-R+ transplantation [4]. Also, two recent trials [5,6[ and a single centre study 
[7] showed higher infection rates in D+R+ compared with D-R+ transplantation. Because these 
latter studies focussed on (often asymptomatic) CMV infection, rather than symptomatic 
disease, and because all used either antiviral prophylaxis or pre-emptive therapy of CMV 
infection, it remains unclear whether disease rates differ between D+R+ and D-R+ 
transplantation, particularly under contemporary immunosuppression without antiviral 
prophylaxis.  
 
Following D+R+ transplantation, some CMV cases may result from donor-derived infection, 
although the mechanism behind this is incompletely understood [4,8]. Although lack of 
protective immunity to newly infecting strains may be important [9] other mechanisms may 
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also play a role. For example, human leucocyte antigen (HLA) mismatch between donor and 
recipient may result in failure of “cognate” immunity to control viral infection in donor tissue. 
In this regard, clinical data is conflicting, with studies from the 1980s and 1990s suggesting 
increased CMV disease rates with increased HLA Class II mismatch [10,11], but others 
suggesting reduced rates in this setting [12,13]. One of these studies also identified HLA Class 
I mismatch as a risk factor for disease [11]. 
 
The initial purpose of this study was to evaluate the impact of donor CMV serostatus on 
disease risk in seropositive recipients, and whether the risk is modified by HLA Class I 
mismatch. We then utilised HLA-peptide tetramers to determine the specificity of cellular 
immunity to defined CMV peptides presented through either donor or recipient HLA alleles, 
and examined the development of T-cell responses (or lack of them) against CMV primed 
‘directly’ on donor cells. These findings should be of value in the clinical management of CMV 
infection in this setting and are of considerable interest in further understanding the 
mechanism of viral infection in solid organ transplantation. 
 
2.3 CONCISE METHODS 
2.3.1 Risk of CMV disease and donor-recipient serostatus: retrospective cohort 
 
A retrospective analysis of the prospectively maintained departmental database identified 
569 adult patients (≥18 years) undergoing solitary kidney transplantation between May 2007 
and June 2011 at Queen Elizabeth Hospital Birmingham. This start date was chosen because 
at that time a standardised immunosuppression regimen was introduced. This consisted of 
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Basiliximab induction followed by tacrolimus (trough level 5-8ng/ml initially, measured by 
liquid chromatography-tandem mass spectrometry), mycophenolate mofetil (2g daily 
initially) and prednisolone (20mg daily, reducing to 5mg maintenance by 3 months post 
transplantation). Transplantation proceeded if the cross match between donor and recipient 
was negative by flow cytometry and cytotoxicity.  
 
Baseline information was collected on the pre-transplant CMV serostatus of the recipients 
and their donors, donor and recipient age and sex, cause of renal failure, HLA mismatch, 
source of transplant (live related; live unrelated; deceased donor following brain death [DBD]; 
deceased donor following cardiac death [DCD]). Post-operative events of delayed graft 
function (requirement for dialysis during the first post-operative week) and biopsy proven 
acute rejection (any time; any histological grade) were collected.  
 
CMV prophylaxis with 100 days of valganciclovir was given to the D+R- group only, with dose 
adjustment for renal function. Testing for CMV was based on clinical suspicion of disease; no 
protocolised assessment of CMV infection was undertaken in this cohort. CMV disease was 
diagnosed according to international guidelines and was based on one or more of the 
following in association with the finding of CMV viraemia: fever; new onset severe malaise; 
leucopenia; thrombocytopaenia; hepatitis (alanine transaminase or aspartate transaminase 
levels greater than twice the upper limit of normal); tissue invasive disease proven by 
histology. For our laboratory, a copy rate of >500 copies/ml of whole blood represents 
significant CMV viraemia. For the purpose of the current analysis, CMV disease of any severity 
was evaluated (i.e. no distinction was made between mild CMV “syndrome” and severe tissue 
invasive disease). 
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2.3.2 Evaluation of the HLA restricted cellular response in CMV reinfection 
(seropositive donors): prospective cohort 
 
Between February 2009 and October 2010, 36 adult recipients of kidney transplants from 
CMV seropositive donors were enrolled into a prospective study to evaluate the immune 
response to CMV (D+R-: 17; D+R+: 19). The immunosuppression and antiviral prophylaxis 
strategy was identical to the departmental protocol described above.  
 
Class I CMV tetramers were used to examine HLA-specific cell mediated immunity to CMV. 
We first identified donor-recipient pairs for which the donor expressed an HLA-A or HLA-B 
antigen not expressed by the recipient, and where the recipient expressed an HLA-A or HLA-
B antigen not expressed by the donor. We then narrowed this selection down to donor-
recipient pairs for which a class I CMV tetramer specific to the mismatched HLA for both the 
donor and recipient was available (see below for details of available tetramers). In this way, 
we were able to distinguish circulating CD8+ T cells which were specific for CMV epitopes 
presented by donor HLA (but not recipient HLA) on one hand, and recipient HLA (but not 
donor HLA) on the other. Using these criteria, we identified 11 recipients of kidneys from 
seropositive donors (8 D+/R+ pairs and 3 D+/R- donor-recipient pairs) suitable for analysis. In 
these patients, serial blood samples were taken for analysis post transplantation (1, 3, 6 and 
12 months). 
 
All CMV peptides used were synthesized commercially by Alta Biosciences (Birmingham, U.K.). 
Peptides incorporated in the tetramers (and the protein from which they are derived) were 
as follows: HLA-A1 restricted epitopes YSEHPTFTSQY (pp65) and VTEHDTLLY (pp50), HLA-A2 
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restricted epitopes NLVPMVATV (pp65) and VLEETSVML (IE-1), HLA-B7 restricted epitopes 
TPRVTGGGAM and RPHERNGFTVL (both pp65) and HLA-B8 restricted epitopes ELKRKMIYM 
and QIKVRVDMV (both IE-1). Tetramerization was carried out using Streptavidin-APC 
(Invitrogen, Paisley, UK).  
 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised blood of the 
transplant recipient by density gradient centrifugation using RPMI-1640 medium (Sigma) and 
cryopreserved in fetal calf serum (FCS) containing 10% DMSO. This was performed within 6 
hours following venepuncture. To identify virus-specific CD8+ T cells by flow cytometry, 1x106 
PBMCs were stained with tetramer at 37ºC for 15 minutes, followed by staining of surface 
markers. Cells were then analysed on a Becton-Dickinson LSRII flow cytometer and using 
DIVA-software. 
 
2.3.3 Predicting post-transplant CMV infection by pre-transplant assessment of cell 
mediated immune response to CMV: prospective cohort 
 
The predictive utility of pre-transplant cell mediated immunity to CMV was evaluated in 38 
adult seropositive transplant recipients receiving kidneys from either seropositive or 
seronegative donors (19 D+R+; 19 D-R+) between February 2009 and October 2010, using the 
departmental immunosuppression protocol described above. No patient received CMV 
prophylaxis. The frequency of circulating CMV-reactive T cells was determined prior to 
transplantation by antigen stimulation and subsequent detection of cytokine production. 
Briefly, fresh PBMCs were stimulated with CMV-derived peptides for 16 hours. Peptide pools 
were derived from either IE-1 (to assess the CD8 response) or pp65 (which can assess both 
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CD4 and CD8 responses – see below) were used at a final concentration of 1μg/ml per peptide 
(all Alta Biosciences, Birmingham, UK). 10μg/ml BrefeldinA (Sigma-Aldrich, Gillingham, UK) 
was added to block cytokine secretion after 1 hour of incubation. As a positive control cells 
were stimulated with staphylococcus enterotoxin B (SEB) (0.2μg/ml final concentration; 
Sigma-Aldrich) and unstimulated cells served as a negative control. Cells were then stained 
with anti-CD4 and anti-CD8 antibodies (BD Biosciences, Oxford, UK), fixed using 4% 
paraformaldehyde, and permeabilised with 0.5% Saponin. Intracellular Interferon (IFN)-γ was 
detected with anti-IFN-γ-FITC (BD Biosciences). Analysis was performed on a Beckton-
Dickinson LSRII flow cytometer with FlowJo software. 
 
The endpoint for this investigation was the development of CMV replication (irrespective of 
the development of symptomatic disease) within the first 12 months following 
transplantation. Serial whole blood samples were taken for CMV DNA PCR in these patients 
at day 0 (prior to transplantation), and then weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 28, 34, 
40, 46, and 52. This cohort of patients were contained within the larger “retrospective” cohort 
described above. However, the clinical team remained unaware of the results of either the T-
cell responses or the PCR results, and no changes in clinical management resulted from this 
series of experiments.  
 
2.3.4 Immunohistochemistry analysis of implantation kidney biopsy tissue 
 
Paraffin embedded tissue sections obtained from 5 seropositive kidney transplant donors 
immediately prior to transplantation (“implantation biopsies”) were examined for HCMV-IE 
(reacts with an immediate early non-structural antigen of 68-72kDa, antibodies 
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IgG2a, Chemicon International), HCMV-LA (reacts with a late protein of 47-55kD, antibodies 
IgG2a, Chemicon International) and HCMV-pp65 (IgG1, Novacostra, CA). Antibodies against 
smooth muscle cells alpha actin (IgG2a, Biogenex, San Ramon, CA), vWF (IgG1, 
DakoCytomation, Denmark) and tissue stained by exclusion of primary antibodies were used 
as controls.  Comparison was made with biopsies from 3 seronegative individuals.  
 
Briefly, the sections were deparaffinized in xylene (Sigma Aldrich), rehydrate in alcohol series, 
post fixed with 4% neutral buffered formalin (Apoteketpharmaci, Stockholm, Sweden), 
treated with pepsin (Biogenex, San Ramon, CA), and then incubated in citrate buffer 
(Biogenex). Endogenous peroxidase was blocked by treating sections with 3% H2O2 (Sigma-
Aldrich), endogenous avidin/biotin was blocked using avidin/biotin blocking kit 
(DakoCytomation, Glostrup, Denmark), and FC receptor blocker (Innovex Biosciences) was 
used to block FC-Receptors.  Finally, the tissue sections were treated with background buster 
(Innovex Biosciences). All sections were incubated with primary antibodies as mentioned 
above or without primary antibodies (only diluents) overnight at 4°C. Antibodies were 
visualized using biotinylated secondary goat antibodies against primary mouse antibodies 
(Biogenex), streptavidin-conjugated horseradish peroxidase and diaminobenzidine (Innovex 
Biosciences).  
 
The study was approved by the North Staffordshire Research Ethics Committee, and 
conducted in accordance with the guidelines of the Declaration of Helsinki. 
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2.3.5 Statistical analysis 
 
Data are presented as mean ± standard deviation unless otherwise described. Continuously 
distributed data was compared using Student’s t-test, and categorical data using Chi-square 
testing.  
 
Survival analysis was conducted using Kaplan-Meier methodology, with the log rank test used 
to assess significance. The development of CMV disease in the retrospective analysis was 
considered as a time to event outcome. This analysis factored both death and graft loss as 
competing risks, and so the analysis was performed using a competing risks regression model 
using the methods described by Fine and Gray. For all analyses, initially the effect of each 
variable on the outcome was considered separately in a series of univariate analyses. 
Variables showing some evidence of effect (p<0.15) were included in a subsequently 
multivariate analysis. A stepwise backwards selection procedure was performed to retain only 
the statistically significant variables in the final model.  
 
In addition, there was specific interest with regard to the influence of donor-recipient HLA 
mismatch on the development of CMV disease. First, a statistical interaction between donor-
recipient HLA mismatch and donor-recipient CMV serostatus with regard to time to CMV 
disease was evaluated. When such an interaction was found, subgroup analysis (by serostatus 
combination) was performed using the competing risk model described above.  
 
In the first instance, only pre-transplant demographics were considered in the model, and 
episodes of delayed graft function and biopsy proven acute rejection were not evaluated as 
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these can be considered as intermediate end points which may confound the analysis. 
However, in a set of secondary analyses these post-transplant events were evaluated as time-
dependent covariates.  
 
For all analyses, a type 1 error rate below 5% (p<0.05) was considered statistically significant. 
 
Assessment of the cell mediated immunity assay in regard to predicting CMV replication in 
the first year was evaluated by the following parameters of predictive performance: 
sensitivity, specificity, positive and negative predictive values. These measures were 
calculated following the determination of the optimal cut-off value from Receiver Operating 
Characteristic (ROC) curve analysis. The area under the ROC curve (c-statistic) was calculated 
as a global measure of prognostic performance. 
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2.4 RESULTS 
2.4.1 The incidence of CMV disease is related to donor and recipient CMV serostatus 
 
The demographics and clinical features of the 569 patients are described in table 2.1 
Table 2.1 Patient demographics 
 
 
1 Donation after Brain Death 
2 Donation after Cardiac death 
 
 In these, 77 episodes of CMV disease occurred, and were associated with donor and recipient 
serostatus (Figure 2.1; p=0.003). D-R- transplantation was associated with the lowest risk of 
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disease (3/151; 2%). CMV disease was seen in 19.8% (23/117 patients) of the D+R- group. Of 
these, 3 patients experienced CMV disease during the 3-month period of antiviral prophylaxis, 
with suboptimal valganciclovir dosing (adjusted for allograft function) in all cases. 
Interestingly, risk was highest in seropositive recipients of seropositive donors (D+R+) where 
39/179 patients (21.9%) experienced CMV disease. In contrast 12/122 patients (9.9%) in the 
D-R+ group developed CMV disease.  
 
 
Figure 2.1    CMV disease based on donor-recipient CMV serostatus 
 
Development of CMV disease by donor-recipient risk based on serostatus combination. Data shown 
for first 12 months in light of few episodes of CMV disease beyond this point. 
 
Median peak viral loads (copies/ml) during infections were also associated with serostatus: 
D-R-: 2.2x107 (range: 1.6x106-3.1x107); D+R-: 3.1x105 (571-7.7x106); D+R+: 1.3x104 (504-
1.7x108); D-R+: 1.1x104 (1025-1.9x105) (p<0.001). Histological evidence of CMV infection was 
gastro-intestinal in all cases but was uncommonly sought and proven in only 5 patients. 
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2.4.2 Multivariate analysis confirms donor serostatus influences CMV disease rates 
in seropositive recipients  
 
Table 2.2 shows the univariate relationships between CMV serostatus (and other 
demographic variables) and time to CMV disease.  
 
Table 2.2  Risk factors for CMV disease 
 
 
 
Compared with D-R+ transplantation (selected as the reference group), D-R- transplantation 
was associated with reduced risk, and D+R- with increased risk for CMV disease (Table 2.2). 
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In addition, increased risk of CMV was seen when comparing D+R+ and D-R+ serostatus 
groups (HR:2.61[95%CI: 1.36-5.01]; p=0.004 for this specific comparison).  
 
In the multivariate model, the only independent factor associated with time to CMV disease 
was donor-recipient serostatus, and therefore the effect identical to that in the univariate 
analysis (Table 2.2). Adjusting the model for post-transplant delayed graft function and acute 
rejection resulted in no material difference in the relationship (HR [D+R+ versus D-R+]:2.42 
[95%CI:1.31-4.47]; p=0.007). 
 
2.4.3 Total HLA class I mismatch between donor and recipient increases CMV 
disease risk in D+R+ transplantation 
 
No association was evident between HLA mismatch at either Class I (combined HLA-A and 
HLA-B) or Class II (HLA-DR) loci and time to CMV disease (Table 2.2). However, a significant 
statistical interaction was seen between serostatus group and total HLA Class I mismatch 
(p=0.02).  
 
To illustrate this, the association between total HLA Class I mismatch and time to CMV was 
evaluated for each serostatus risk group. In D+R+ transplantation (n=179), a significant 
relationship was evident between HLA Class I mismatch and time to CMV disease, and this 
remained significant in the multivariate model (HR [per mismatch]:1.43[95%CI:1.12-1.82]; 
p=0.02). Kaplan-Meier estimates of CMV-free survival in the D+R+ cohort are shown in Figure 
2.2 (p=0.03).  
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The effect of HLA Class I mismatch was not evident in the other three serostatus groups (p>0.3 
for all). In addition, no statistical interaction was seen between serostatus group and Class II 
mismatch (HLA-DR only; p=0.13). 
 
 
Figure 2.2   Donor-recipient HLA mismatch and time to CMV disease.  
Influence of donor-recipient HLA mismatch on time to CMV disease in the D+R+ serostatus pairing. 
Data are shown for first 12 months in light of few episodes of CMV disease beyond this point. 
2.4.4 Transplant patients fail to mount a CD8+ T-cell response to immunodominant 
CMV epitopes selectively presented by donor MHC 
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We next investigated the CD8+ T-cell response to CMV peptides presented exclusively by 
either donor or recipient HLA alleles. We prospectively identified 11 instances of 
transplantation from CMV seropositive donors where both the donor and recipient expressed 
at least one unique HLA Class I allele and where appropriate HLA-peptide tetramers were 
available to study T-cell immune responses against immunodominant CMV peptides 
presented through these two alleles. In 8 cases the recipient was also CMV seropositive; in 3 
cases the recipient was seronegative. 
 
Following transplantation, 4 of the 8 recipients in the D+R+ group displayed CD8+ T-cell 
responses to peptides presented by recipient-specific HLA alleles. Representative results for 
one individual (and gating strategy) are shown in Figure 2.3A and the upper row of Figure 
2.3B, demonstrating the HLA A1-restricted CD8+T-cell response to the VTEHDTLLY peptide 
(recipient type: HLA-A1, A8; donor: HLA-A2, A3). In the remaining 4 patients no such CD8+ T-
cell response was detected. However, and of particular interest, no immune response 
restricted through a donor-specific HLA allele was detected in any of the 8 recipients at any 
point during the first-year post transplantation (p=0.02 comparing recipient and donor-
restricted responses). Similarly, none of the 3 patients in the D+R- group mounted a CD8+ T-
cell response to CMV peptides restricted by a donor-specific HLA allele. However, one 
recipient did develop a response to a peptide restricted by a recipient-specific allele, which 
was not evident early post transplantation, but was then evident at 6 months and persisted 
to 18 months post-transplantation (HLA-A1 restricted YSE peptide; Figure 2.3B lower row).  
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Figure 2.3   CD8+ T-cell responses against recipient-HLA-presented CMV epitopes 
CD8+ T-cell responses against recipient-HLA-presented CMV-derived epitopes can be detected in both 
CMV-seropositive recipients of seropositive donor organs (D+R+) and CMV-negative recipients of 
seropositive organs (D+R-). Gating strategy is shown in (A). The upper row of (B) shows an example of 
a serial evaluation of the CD8+ T-cell response to the HLA-A1 restricted epitope VTE (pp50) in the D+R+ 
setting at time of transplantation (d0), day 14, 3 months and 12 months post transplantation (B; top 
row). The lower row of (B) shows the T-cell response to the HLA-A1 restricted epitope YSE (pp65) in a 
CMV-seronegative recipient of a CMV-seropositive donor organ, which was not evident early post-
transplantation, but then emerged and persisted through to 18 months post-transplantation. 
 
Taken together across 11 transplant procedures, 5 recipients developed a CD8+ T-cell 
response to CMV peptides restricted by recipient-specific HLA alleles, whereas none 
demonstrated a response to epitopes restricted by donor-specific alleles (p=0.01). 
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2.4.5 CMV within transplanted tissue from seropositive kidney transplant donors 
is common 
 
Histological examination of implantation biopsies from 10 seropositive kidney transplant 
donors revealed evidence of CMV protein expression in all cases (HCMV-IE, HCMV-LA and 
HCMV-pp65; Figure 2.4). Staining was absent in seronegative controls.  
 
 
Figure 2.4A   HCMV IE immunostaining of implantation biopsy from seropositive 
donor 
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Figure 2.4B HCMV LA immunostaining of implantation biopsy from seropositive                  
donor 
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Figure 2.4C HCMV pp65 immunostaining of implantation biopsy from seropositive 
donor 
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2.4.6 The predictive utility of assessment of the pre-transplant CMV-specific T-cell 
immune response differs between D+R+ and D-R+ transplantation  
 
Finally, the prognostic value of CMV-specific cellular immunity immediately prior to 
transplantation was evaluated in CMV seropositive recipients. In D-R+ transplantation (n=19), 
a median 0.13% of total CD8+T cells responded to an IE-1 peptide mix as measured by IFN-γ 
production (range 0-8.18%), and 0.06% (range 0-4.35%) of total CD4+ T cells responded to 
pp65-derived peptides. Six patients (31%) in this group developed detectable CMV replication 
during the first year. In D+R+ transplantation (n=19), a median 0.13% CD8+ T cells responded 
to IE-1 epitopes (range 0-23.05%), and 0.05% CD4+ T cells (range 0-1.43%) responded to pp65 
epitopes, with 9 patients (47%) displayed CMV replication.  
 
ROC curve analysis defined the optimal prognostic cut-off, and then sensitivity, specificity, 
and positive and negative predictive values at that cut-off were calculated. Results are shown 
in Table 2.3. 
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Table 2.3 Prognostic performance of pre-transplant assays of cellular immunity to 
CMV. 
 Endpoint of CMV infection during first 12 months post transplantation. NPV=Negative 
Predictive Value; PPV=Positive Predictive Value 
 
 In D-R+ transplantation, a CD8+ T-cell response of 0.16% (i.e. when 0.16% total CD8+ cells 
produced IFN-γ following IE-1 peptide stimulation) was associated with moderate to good 
prediction (c-statistic 0.76) for CMV replication. From a clinical perspective, in 83% of patients 
experiencing CMV replication less than (or equal to) 0.16% total CD8+ T cells responded to IE-
1 peptide stimulation prior to transplantation; 86% of patients with greater than 0.16% total 
CD8+ T cells responding to IE-1 did not develop CMV replication within 12 months post-
transplantation. The CD8+ T-cell response to pp65 demonstrated identical prognostic 
performance to the IE-1 CD8+ T-cell response, although the optimal cut-off value was 0.08% 
total CD8+ T cells. 
 
Conversely, the pre-transplant CD8+ T-cell response did not demonstrate prognostic utility in 
D+R+ transplantation (Table 2.3). In fact, of 9 recipients in this subgroup displaying an IE-1 
response ≥0.16% total CD8+ T cells, 5 developed CMV replication, and 4 did not. Interestingly, 
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and despite the small numbers studied, there was some suggestion that these 5 patients 
developing post-transplant CMV replication displayed increased HLA Class I mismatch in 
comparison to the 4 patients in whom this percentage of CMV-responding CD8+ T cells was 
“protective” (Class I mismatch: 4,3,3,2,2 versus 3,2,1,1 respectively; p=0.1).   
The relationship between the IE-1 CD8+ T-cell response and risk of CMV replication in D-R+ 
and D+R+ transplantation is shown in Figure 2.5.  
 
 
 
Figure 2.5 IE-1 CD8+ T-cell response in predicting post-transplant CMV infection 
The relationship between the IE-1 CD8+ response and the probability of CMV infection over the first 
post-transplant year, comparing D-R+ and D+R+ serostatus pairings.  
  
The CD4+ response (pp65) did not demonstrate prognostic utility in either D-R+ or D+R+ transplantation 
(Table 2.3). 
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2.5 DISCUSSION 
 
This study demonstrates important characteristics of CMV infection in kidney transplant 
recipients. First, CMV seropositive recipients receiving contemporary immunosuppression are 
at increased risk of clinical CMV disease when receiving kidneys from CMV seropositive 
compared with seronegative donors. This observation represents a “real world” scenario, 
dealing specifically with patients experiencing clinically manifest CMV disease, thereby 
extending data from previous clinical trials addressing asymptomatic CMV 
infection/replication. [5,7] Although “strain-specific” mismatch is cited as an underlying 
mechanism for this phenomenon, [9] substantial data exist which question this hypothesis 
(discussed further below). We therefore investigated whether donor-recipient HLA mismatch 
impaired development of cognate cellular immunity to CMV within transplanted donor tissue. 
Indeed, further analysis demonstrated increased risk of CMV disease with greater HLA Class I 
mismatch. To investigate the underlying mechanism, we utilised HLA-peptide tetramers to 
interrogate the development of CD8+ T-cell immunity against peptides presented through HLA 
alleles specific for either recipient or donor. Notably we observed that although cellular 
responses to CMV peptides presented through recipient-specific HLA alleles were frequently 
detected, CD8+ T-cell responses to peptides presented solely by donor-specific HLA alleles 
were not generated within 12 months post-transplantation.  
 
The latter observation is relevant to current theories of the relative roles of different antigen 
presentation pathways in viral infection. These include direct presentation by infected donor 
antigen presenting cells (APCs), presentation by recipient APCs “cross dressed” with donor-
derived MHC: viral peptide complexes transferred from donor immune or parenchymal cells, 
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and cross-presentation by recipient APCs which have engulfed and processed circulating 
virions. [14,15] Recipients’ failure to develop CD8+ immune responses through donor-specific 
HLA alleles suggests that priming and expansion of immune responses to donor-transmitted 
CMV does not result from direct presentation or “cross dressing”. This novel finding with 
regard to transplantation-associated viral transmission resonates with data from models of 
murine CMV, suggesting cross-presentation as the primary pathway to antiviral immunity, 
[16-18] with direct priming inhibited due to CMV-mediated downregulation of activating 
costimulatory molecules (such as CD86) and upregulation of inhibitory ligands (such as PD-L1) 
on APCs, [19-21] along with inhibition of dendritic cell maturation and antigen presentation 
[22,23]. 
 
Absence of directly primed CD8+ T-cell immune responses raises questions regarding how 
infection is ultimately controlled within donor tissue. Several possibilities include CD4+ T-cell 
immunity, natural killer cells and humoral immunity. However, sensitive DNA-based 
techniques commonly detect CMV persistence post-transplantation in kidneys from 
seropositive donors, [24] suggesting donor tissue may act as a ‘reservoir’ for infection, which 
may later become clinically manifest. [25] Certainly the pre-implantation histological data 
from the current study suggests CMV transmission peri-transplantation is very common. 
Following CMV reactivation, HLA Class I upregulation occurs in infected and surrounding cells, 
[26-29] with subsequent presentation of CMV antigens to CD8+ T -cells. [30,31] In D+R+ 
transplantation, pre-existing cellular immunity may control spread of donor-derived virus, but 
donor-recipient mismatching at Class I loci may impair the efficacy of this response, and so 
increase the likelihood of clinical disease, as seen in the current study. HLA Class I mismatch 
may be less important in the setting of D+R- or D-R+ transplantation, because control of CMV 
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infection in the former is primarily contingent on a de novo immune response (rather than a 
pre-existing one), and the latter depends on responses to recipient HLA-presented virus. 
 
This study highlights differences in risk of CMV when seropositive recipients receive kidneys 
from donors either with or without latent CMV infection, i.e. between D+R+ and D-R+ 
transplantation. This finding opposes the view that these groups be considered together as 
an “intermediate risk” category, and supports policies of antiviral prophylaxis or heightened 
surveillance in D+R+ transplantation, particularly in instances of increased donor-recipient 
HLA Class I mismatch. The introduction of a novel CMV strain has been implicated as 
enhancing the risk of CMV disease in D+R+ transplantation [32]. However, it is noteworthy 
that the study showing this effect incorporated ’high level antigenemia’ without symptoms 
within the definition of CMV disease and did not show increased CMV infection rates with 
strain-specific donor-recipient serological mismatch [32]. Also, it is known that human 
immunity to CMV is broadly targeted [33], suggesting “redundancy” in the cellular repertoire. 
Furthermore, mismatching for immunodominant CD8+ epitopes in murine models of CMV has 
minimal effect on disease severity [34]. A primate model also shows that hepatitis C re-
infection rates are similar irrespective of whether the re-infecting strain was homologous or 
heterologous to the original infection [35]. Therefore ‘strain-mismatch’ may not necessarily 
fully explain increased CMV rates in D+R+ transplantation. Indeed, combinations of viral 
variation and HLA mismatch may be important and future study is required to clarify their 
relative contributions. In light of the extreme difficulty in isolating latent viral DNA from 
transplant donors, we were unable to directly address this issue of genotype mismatch in this 
study. 
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Assays of cellular immunity to CMV are emerging research tools. However, this study suggests 
that such in vitro assessments, whereby CMV peptides are presented by recipient HLA (using 
recipient PBMCs) may be misleading, considering that in vivo the virus may be harboured 
within donor tissue, and therefore presented upon reactivation by donor HLA. This may 
account for the inferior prognostic utility of these assays in D+R+ (compared with D-R+) 
transplantation. There was also some suggestion that HLA mismatch played a role in this 
context, and future evaluation of this phenomenon in larger cohorts may be worthwhile. To 
our knowledge this is only the second study to evaluate the prognostic utility of pre-transplant 
cellular immunity to CMV. The first study, published recently [36] also identified an 
association between pre-transplant immunity and post-transplant viral replication in 55 
kidney or lung transplant recipients undergoing either antiviral prophylaxis or pre-emptive 
therapy, but did not compare D+R+ and D-R+ groups specifically, or present metrics of 
prognostic utility.  
 
It can be speculated that these findings may be relevant to other viruses that are transmitted 
in allograft tissue such as Epstein-Barr virus (EBV) or polyoma virus. They may also be relevant 
when considering targets for adoptive cellular transfer therapy in the treatment of viral 
infection where the infection is of donor origin. The requirement for a cellular response 
against donor-presented epitopes may also have implications for vaccine development and 
efficacy in the context of viruses transmitted by transplantation, as identified in the context 
of anti-tumour vaccination [37]. 
 
In conclusion, clinically relevant CMV disease is more common in non-prophylaxed 
seropositive recipients of kidneys from seropositive (compared with seronegative) donors; 
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donor-recipient HLA Class I mismatch modifies this risk. We suggest that CD8+ T-cell immune 
responses against CMV transmitted within grafted tissue fail to develop, although cannot yet 
claim this as definitive pending further study in other cohorts. Nevertheless, these preliminary 
findings have considerable implications for the clinical management and immunological 
understanding of viral infection in transplantation. 
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3.1 ABSTRACT 
 
Emerging data suggests that expansion of a circulating population of atypical, cytotoxic CD4+ 
T cells lacking costimulatory CD28 (“CD4+CD28null” cells) is associated with latent CMV 
infection. The purpose of the current study was to increase the understanding of the 
relevance of these cells in 100 unselected kidney transplant recipients followed prospectively 
for a median of 54 months. Multicolour flow cytometry of PBMCs prior to transplantation and 
serially post-transplantation was undertaken. CD4+CD28null cells were found predominantly in 
CMV-seropositive patients, and expanded in the post-transplant period. These cells were 
predominantly effector-memory phenotype, and expressed markers of endothelial homing 
(CX3CR1) and cytotoxicity (NKG2D and perforin). Isolated CD4+CD27-CD28null cells proliferated 
in response to PBMCs previously exposed to CMV-derived (but not HLA-derived) antigens, 
and following such priming incubation with glomerular endothelium resulted in signs of 
endothelial damage and apoptosis (release of fractalkine and von Willebrand factor; 
increased caspase 3 expression). This effect was mitigated by NKG2D-blocking antibody. 
Increased CD4+CD28null cell frequencies were associated with delayed graft function, and 
lower eGFR at end follow-up. This study suggests an important role for this atypical cytotoxic 
CD4+CD28null cell subset in kidney transplantation, and points to strategies that may minimize 
the impact on clinical outcomes. 
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3.2 INTRODUCTION  
 
Cytomegalovirus (CMV) is a ubiquitous β-herpesvirus which may cause significant clinical 
disease in transplanted patients. It is also now appreciated that CMV can exert a range of 
“indirect effects”, including allograft dysfunction, vasculopathy and glomerulopathy, 
although the mechanisms underlying these phenomena are unclear (1-3).  
 
Latent CMV infection in patients with end-stage renal disease (ESRD) is associated with 
expansion of circulating, late-differentiated, cytotoxic CD4+ T cells. These are characterised 
by absence of the costimulatory molecule CD28 from the cell surface (“CD4+CD28null”)(4). 
Although also recognised in patients with autoimmune conditions such as multiple sclerosis, 
rheumatoid arthritis and vasculitis (5-7), these CD4+CD28null cells are unresponsive to 
candidate autoantigens (5, 6), but rather respond to CMV-derived proteins. Furthermore, one 
study demonstrated emergence of CD4+CD28null cells in 4 kidney transplant recipients 
following primary CMV infection (8), although evaluation of these cells’ reactivity to 
alloantigen has not yet been studied.  
 
In contrast to CD28-expressing CD4+ cells (“CD4+CD28+”), CD4+CD28null cells express cytotoxic 
mediators such as perforin (4, 5, 8), and cells isolated from patients with acute coronary 
syndromes promote damage to human umbilical vein endothelial cells (HUVEC) in vitro (9). 
Interestingly, exposure of CD4+ cells to CMV antigens (but not other viral antigens) promotes 
expansion of CD4+ cells expressing the killer lectin-like receptor NKG2D (10, 11), also 
uncommonly expressed on CD4+ T cells (10). Upon ligation, NKG2D initiates an intracellular 
cascade culminating in perforin exocytosis and consequent cytotoxicity.  
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The purpose of this study was to gain greater understanding of the epidemiology, biology, 
and clinical consequences of these cytotoxic CD4+ cells in the relatively understudied field of 
kidney transplantation. We evaluated kidney transplant patients from the time of 
transplantation, undertaking serial examination of circulating CD4+CD28null cell frequencies, 
demonstrating a close relationship with CMV-serostatus. These cells proliferated to CMV-
derived antigens, but not to HLA-derived antigens, and demonstrated toxicity to glomerular 
endothelial cells in vitro, highlighting the role of NKG2D. Elevated cell frequencies were 
associated with relevant clinical outcomes to 5 years post-transplantation.  
 
3.3 CONCISE METHODS 
3.3.1 Clinical Cohort 
 
One hundred unselected recipients of solitary kidney transplants were enrolled into this 
prospective study between 2009 and 2010. All patients underwent transplantation and 
follow-up at Queen Elizabeth Hospital Birmingham. Local ethics committee approval was 
granted for the study. 
 
Prior to transplantation, baseline donor and recipient information was collected: donor and 
recipient age and sex, inflammatory cause of renal failure (glomerulonephritis; vasculitis; 
lupus), HLA mismatch (class I and class II), source of transplant (live related; live unrelated; 
deceased donor following brain death [DBD]; deceased donor following cardiac death [DCD]); 
dialysis modality prior to transplantation (pre-emptive versus haemodialysis versus 
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peritoneal dialysis). Transplantation proceeded provided the cross match between donor and 
recipient was negative by flow cytometry and cytotoxicity.  
 
Immunosuppression regimen was identical for all participants, and consisted of Basiliximab 
induction followed by maintenance tacrolimus (Prograf; trough level 5-8ng/ml initially, 
measured by liquid chromatography-tandem mass spectrometry), mycophenolate mofetil 
(Cellcept; 2g daily initially) and prednisolone (20mg daily, reducing to 5mg maintenance by 3 
months post transplantation). Data collected subsequently in the course of standard clinical 
care was evaluated: Post-operative events of delayed graft function (requirement for dialysis 
during the first post-operative week) and biopsy proven acute rejection (any time; any 
histological grade) were collected.  
 
Estimated glomerular filtration rate (eGFR) was calculated using the 4 variable MDRD 
(Modification of Diet in Renal Disease) equation, with IDMS (Isotope Dilution Mass 
Spectrometry) aligned creatinine measurements; early morning urine albumin: creatinine 
ratio (UACR) measurement on a “spot” urine sample was used as the measure of proteinuria, 
and high sensitivity C-reactive protein (hsCRP) as the marker of inflammation. These were 
collected at each clinic review following transplantation. 
 
3.3.2 Assessment of CMV serostatus, infection, and disease 
 
Pre-transplant CMV serostatus of the recipients and their donors was collected.  CMV 
prophylaxis with 100 days of valganciclovir was given to the D+R- group only, with dose 
adjustment for renal function. Serial whole blood samples were taken for CMV DNA PCR in all 
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patients at day 0 (prior to transplantation), and then weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24, 
28, 34, 40, 46, and 52. The clinical team remained unaware of these results and no changes 
in clinical management ensued (it is not unit policy to undertake viral load testing and pre-
emptive therapy in the context of asymptomatic CMV infection, as is the case in most centres, 
and so these assessments were undertaken for research purposes only). Additional sampling 
was undertaken at the time of clinical suspicion of CMV disease, which was then diagnosed 
according to international guidelines and was based on one or more of the following in 
association with the finding of CMV viraemia: fever; new onset severe malaise; leucopenia; 
thrombocytopaenia; hepatitis (alanine transaminase or aspartate transaminase levels greater 
than twice the upper limit of normal); tissue invasive disease proven by histology. For our 
laboratory, a copy rate of >500 CMV genome copies/ml of whole blood represents significant 
CMV viraemia.  
 
Patients who were CMV seronegative at the time of transplantation underwent repeat 
serological testing at 12 months post transplantation to identify those who have developed 
asymptomatic infection within the first year, for whom no DNAemia was detected by 
protocolised testing as above. 
 
3.3.3 Immunophenotyping 
 
Multicolour flow cytometry was used to undertake detailed phenotyping of patients’ 
peripheral blood mononuclear cells (PBMCs) prior to transplantation and then 14 days, 3 
months, and 12 months post-transplantation. PBMCs were isolated from heparinised blood 
of the transplant recipient by density gradient centrifugation using Ficoll-Paque (Fisher, UK) 
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and cryopreserved in fetal calf serum (FCS) containing 10% DMSO. This was performed within 
6 hours following venepuncture.  
 
Based on surface expression of CD27 and CD45RA, the broad differentiation status of 
CD4+CD28null cells and their CD4+CD28+ counterparts were defined as follows. Naïve-like: 
CD27+CD45RA+; Central memory-like (CM): CD27+CD45RA-; Effector memory-like (EM): CD27-
CD45RA-; Effector memory cells re-expressing RA (“EMRA”): CD27-CD45RA+. The panels of 
antibodies used for flow cytometric analyses are outlined in the supplementary data.  
 
3.3.4 Isolation of CD4+CD27-CD28null and CD4+CD27-CD28pos Cells  
 
At 12-months post transplantation, heparinised blood was taken from patients shown to have 
a high CD4+CD27-CD28null cell count (>10% total CD4+ T cells) and PBMCs were isolated by 
Ficoll-Paque (Fisher, UK) gradient. CD4+CD27-CD28null and CD4+CD27-CD28pos cells were 
isolated first by positive selection using a CD4+ T-cell Isolation Kit, followed by selection of 
CD27 negative cells (using anti-CD27 human microbeads) and separation of CD28+ and 
CD28null cells within this population using a CD28 Microbead Kit (Miltenyl Biotec, UK), in 
accordance to manufacturer’s instructions. These cells were used in 2 experiments to 
investigate i] their proliferative capacity in response to CMV-antigen and HLA-derived 
peptides, and ii] their ability to induce damage on purified glomerular endothelial cells, as 
described next. 
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3.3.4.1 Proliferation Assays (CMV- and HLA-derived peptides)  
 
CD4+CD27-CD28null and CD4+CD27-CD28pos sorted cells were labelled with 0.5µM CFSE 
(Molecular Probes/Invitrogen) in PBS for 5 min at 37°C followed by 5 min in ice-cold RPMI-
1640 containing 5% human AB serum (Sigma, UK). Cells were then seeded at 105 with 105 
antigen-pulsed irradiated autologous PBMCs in RPMI-1640 containing 5% human AB serum 
and incubated at 370C with 5% CO2 for 5 days. These autologous PBMCs had been pulsed for 
4h prior to irradiation with either i) CMV lysate [from fibroblasts infected with CMV strain 
AD69], ii) α3-domain derived Class-I HLA peptides (also used in ELISPOT assay described 
below; Thermo, UK;) or iii) control culture media. Cells were surface stained with CD3-APC, 
CD4-APC-Cy7 (eBiosicences) and Yellow Dead Cell Stain Kit ((Molecular Probes/Invitrogen), 
then analysed using a Cyan Flow Cytometer (Beckman Coulter).  
 
The α3-domain derived Class-I HLA peptides used in the second part of this experiment are 
known targets for cellular alloresponses, and their use allows inter-patient assay 
standardization (20,21). The responding cells are CD28- expressing effector-memory CD4+ 
cells which recognise cryptic, autologous HLA-derived peptide epitopes, such that inter-
patient standardisation can be undertaken without using distinct HLA peptides tailored to the 
donor and recipient HLA type (20).  
 
3.3.4.2 Analysis of Damage to Glomerular Endothelial Cells 
 
Conditionally immortalized human glomerular endothelial cells (GEnC) were kindly gifted by 
Dr S. Satchell, Bristol, UK. These were maintained in supplemented endothelial basal medium-
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2 (Lonza, UK) as described previously (26). GEnC cells were grown until 90% confluence at 
330C, then at 370C for at least 24h prior to addition of T cells. 
 
PBMCs were isolated from patients and incubated for 16h with either CMV lysate, an α3-
domain derived HLA Class I peptide, or culture media. CD4+CD27-CD28null and CD4+CD27-
CD28pos cells were then isolated as described above, with 105 cells per well incubated with 
GEnC, and seeded in 24 well plates for 1 hour using transwell inserts to determine the role 
for chemokines involved in lymphocyte migration (specifically fractalkine in this study). One 
well per patient was incubated with either 1µg/ml antiNKG2D antibody or isotype control (BD 
Biosciences) for 2h prior to addition of T cells. Cells were stained for activated caspase 3 (as a 
marker of apoptosis; BD Biosciences) following T-cell migration, whereby GEnC and T cells 
were differentiated by staining for cell-specific markers anti-CD31-APC and anti-CD4-PE 
(eBiosciences) respectively, and analysed using Cyan flow cytometer (Beckman Coulter); In 
addition, fractalkine production was measured in the supernatants collected from GEnC 
incubated with T cells by Recombinant Human CX3CL1/Fractalkine ELISA Kit according to 
manufacturer’s instructions (R & D Systems, UK); Von Willebrand Factor (vWF) was also 
measured in supernatants by sandwich ELISA, using unconjugated (capture) and conjugated 
(detection) vWF antibodies (DAKO, UK).  
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3.3.5 Enzyme Linked Immunosorbent Spot Assay to detect anti-HLA cellular 
response 
 
A γ-interferon ELISPOT assay to evaluate the cellular immune response of transplant 
recipients to non-polymorphic HLA-derived peptides was undertaken as previously described 
(20, 21), and described briefly above.  
 
3.3.6 Statistical analysis 
 
Data are presented as mean ± standard deviation, unless otherwise stated; the figures 
demonstrate data distribution as mean, standard error, median, range, interquartile range 
and percentiles as described in figure legends. Non-normal distributed data underwent 
transformation as necessary prior to analysis. Of note, CD4+CD27-CD28null cell frequencies 
displayed heavily positive skewing, such that straightforward attempts (such as logarithmic 
transformation) to transform into a more normally distributed scale were not possible. 
Instead, these data were evaluated using negative binomial regression analysis. Other 
continuously distributed end-point data was evaluated using linear regression analysis; 
categorical endpoints were evaluated by logistic regression; time to event outcomes were 
analysed using a Cox proportional hazards model. For all analyses, initially the effect of each 
predictor variable on the outcome was considered separately in a series of univariate 
analyses. Post-transplant events of acute rejection and CMV infection were analysed as time-
dependent variables as required. Variables showing some effect in the univariate analysis 
(p<0.15) were included in a subsequent multivariable analysis, with a stepwise backwards 
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selection procedure to retain only the statistically significant variables in the final model. For 
all analyses, a type 1 error rate below 5% (p<0.05) was considered statistically significant. 
 
Another feature of the data was the fact that there were several measurements for each 
subject. To allow for the non-independence of the data, multilevel statistical methods were 
used for data analysis in the linear regression and negative binomial models. Two-level 
models were used with individual measurements nested within patients. This was 
implemented using the xtnbreg procedure with the Stata statistical software package. For 
time to event analyses, predictor variable was analysed as time-dependent covariates; for 
analyses of single endpoints (either categorical or continuously distributed), averaged values 
(over the course of the study) for predictor variables were entered. 
 
For other analyses, continuously distributed parametric data was compared using Pearson’s 
correlation coefficient and Student’s t-test; non-parametric data was analysed by Mann-
Whitney testing (with Bonferroni correction for multiple comparisons where appropriate); 
multiple-group independent non-parametric data was analysed by Kruksall-Wallis testing, 
with Friedman testing used for multiple-group non-independent (multiple comparisons over 
time) non-parametric data. Categorical data was compared using Chi-square testing. Inter-
test concordance was evaluated using the kappa (κ) statistic. 
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3.4 RESULTS 
3.4.1 Clinical outcomes 
The clinical cohort is described in Table 3.1. Over the study duration, three patients died (from 
sepsis), and four lost their grafts (primary non-function with nephrectomy 2 months post-
transplantation, early acute rejection, recurrent disease, late [14 months] acute rejection); all 
patients underwent serial sampling (as described in “methods”) until death or graft failure 
(95 patients were alive with graft function at 12 months post-transplantation). For the entire 
cohort, median follow-up was 54 months (range 2-60 months). For the 93 patients alive with 
graft function at the end of the study, mean eGFR at the end of follow-up was 
52±17ml/min/1.73m2, and median UACR was 2.6 mg/mmol (IQR:1.0-6.6; range 0.3-280). 
Twenty-three patients experienced DGF, and twenty-five acute rejection (≥Banff grade 1). 
 
In the D-R- group, 1 patient developed detectable CMV DNAemia (with clinical disease) and 1 
seroconverted without prior detectable DNAemia. In the D+R- group (prophylaxed for 100 
days), 5 patients developed detectable DNAemia (2 clinical disease) and 3 seroconverted 
without detectable DNAemia. In the D-R+ group, 6 patients developed detectable DNAemia 
(1 clinical disease). In the D+R+ group, 9 patients developed detectable DNAemia (3 clinical 
disease). 
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Table 3.1  Patient demographics 
 
 
1 Donation after Brain Death 
2 Donation after Cardiac death 
3 Requirement for dialysis within the first week post transplantation 
4 Denotes the development of asymptomatic CMV viremia on protocol sampling, or the de novo 
development of anti-CMV antibody in those patients who were seronegative at the time of 
transplantation – none of these patients displayed evidence of clinical disease (see text for details) 
5 Denotes the development of symptomatic CMV disease requiring clinical intervention 
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3.4.2 CD4+CD28null cell frequencies, expansion and CMV status 
 
Circulating CD4+CD28null cell frequencies (expressed as a percentage of total CD4+ cells), and 
the flow cytometry gating strategy these results are based on, are shown in Figure 3.1 (A and 
B). 
 
Figure 3.1A Flow cytometry gating strategy for identification of CD4+CD28null cells 
 
The gating strategy (Figure 3.1A) and results (Figure 3.1B) for the flow cytometry identification of 
CD4+CD28null cells is shown. CD4+CD28null cell frequencies (expressed as a proportion of total CD4 cells) 
over time are shown as median (line), interquartile range (boxes) and range (whiskers). This 
demonstrates significant differences in cell frequencies across CMV-serostatus subgroups at all 
timepoints (Kruksall-Wallis p<0.05 for all) and evidence of expansion of CD4+CD28null cells in CMV 
seropositive recipients over the first-year post-transplantation, which was not see in their CMV-
seronegative counterparts (Friedman test p<0.001 for D-/R+ and D+/R+ groups). Samples available 
and analysed for 100 patients pre-transplant, 94 patients at 14 days, 92 patients at 3 months, and 90 
patients at 12 months. Figure 3.1C demonstrates the expansion of CD4+CD28null cells in 10 patients 
who were seronegative at the time of transplant and who developed CMV infection during the first 
12 months post transplantation (2 received kidneys from CMV-seronegative donors, and 8 from CMV-
seropositive donors). 
 
 
 CD4+CD28null frequencies were higher in seropositive recipients than seronegative recipients 
at all timepoints (p<0.05 for all; Figure 3.1B). This was particularly evident at the 12-month 
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timepoint, as there was expansion of CD4+CD28null frequencies in CMV-seropositive 
individuals over time that was not seen in the (overall) CMV-seronegative patients. 
Multivariable analysis (Table 3.2) showed recipient serostatus and time post transplantation 
as the significant independent predictors of CD4+CD28null cell frequencies. In the entire 
cohort, although development of CMV infection (detection of DNAemia or “silent” 
seroconversion) was associated with CD4+CD28null expansion on univariate analysis, this did 
not hold in the multivariate analysis.  
Table 3.2  Predictors of CD4+CD28null cell frequencies 
 
 
Table 3.2 shows the predictors of CD4+CD28null cell frequencies (expressed as a proportion of 
total CD4+ cells) in the study population. Results from univariate and multiple regression 
models displayed. The effect sizes are summarised in the form of ratios. For the categorical 
variables these represent the ratio of CD4+CD28null cell frequencies in each category relative 
to a baseline category. For the continuous variables, these represent the change in ratio for a 
one-unit increase in that variable (unless otherwise indicated).  
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*denotes either i] detection of CMV DNAemia (either clinically manifest or silent) prior to sampling 
time or ii] recipient seroconversion prior to sampling time 
**denotes primary renal disease due to inflammatory nephritis (e.g. vasculitis, lupus, 
glomerulonephritis) 
***defined as dialysis requirement in first week post transplantation 
****Biopsy proven rejection (any grade) prior to sampling time 
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Figure 3.1B   CD4+CD28null frequencies over time in the donor-recipient CMV serostatus groups 
Although as mentioned above, there was no expansion of CD4+CD28null cells in CMV-seronegative 
recipients, the individuals who did experience primary CMV infection within the first year (either with 
or without clinical disease as described above; n=10), displayed increases in CD4+CD28null frequencies 
from 0.2±0.15% pre-transplant to 2.5±1.8% at 12 months post-transplantation (p=0.009). Multiple 
regression analysis (adjusted for variables in Table 3.2) demonstrated prior CMV infection as the only 
predictor of CD4+CD28null frequencies in these patients (ratio:9.67 (95%CI:3.30-28.40; p<0.001). Figure 
3.1C demonstrates the evolution of CD4+CD28null cells in these 10 specific patients. 
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Figure 3.1C Evolution of CD4+CD28null cells following primary CMV infection 
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3.4.3 Episodes of inflammation are associated with expansion of CD4+CD28null cells 
in CMV-seropositive recipients 
 
In vitro work and clinical data from patients with critical illness suggests importance of 
inflammation in driving CMV reactivation (12-15). Because information was lacking in regard 
to inflammatory events or markers prior to transplantation, we undertook a separate “delta 
analysis” identifying factors associated with changes (“deltas”) in cell frequencies between 
sampling timepoints (i.e. baseline to 14 days; 14 days to 3 months; 3 months to 12 months). 
Analysis focused on the relationship between the highest recorded (peak) hsCRP 
measurement during these timepoints and the delta CD4+CD28null frequencies between these 
timepoints. Peak hsCRP values demonstrated positive skewing (median:21mg/L; range 0.3-
140mg/L); delta CD4+CD28null frequencies were normally distributed (mean:1.0±3.8; range -
11.1 to 16.7). In the entire cohort, some association between hsCRP and delta CD4+CD28null 
cells was seen (coefficient:0.5;95%CI:0.1-1.1; p=0.07). A significant statistical interaction 
between peak hsCRP and recipient CMV-serostatus was seen (p<0.05), with a significant 
relationship between hsCRP and delta count only in CMV-seropositive recipients 
(coefficient:1.0; 95%CI:0.2-1.8; p=0.02). 
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Figure 3.2 Association between delta CD4+CD28null cell count and peak hsCRP 
across sampling time points 
 
Sampling time points were baseline to 14 days; 14 days to 3 months; and 3 months to 12 months. The 
“delta count” (as described in “methods”) represents the absolute change in CD4+CD28null frequency 
(expressed as the percentage of total CD4+ cells) between time points. Curves shown represent lines 
of best fit from the regression analyses undertaken. Figure 3.2A demonstrates the relationship 
between delta count (all time points considered) and hsCRP in all studied patients. This shows the 
influence of inflammation on CD4+CD28null cell expansion was only evident in CMV-seropositive 
recipients. Further analysis of this CMV-seropositive group (only) is represented in Figure 3.2B. This 
shows the influence of time post-transplantation on the relationship between hsCRP and delta 
CD4+CD28null cell count, whereby this effect of inflammation-associated CD4+CD28null cell expansion is 
only seen beyond 14 days post-transplantation in this CMV-seropositive group. 
  
Figure 3.2A shows the line of best fit demonstrating the relationship between hsCRP and 
expansion of CD4+CD28null cells (based on the output from the regression analysis) in both 
serostatus groups. Indeed, hsCRP was the only independent predictor of delta count in 
seropositive recipients when adjusted for variables in Table 3.2, including the development 
of CMV viremia between timepoints. Furthermore, in subgroup analysis of these CMV-
seropositive patients in whom CD4+CD28null cell expansion was seen, a further interaction 
between hsCRP and timepoint was evident (p=0.007), and suggested episodes of 
inflammation had a greater effect upon CD4+CD28null cell expansion at times beyond 14 days 
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post-transplantation. This relationship is demonstrated in Figure 3.2B.  In summary, this 
suggests episodes of inflammation may drive expansion of CD4+CD28null cells in CMV-
seropositive recipients, particularly beyond 14 days post-transplantation. 
 
3.4.4 In CMV-seropositive recipients CD4+CD28null cells display predominant 
effector memory-like or EMRA-like phenotype 
 
In CMV-seropositive individuals the majority of CD4+CD28null cells displayed either an EM or 
EMRA phenotype compared to CD4+CD28+ cells (Figure 3.3; Panels A/B versus Panels C/D; 
p<0.001). This confirms CD4+CD28null cells in CMV-seropositive individuals as a “late-
differentiated”, antigen-experienced population; this data is compatible with the concept 
that CD4+ cells lose surface CD27 and then CD28 during differentiation (4-8).  
 
CMV-seronegative recipients’ CD4+CD28null cells more commonly expressed CD27 than those 
from seropositive individuals, thereby displaying a ‘naïve-like’ or ‘CM-like’ phenotype. This 
pattern of loss of CD28 without loss of CD27 may represent recent CD4+-cell activation and 
temporary downregulation of CD28 in isolation, as previously suggested (16). This is shown in 
Figure 3.3 (panels E and F) which show data from CMV-seronegative patients excluding 
patients who experienced CMV infection in the first 12 months post transplantation (as 
described above); these data therefore demonstrate the ‘natural history’ of the (lack of) 
evolution of CD4+CD28null cells across the first-year post-transplantation in recipients who  
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Figure 3.3 Phenotype of CD4+CD28null and CD4+CD28+ cells according to donor-
recipient CMV serostatus pairing 
 Frequencies of naïve, central memory (CM), effector memory (EM) and effector memory re-
expressing RA (EMRA) cells within the CD4+CD28null and CD4+CD28+ cell populations are shown (as 
defined by CD27 and CD45RA co-expression; see methods). In CMV-seropositive recipients the 
majority of CD4+ CD28null cells display an EM-like or EMRA-like phenotype (A and B), contrasting with 
their phenotype in CMV-seronegative recipients (E and F), and also with the phenotype of CD4+ CD28+ 
cells from either seropositive or seronegative recipients (C, and D and G and H). Samples available and 
analysed for 100 patients pre-transplant, 94 patients at 14 days, 92 patients at 3 months, and 90 
patients at 12 months. Data normally distributed and displayed as mean and standard error. To 
demonstrate the “natural history” of the evolution of cell frequencies in CMV-seronegative patients, 
the data shown in Panels E through H exclude patients who were CMV-seronegative at the time of 
transplant and who developed evidence of CMV infection during the first-year post transplantation 
(total n=10 as described further in text). “Representative” flow cytometry readouts for the evaluation 
of CD4+CD28null cell phenotype are shown in Figures 3I and 3J. Figure 3.3I shows data from a CMV-
seropositive patient sampled at month 12 (CD4+CD28null cells comprised 4% of total CD4+ population); 
Figure 3.3J shows data from a CMV-seronegative patient also sampled at month 12 (donor CMV-
seronegative; no CMV disease, infection or seroconversion by 12 months; CD4+CD28null cells comprised 
0.6% of total CD4+ population). Although the results from CMV-seronegative patients are 
interpretable, results are not as robust as for the case of seropositive patients displaying higher CD4+ 
CD28null cell frequencies. 
 
were CMV-seronegative at the time of transplantation. It should be specifically highlighted 
that the low CD4+CD28null cell frequencies in CMV-seronegative patients means that the 
surface phenotyping results in these patients require cautious interpretation (representative 
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flow cytometry readouts for seropositive and seronegative patients are shown in Figures 3I 
and 3J respectively).  
 
We next analysed those CMV-seronegative patients who developed primary CMV infection 
during the first-year post-transplantation (described above and Figure 3.1B). In these 
patients, phenotype characteristics resembled those of CMV-seropositive patients, with an 
EM or EMRA phenotype in 44±8% and 31±6% of these patients at 12 months respectively. 
These proportions were greater than the proportion of EM or EMRA seen at baseline in these 
patients, and also greater than the proportions in CMV-seronegative patients who did not 
experience CMV infection during the first year (p<0.05 for all comparisons).  
 
CD4+CD28+ cells from CMV-seronegative and CMV-seropositive individuals displayed a similar 
phenotype as shown in Figure 3.3 Panels C/D and G/H (the latter again excluding patients 
experiencing CMV infection in the first 12 months post-transplantation). These described 
phenotype characteristics were stable during the first-year post-transplantation. 
 
3.4.5 CD4+CD27-CD28null cells display markers of endothelial homing and cytotoxic 
potential 
 
Further detailed immune phenotyping of CD4+CD28null and their comparator CD4+CD28+ cells 
were then undertaken. As CD4+CD28null cells were essentially limited to CMV-seropositive 
patients, phenotyping was undertaken 12 months post-transplantation in this group (49 
patient samples available from the 52 CMV-seropositive patients alive with graft function at 
12 months). As also described above, the majority of CD4+CD28null cells in CMV-seropositive 
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individuals display an effector-memory phenotype, whereas many CD4+CD28+ cells display 
naïve-or CM-like characteristics. Therefore, we compared specifically the flow cytometry 
characteristics of the effector-memory subsets of both cell types, i.e. CD4+CD27-CD28null 
versus CD4+CD27-CD28+ cells, with CD4+CD27-CD28null cells representing a later differentiated 
population of effector-memory cells. We did not attempt to differentiate EM and EMRA in 
these analyses.  
 
Of particular interest, CD4+CD27-CD28null cells displayed increased expression of the natural 
killer (NK) cell marker NKG2D and also of perforin. Figure 3.4A shows the gating strategy for 
these phenotype characteristics. Figure 3.4B shows the summary data for these and other 
surface phenotype characteristics for which differences between CD4+CD27-CD28null and 
CD4+CD27-CD28+ cells were seen. CD4+CD27-CD28null cells also displayed increased expression 
of the late-differentiation marker CD57. Another NK receptor, CD56, was also expressed at 
higher levels although the difference was not as marked as for NKG2D.  
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Figure 3.4A NKG2D expression, perforin release in CD4+CD28null and CD4+ CD28+ 
cells 
Example gating strategy and summary data demonstrating phenotypic comparison between 
CD4+CD27-CD28null and CD4+CD27-CD28+ cells in 49 CMV seropositive recipients alive with graft 
function at 12 months post-transplantation. Initial gating to define CD4+CD27-CD28null and CD4+CD27-
CD28+ cells was conducted as shown in Figure 3.1A. Figure 3.4A then demonstrates surface staining 
for NKG2D and intracellular staining for perforin in CD4+CD27-CD28null cells (lower panel), which was 
absent in the CD4+CD27-CD28+ compartment (upper panel). 
 
Furthermore, expression of the fractalkine receptor CX3CR1 was almost exclusive to 
CD4+CD27-CD28null cells, suggesting capability of homing to fractalkine-releasing inflamed 
endothelium. Of relevance to endothelial homing and tissue invasion potential was increased 
expression of CD11a (component of LFA-1) and CD49d (component of VLA-4) in the 
CD4+CD27-CD28null population.  It is worth noting that CD11a and CD49d may also act as co-
stimulation molecules as well as purely adhesion molecules (17, 18). CD4+CD27-CD28null cells 
also expressed higher levels of other co-stimulation receptors CD134 (OX-40) and CD137 (4-
1BB), albeit at low absolute levels in the resting state. 
 
In comparison, Figure 3.4C shows surface characteristics which did not differ between 
CD4+CD27-CD28null and CD4+CD27-CD28+ cells (p>0.05 for all comparisons). Specifically, 
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despite increased expression of NK markers on CD4+CD27-CD28null cells, expression of the 
Vα24Vβ11 TCR, which is characteristically expressed on iNKT cells, was low and comparable 
to that in CD4+CD27-CD28+ cells. No difference in expression of the lymph node homing 
molecule CD62L was seen between CD4+CD27-CD28null and CD4+CD27-CD28+ cells, in keeping 
with the effector-memory characteristics of both these cell subsets. Despite the “late 
differentiation” status of CD4+CD27-CD28null cells, expression of the inhibitory co-stimulation 
molecules KLRG-1 or PD-1, considered markers of T-cell “exhaustion”, was not increased. 
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Figure 3.4B Phenotypic differences and similarities between CD4+CD28null and 
CD4+CD28+ cells 
demonstrates summary data for those phenotype characteristics which differed between CD4+CD27-
CD28null and CD4+CD27-CD28+ cells (p<0.05 for all); Figure 3.4C demonstrates phenotyping 
characteristics where no difference was observed between these cell subsets. Data normally 
distributed and displayed as mean and standard error. 
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3.4.6 CD4+CD27-CD28null cells from CMV-seropositive transplant recipients 
proliferate in response to CMV lysate but not HLA-derived peptide 
 
CD4+CD27-CD28null and CD4+CD27-CD28+ cells were isolated from CMV-seropositive recipients 
12 months post-transplantation (n=10), and examined for their proliferative responses to 
irradiated autologous PBMCs alone (“control”), or PBMCs previously exposed to either CMV-
derived or HLA-derived peptides. Figure 3.5 demonstrates representative flow cytometry 
analyses (left panel) and summary data (right hand panels).  
 
Figure 3.5 Proliferation of CD4+CD28null and CD4+CD28+ cells from CMV positive 
patients 
Flow cytometric analysis demonstrating proliferation of CD4+CD27-CD28null and CD4+CD27-CD28+ cells 
from CMV positive renal transplant patients (n=10). Proliferation of CD4+CD27-CD28null and CD4+CD27-
CD28+ cells was evaluated by CFSE dilution. Cells were pulsed with irradiated autologous PBMCs 
previously exposed to either control culture media, CMV lysate, or HLA peptide. Example plots of flow 
cytometric analysis are displayed in left hand panel with summary data from the 10 subjects shown in 
right hand panel. Differences in proliferation across groups was seen (p<0.005 by Kruksall-Wallis), with 
proliferation of CD4+CD27-CD28null cells pulsed with CMV lysate significantly increased compared to 
either control (no antigen), HLA pulsed CD4+CD27-CD28null cells, or CD4+CD27-CD28+ cells pulsed with 
CMV lysate (p<0.01 for all post hoc comparisons; Mann-Whitney testing with Bonferroni correction). 
Data displayed as median (bars), interquartile range (boxes) and 10th-90th percentile (whiskers). 
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CD4+CD27-CD28null proliferation in response to CMV antigen was evident in all patients, 
whereas no response to HLA peptide was observed in any (p<0.01). Differences in 
proliferation across groups was seen (p<0.005), with proliferation of CD4+CD27-CD28null cells 
pulsed with CMV lysate significantly increased compared to either control (no antigen), HLA 
pulsed CD4+CD27-CD28null cells, or CD4+CD27-CD28+ cells pulsed with CMV lysate (p≤0.01 for 
all comparisons).  
 
The lack of proliferation of CD4+CD27-CD28null cells to HLA peptide was not a reflection of 
assay sensitivity, as CD4+CD27-CD28+ cells from 50% (5/10) of patients demonstrated 
proliferative responses to HLA-derived peptides (p=0.01). Interestingly, there was complete 
inter-patient concordance between this assay of CD4+CD27-CD28+ cell proliferation to HLA-
derived peptides and the responses in the IFN- ELISPOT assay (“raw” data not shown), with 
all 5 patients responding in one assay also responding in the other, and all 5 patients 
unresponsive in one assay being similarly unresponsive in the other (κ-statistic=1.0; p=0.008). 
 
3.4.7 Glomerular endothelial cell (GEnC) injury following exposure to CD4+CD27-
CD28null cells  
 
PBMCs from CMV-seropositive transplant recipients (n=4) were incubated for 16h in media 
alone (control) or with either CMV lysate or HLA peptide. Thereafter, 105 CD4+CD27-CD28null 
or CD4+CD27-CD28+ cells were isolated and incubated with GEnC for 6 hours.  
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Figure 3.6 Glomerular endothelial cell (GEnC) injury following exposure to CD4+ 
CD28null cells 
Glomerular Capillary Endothelial cells (GEnC) were incubated with 105 CD4+CD27-CD28null or 
CD4+CD27-CD28+ cells isolated from CMV positive renal transplant patients (n=4), incubated for 16h in 
media alone (Control) or stimulated with CMV lysate or HLA peptide prior to sorting. At 6 hours, 
release of vWF, release of fractalkine, and frequency of GEnCs expressing active caspase 3 was 
significantly different across experiments (Kruksall-Wallis p=0.001), and specifically increased 
following prior incubation of CD4+CD27-CD28null cells with CMV lysate compared to either control 
media, HLA peptide (p<0.05 for both comparisons in all experiments; Mann-Whitney testing with 
Bonferroni correction), and also compared with CD4+CD27-CD28+ cells pre-treated with either CMV 
lysate or HLA peptide (p<0.05 for both comparisons in all experiments; Mann-Whitney testing with 
Bonferroni correction). This effect was inhibited by incubation with an NKG2D blocking antibody 
during and two hours prior to the addition of CD4+CD27-CD28null cells (p<0.05 for all experiments; 
Mann-Whitney testing with Bonferroni correction). Data displayed as median (bars), interquartile 
range (boxes) and 10th-90th percentile (whiskers). 
 
Figure 3.6 demonstrates release of vWF and fractalkine from GEnC, and increased 
intracellular active caspase 3 expression within GEnC following incubation with CD4+CD27-
CD28null cells pre-exposed to CMV lysate. This was not seen with CD4+CD27-CD28null cells pre-
incubated with HLA-derived peptide, nor with CD4+CD27-CD28+ cells pre-incubated with 
either CMV-derived HLA-derived peptide (p<0.05 for all comparisons). Of particular note, all 
effects were attenuated by addition of NKG2D-blocking antibody to GEnC for 2 hours prior to, 
and then during their incubation with CD4+CD27-CD28null cells (p<0.05 for all comparisons).  
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3.4.8 Increased circulating CD4+CD28null cells are independently associated with 
delayed graft function and inferior medium-term allograft function  
 
CD4+CD28null frequencies immediately prior to transplantation were significantly associated 
with post-operative DGF. This relationship held when adjusted for baseline demographics, 
including donor/recipient CMV serostatus (multivariate model shown in Table 3.3). 
Graft failure was uncommon, and so not investigated as an outcome. However, eGFR at the 
end of follow up was associated with increased CD4+CD28null cell frequencies (averaged over 
follow-up), with 7.3ml/min lower eGFR for each log10 increase in CD4+CD28null cells in the 
multivariate analysis which included adjustment for DGF and also for peak hsCRP averaged 
over time (p=0.03; Table 3.3). No statistical interaction between CD4+CD28null cells and either 
DGF or acute rejection was seen for the eGFR endpoint. Results were similar when 
CD4+CD28null cell frequencies specifically at 12 months were analysed as the predictor variable 
(Beta = -7.8 (-14.9, -0.7); p=0.02). 
 
No association was found between CD4+CD28null cells (averaged over follow-up) and log-
transformed UACR at end of follow-up, or between baseline CD4+CD28null cells and time to 
acute rejection (final multivariate models shown in Table 3.3). 
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Table 3.3  Predictors of clinical endpoints 
 
 
Table 3.3 shows final multivariate model describing relationships between predictor variables 
and clinical outcomes. 
 
Effect size reported as 1 beta coefficient; 2 odds ratios; 3 hazards ratios 
*denotes detectable CMV DNAemia  
**de novo anti HLA donor-specific antibody 
 
 
 
 
 
 
 
 
126 
 
3.5 DISCUSSION 
 
This study represents a detailed, prospective, longitudinal examination of CD4+CD28null cells 
in unselected kidney transplant recipients. Our work demonstrates CD4+CD28null T-cell 
expansion is driven by inflammation on a background of latent CMV infection. CD4+CD28null 
cells isolated from kidney transplant recipients responded to CMV-derived antigens in vitro, 
but not to HLA-derived antigens. Detailed phenotyping of CD4+CD28null cells confirmed their 
late differentiation status and potential for endothelial adhesion, tissue invasiveness, and 
cytotoxicity. In addition, exposure of CD4+CD28null cells to glomerular endothelial cells in vitro 
resulted in NKG2D-dependent endothelial cell activation and apoptosis. This mechanism 
might plausibly explain the association between increased CD4+CD28null cells and important 
clinical endpoints such as DGF and eGFR 5 years post-transplantation. Taken together these 
data point to the importance of this cell subset in kidney transplantation, particularly in regard 
to “indirect” effect of CMV on kidney allograft function and outcome (1-3). 
 
Expansion of circulating CD4+CD28null cells is recognized for CMV-seropositive patients with 
ESRD (4). The current study extends the available evidence in kidney transplantation, again 
showing this circulating subset as “pathognomonic” of latent CMV at the time of 
transplantation. A novel finding is that episodes of significant inflammation are associated 
with subsequent expansion of CD4+CD28null cells. This resonates with increased CD4+CD28null 
cell frequencies in CMV-seropositive patients with ESRD (a state of chronic inflammation) (4), 
and in other autoinflammatory conditions (5-7). In CMV-seropositive recipients, no 
independent association between CD4+CD28null cell expansion and the development of prior 
CMV DNAemia was seen, suggesting the latter was not a “pre-requisite” for expansion of 
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these cells. One plausible explanation for this might be that episodes of inflammation drive 
“abortive” viral replication, whereby inflammation-induced dendritic cell expression of early 
viral antigens is not followed by overt viraemia (13), but might nevertheless incite an immune 
response (in this case CMV-specific CD4+CD28null cells). Regarding this, knowledge of specific 
viral proteins to which CMV-specific CD4+ cells respond would be informative, but is not 
currently available and was beyond the current study’s scope. But of relevance many healthy 
CMV-seropositive individuals control CMV effectively with a CD8+ T-cell repertoire 
predominantly directed against early-expressed viral proteins, rather than later structural 
components(19).  
 
The relationship between CD4+CD28null cells and CMV-serostatus is likely more than mere 
association, as purified CD4+CD28null cells (specifically CD4+CD27-CD28null cells) isolated from 
patients proliferated to CMV antigens in vitro. Importantly, CD4+CD27-CD28null cells 
demonstrated no evidence of HLA-alloreactivity, this being confined to the CD28-expressing 
CD4+CD27-CD28+ subset. The robustness of this important and novel finding is supported by 
the perfect concordance between this proliferation assay and IFN- release in a 
“confirmatory” ELISPOT assay, which is specifically relevant because previous studies showed 
the responding cells in this ELISPOT assay also demonstrate an EM-like CD4+CD28+ phenotype 
(20, 21).  
 
Further detailed immune phenotyping was undertaken on samples available 12 moths post 
transplantation. And so, although the temporal dynamics of the findings cannot be assessed 
(and was not a primary aim of the study), we can confirm CD4+CD27-CD28null cells as late-
differentiated (expressing CD57), effector memory cells with increased cytotoxic potential 
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(expressing NKG2D and perforin). They express very low levels of the lymph node homing 
receptor CD62L, but high levels of the receptor for fractalkine (a chemokine of endothelial 
origin) along with increased expression of adhesion molecules, collectively suggesting 
capabilities of endothelial homing and tissue-invasiveness.  
 
Increased CD4+CD27-CD28null expression of fractalkine receptor (CX3CR1) makes biological 
sense regarding CMV cellular immunity, as endothelium is a key site of CMV latency and 
reactivation (22). However, the current study suggests that an unwanted consequence of 
CMV immunosurveillance may be development of endothelial injury, which was mediated by 
CD4+CD27-CD28null cells in vitro. Preincubation of PBMCs with CMV antigen was required to 
induce this injury, which was mitigated by addition of NKG2D-blocking antibody. This NK 
receptor represents an integral component of CMV immunosurveillance and immunoevasion 
(23), was upregulated on CD4+CD27-CD28null cells isolated from patients in the current study, 
and we propose as an important component of the cytotoxic effects (either protective or 
pathogenic) of these cells. Indeed HUVEC injury by CD4+CD28null cells in the context of 
coronary disease is independent of conventional T-cell receptor ligation (9), and so the current 
study extends these observations specifically to glomerular endothelial injury, highlighting 
the importance of CMV and NKG2D in the process. Although not specifically addressed in the 
current study, it is recognized that human endothelial cells express NKG2D ligands (24), and 
it is likely (albeit unproven) that the same holds for GEnC. These results also align with other 
broader observations (from non-transplant cohorts) including induction of NKG2D on CD4+ 
cells exposed to CMV antigen (10, 11), degranulation of NKG2D-expressing CD4+ cells in the 
presence of endothelial cells (24), endothelial fractalkine release following exposure to CD4+ 
cells from CMV-seropositive individuals (albeit not further characterised phenotypically) (25), 
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and CMV-induced endothelial damage in a rodent model which is independent of endothelial 
infection (26).  
 
The use of GEnC is relevant as these glomerular cells display unique structural and functional 
properties which are not shared by endothelial cells of different vessels, anatomical locations, 
or species (27). The conditionally immortalized cells (“ciGEnC”) used in this study retain 
similar morphological and physiological characteristics as primary culture human GEnC (27), 
and therefore give informative insights into events occurring in vivo. Indeed a major 
component in the pathogenesis of both DGF and chronic allograft dysfunction is endothelial 
injury (28, 29), and therefore the mechanism of endothelial injury described above may 
explain the independent associations between CD4+CD28null cell expansion at baseline and 
the development of DGF, and also between CD4+CD28null cell numbers during the first year 
post-transplantation and renal function at 5 years post-transplantation. Further insight into 
this may be gained from detailed histological evaluation, which might demonstrate precise 
anatomic localization of CD4+CD28null cells, and also further characterize their phenotype, 
specifically in regard to whether they represent a subpopulation of CD4 tissue-resident 
memory cells. This will be the focus for future work. 
 
Although sampling was not continued beyond the first year, the intensive protocol and 
detailed phenotyping conducted during this critical period adds robustness and relevance to 
these findings, which are novel to transplantation but resonate with the inverse association 
between circulating CD4+CD28null cells and renal function in a cross sectional study of stable 
patients with renal vasculitis (6). This link between CMV, inflammation (discussed above) 
cytotoxic CD4+CD28null cell expansion, endothelial injury and allograft dysfunction may 
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contribute to explaining the well-recognised but incompletely understood association 
between inflammation and graft outcome (30, 31), and may even go towards explaining the 
so-called “transplant paradox” whereby improvements in acute rejection rates have not been 
mirrored by long-term improvement in graft survival (32).  
 
In summary, this study reveals that expansion of CMV-related, cytotoxic CD4+CD28null cells is 
an important biomarker for, and potential mediator of, adverse events following kidney 
transplantation. Interventions to avoid and reduce CMV infection (33) and potentially novel 
strategies to interfere with CD4+CD28null cell toxicity (34) may result in further improvements 
in allograft outcome. 
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4.1 ABSTRACT 
 
Increasing human longevity has prompted increasing attention towards the clinical 
importance of T-cell immunosenescence, and it has been suggested that cytomegalovirus 
(CMV) infection may drive this phenomenon. In this study we longitudinally and repeatedly 
examined a cohort of one hundred kidney transplant recipients from the time of 
transplantation, focussing on identifying the most informative phenotypic markers of 
immunosenescence, establishing the potential link between CMV and immunosenescence 
and determining the impact of immunosenescence upon the incidence of infectious 
complications.  We also examined the relationship between T-cell immunosenescence and 
innate immunity (neutrophil function) in vitro.  Our results show CD8+CD28null cell frequencies 
as a robust, plausible and convenient marker of “immunosenescence”, with CMV latency and 
post-transplant CMV infection associated with increased CD8+CD28null cell frequencies. In 
turn, increased CD8+CD28null cell frequencies were associated with increased risk of clinically-
relevant infection episodes post-transplantation, with some evidence of an association with 
reduced rejection rates; this marker of T-cell immunosenescence was associated with 
impaired neutrophil migration in vivo, suggesting a potential mechanism for these 
relationships.  In summary, this work suggests an important role of CMV in shaping the 
underlying immune architecture of transplant recipients, and impacting on ‘downstream’ 
clinical events. Further understanding of these complex virological and immunological 
relationships may ultimately lead to informed improvements in clinical care. 
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4.2 INTRODUCTION 
 
With increases in human longevity, aging of the immune system (‘immunosenescence’) has 
received increased attention. Although no consensus definition based on such cell 
phenotypes has been developed to date, immunosenescence is characterised by 
accumulation of memory T cells, including late differentiated CD8+ cells which as a response 
to chronic antigenic stimulation may lose expression of the costimulatory molecule CD28 
(‘CD8+CD28null ’ cells) or regain expression of CD45RA (effector memory re-expressing RA; 
‘EMRA’)[1, 2]. Because this effect of chronic antigenic stimulation is quantitatively far greater 
in the CD8 compartment then the CD4 compartment, a further phenotypic feature of T-cell 
immunosenescence is an inverted CD4:CD8 ratio. Finally, the accumulation of memory cells 
relative to naïve cells, coupled with reduced thymic output of naïve cells with aging, may 
result in an increased memory: naïve cell ratio within the CD8 compartment [1-3].  
 
These markers of immunosenescence have clinical correlates in the general population, and 
specifically are associated with increased risk for infection and mortality, and a reduced 
vaccine response [4-8]. Perhaps best-recognised are a series of studies of elderly Scandinavian 
individuals where a so-called ‘immune risk profile’ (‘IRP’), a key component of which is 
accumulation of circulating CD8+CD28null cells, is associated with these adverse clinical 
sequelae [5, 9-11].  
 
Human cytomegalovirus (CMV) is characterised by lifelong latency following initial infection, 
and during that time periods of intermittent (but limited) reactivation. CMV elicits a 
particularly profound CD8 immune response, with expansion of CMV-specific memory CD8 
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cells, such that in certain individuals up to 50% of circulating CD8 cells may display CMV 
specificity, and up to 20% may be specific even for a single viral protein, sometimes 
demonstrating clonal expansion [12]. This dramatic immune response, known as ‘memory 
inflation’ is not shared by other chronic viral infections [13, 14], and is also characterised by 
accumulation of late-differentiated CD8+CD28null and CD8 EMRA subsets as part of this 
ongoing chronic antigenic stimulation [15].  
 
It has therefore been suggested and increasingly accepted, that CMV infection is a major 
driver of the immune phenotype characteristic of immunosenescence, and this topic has been 
the subject of a number of reviews and International workshops [14–18]. It is also realised 
that children and young adults infected with CMV may also display similar cell phenotypes, 
thereby extending the concept of immunosenescence from aging per se to a more generalised 
phenomenon [19]. Yet despite this, data within the field of transplantation remains limited. 
The link between CMV and the immunosenescence phenotype is not clearly established in 
transplantation, although a recent study demonstrated expansion of CD8+CD28null cells in 11 
kidney transplant recipients experiencing primary CMV infection [20].  And whilst the effect 
of age in determining outcomes of kidney transplantation has been detailed in numerous 
epidemiological studies, the role of immunosenescence (based on cell phenotype 
characteristics) has received little attention. Increased frequencies of CD8 EMRA and 
CD8+CD28null cells at the time of transplantation have been associated with freedom from 
early biopsy-proven acute rejection [21, 22]; CD8 EMRA frequencies were also associated with 
(a trend towards) increased risk of graft dysfunction over the long term in prevalent patients 
[23]. In a cross sectional ‘extended phenotype’ study, CD8+CD28null cell frequencies were 
higher in patients with histological lesions of ‘chronic rejection’ in comparison to those with 
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drug-free operational tolerance [24]. Surprisingly only one (very recent) study addressed 
infection as an endpoint, with no association found between CD8+CD28null cell frequencies or 
CD4:CD8 ratio and episodes of infection [25]. These studies of transplant cohorts 
understandably addressed the ‘transplant-specific’ end measures as described; the potential 
role of CMV in driving the studied markers of immunosenescence was not a focus in most of 
these particular studies. 
 
Finally, an increasingly recognised phenomenon is immunosenescence of the innate immune 
system, in particular abnormalities of neutrophils which represent the most abundant 
circulating immune cell and a first line of defence against pathogens [26, 27]. Yet far less work 
has been undertaken in this area compared with T-cell immunosenescence, and is lacking in 
the field of transplantation. Overviews of this subject in transplantation to date have 
necessarily extrapolated data from non-transplant settings [28-30].  
 
In this study we longitudinally and repeatedly examined a cohort of kidney transplant 
recipients from the time of transplantation, focussing on identifying the most informative 
single cell-phenotype marker of immunosenescence, establishing the link between CMV and 
immunosenescence, and then the relationship between immunosenescence and episodes of 
infection as an important and relevant endpoint in transplantation. We conclude that 
CD8+CD28null cells represented the best marker of immunosenescence in the studied cohort, 
and that pre-transplant CMV latency, and post-transplant CMV infection are associated with 
such increased CD8+CD28null cell frequencies. Furthermore, increased CD8+CD28null cell 
frequencies are associated with subsequent episodes of clinically relevant infection and also 
with impaired neutrophil migration characteristics in vitro. This work has informed the 
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understanding of the risk factors for, biomarkers of, and potential mechanism of 
immunosenescence and infection in the context of transplantation.  
 
4.3  RESULTS 
4.3.1 Clinical outcomes 
 
The clinical cohort is described in Table 4.1; median follow-up from transplantation was 54 
months (range 2-60 months). Three patients died (from sepsis), and four lost their grafts 
(primary non-function, early acute rejection, recurrent disease, late [14 months] acute 
rejection). For the remaining patients, mean eGFR at the end of follow-up was 
52±17ml/min/1.73m2, and median UACR was 2.6 mg/mmol (IQR:1.0-6.6; range 0.3-280). 
Twenty-three patients experienced DGF, and twenty-five biopsy-proven acute rejection 
(≥Banff grade 1).  
 
Clinical and standard laboratory data pertinent to the study was available for all patients at 
all timepoints; immunophenotyping analyses were complete for >95 of patients (who were 
alive with graft function) across timepoints; CMV cell-mediated immunity assays were 
undertaken at 12-months post-transplantation, and were available in 70 patients (some 
samples unavailable for analysis for technical reasons related to collection and storage). 
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Table 4.1 Patient demographics and clinical outcomes 
 
 
1 Donation after Brain Death 
2 Donation after Cardiac death 
3 Requirement for dialysis within the first week post transplantation 
4 Denotes the development of anti-CMV antibody in patients who were seronegative at the time of 
transplantation with or without the detection of CMV DNA in blood on either protocol or indication 
sampling (see text for details) 
5 Denotes the development of symptomatic CMV disease requiring clinical intervention 
6 Urinary Tract Infection shown for completeness, but excluded from analysis due to rationale 
described in ‘methods’, i.e. likelihood that UTI is more related to surgical/ureteric/anatomical factors 
rather than the immunological architecture 
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4.3.1.1 Immunophenotyping shows CD8+CD28null cell frequencies as a robust 
marker of “immunosenescence” 
 
Representative flow cytometry results for the investigation of the candidate markers of 
immunosenescence are shown in Figure 4.1. Cluster analysis using samples from patients 12 
months following transplantation is shown in Table 4.2 (similar results for the cluster analyses 
were observed for other timepoints; data not shown). This revealed CD8+CD28null cell 
frequency as the most robust marker of immune senescence (Table 4.2). In turn, recipient 
CMV seropositivity was associated with frequencies of CD8+CD28null cells (p=0.02; Table 4.3). 
In-vitro T-cell response to the CMV-derived peptide IE-1 was also significantly (p=0.013) 
associated with the frequency of CD8+CD28null cells. There was no significant association with 
the CMV-derived peptides pp50 and pp565 (p=0.91, p=0.32 respectively).  
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Figure 4.1 Flow cytometry gating strategy for CD8+CD28nulls cells 
Representative flow cytometry plots displaying gating strategy to determine cell surface phenotype-
based characteristics of putative markers of immunosenescence. Lymphocyte population identified 
within total PBMC population based on viability and CD3 staining (panel 1). CD4+ and CD8+ subsets 
identified from total lymphocyte population based on CD4 and CD8 surface staining (panel 2). 
CD4+:CD8+ ratio calculated accordingly (panel 2). Gating for CD28 within CD8+ population identifies 
CD8+ CD28null population of interest (panel 3). Identification of CD8+ differentiation status based on 
CD27 and CD45RA surface staining allows calculation of i] CD8+ memory: naïve ratio and ii] CD8+ EMRA 
frequencies (panel 4) 
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Table 4.2. Cluster analysis identifying most relevant marker of immune-
senescence   
 
 
Data shown for 90 patients with immunophenotyping samples available 12 months post 
transplantation; results reported as Geometric Mean (95% Confidence Interval); 1 CD8+CD28null and 
CD8 TEMRA frequencies reported as percentage of total CD8 cells; 2 B-cell frequencies reported as 
percentage of total PBMCs 
 
Table  4.3. Relationship between immunosenescence clusters and CMV antibody 
and cell-mediated responses. 
 
 
Data reported in 70 patients with available samples (immunophenotyping coupled with measures of 
CMV antibody and cell-mediated immune [CMI] response assays) 12 months post-transplantation; 
CMI assay results presented as median (interquartile range); p-values from Fisher’s Exact test or 
Mann-Whitney test for antibody and CMI assay results respectively. 
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4.3.1.2 CMV latency and post-transplant infection are associated with Increased 
CD8+CD28null cell frequencies  
 
Having established CD8+CD28null frequencies (as a proportion of total CD8 cells) as the marker 
of immune senescence carrying most ‘weight’ in the cluster analysis, we proceeded to 
evaluate the determinants of these cell frequencies over time, paying particular attention in 
the first instance to the relationship with CMV serostatus.  
 
CD8+CD28null frequencies were normally distributed, and in all tested samples in all patients 
the mean cell frequencies were 44.7±20.9, expressed as a proportion of total CD8 PBMCs 
(median 43%; range 8-94%). Table 4.4 demonstrates the evolution of this cell subset in the 
entire population, and then in subgroups according to donor/recipient CMV-serostatus 
pairing. The key features of this data are summarised as follows: 
 
i] Pre-transplantation, CD8+CD28null frequencies are higher in transplant recipients who are 
CMV-seropositive (ANOVA p=0.001). 
 
ii] This relationship with recipient CMV-seropositive status is maintained over time (i.e. these 
differences are observed at all subsequent timepoints; p<0.01 for all) 
 
iii] There is a statistically significant, although relatively modest, increase in CD8+CD28null cell 
frequencies in CMV-seropositive recipients in the first 2 weeks following transplantation, with 
subsequent stabilisation of cell frequencies at later time points (p=0.03 for -/+ and +/+ CMV-
serostatus pairings; repeated measures ANOVA) 
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iv] No such effect is seen in CMV-seronegative recipients of kidneys from CMV-seronegative 
donors (-/-), where cell frequencies do not change over time. 
 
v] In CMV-seronegative recipients of kidneys from CMV-seropositive donors (+/-), and 
considering this group in entirety, CD8+CD28null cell frequencies increase over time (p=0.01, 
repeated measures ANOVA). More specifically, cell frequencies do not change over the first 3 
months post-transplantation, but then rise by 12 months post-transplantation (post hoc 
p<0.01 for all comparisons with 12-month values) 
 
vi] This effect is related to whether these CMV-seronegative recipients experience CMV 
seroconversion (i.e. whether they develop clinically evident or subclinical CMV infection). 
Specifically, in patients not experiencing CMV-seroconversion, cell frequencies do not change 
over time; serial cell frequencies in this group are no different to those seen in the    -/- group. 
In contrast, CMV-seronegative patients (at the time of transplantation) experiencing 
subsequent CMV-seroconversion display a marked increase in CD8+CD28null cell frequencies 
by 12 months post-transplantation, with values not distinguishable from (and in fact 
numerically slightly higher than) those seen in CMV-seropositive individuals at the equivalent 
timepoint (p<0.01 for all analyses). 
 
Regression analysis was undertaken to evaluate the independent relationship between CMV 
serostatus and CD8+CD28null frequencies, and to investigate other potential predictors. The 
results are shown in Table 4.5, and demonstrate that when compared with D-/R- 
transplantation, the other serostatus combinations were associated with increased cell 
frequencies. This effect was especially marked in the CMV-seropositive recipients. In addition, 
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the development of CMV infection (i.e. detectable viraemia with or without clinically evident 
CMV disease, or in the case of CMV-seronegative recipients evidence of seroconversion at 12 
months post-transplant) was also associated with increased CD8+CD28null cell frequencies. 
These associations both held in the analysis adjusted for the other predictor variables shown 
in Table 4.5.  
 
Renal function (eGFR) was not modelled in this primary analysis in light of the difficulties with 
ascribing values to patients with ESRD prior to transplantation. However, secondary analyses 
in which eGFR values of 0ml/min or 5ml/min were entered for patients requiring dialysis (prior 
to or early after transplantation) showed no association between renal function and 
CD8+CD28null cell frequencies (univariate p>0.05 for both). In addition, post-transplant 
delayed renal allograft function and time post-transplant (other possible ‘surrogates’ for renal 
function) were associated with increased cell frequencies on univariate analysis in the primary 
model, but these did not hold in the adjusted model. 
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Table 4.4 Evolution of CD8+CD28null cell frequencies according to donor/recipient 
CMV-serostatus pairing 
 
 
CD8+CD28null frequencies described as a proportion of total CD8+ cells; data normally distributed and 
presented as mean (standard deviation); 1 repeated measures ANOVA across 
serostatus/seroconversion groupings 
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Table 4.5 Regression analysis describing determinants of CD8+CD28null cell 
frequencies  
 
 
Determinants of CD8+CD28null cell frequencies (expressed as proportion of total CD8+ cells) 
investigated by linear regression analysis adjusted for repeated measures; PD=peritoneal dialysis; 
HD=haemodialysis; PRE=pre-emptive transplantation; HLA=human leucocyte antigen; Ag=antigen; 
hsCRP=high sensitivity C-reactive protein  
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In summary, the CMV-serostatus of recipients at the time of transplantation, and the 
development of CMV infection following transplantation, have a profound effect on 
CD8+CD28null cell frequencies, with strong and independent associations of positive recipient 
serostatus and subsequent infection and increased cell frequencies. 
 
4.3.1.3 Higher CD8+CD28null cell frequencies are associated with increased risk of 
infection 
 
A significant number of patients developed clinically-relevant infection following 
transplantation (Table 4.1). Episodes of infection within 2 weeks of transplantation, and 
urinary tract infections at any time, were excluded for reasons described in ‘methods’. The 
clinical events of this analysis therefore represented 17 patients experiencing lower 
respiratory tract infections, 5 with gastrointestinal infections, 2 with fungal infections, and 20 
with other miscellaneous infections (these included pilonidal abscess, skin infections, breast 
abscess and bacterial peritonitis). Asymptomatic cytomegalovirus infection occurred in 
eighteen patients whilst seven patients developed clinical disease. As discussed in ‘methods’ 
these CMV infections were considered potential predictors of infection, rather than episodes 
of infection in themselves. 
 
On multivariate analysis (Cox model with time-dependent modelling), higher CD8+CD28null cell 
frequencies were independently associated with increased risk of infection (p=0.005; Table 
4.6). Delayed graft function was also associated with increased risk of infection in the final 
model (p=0.006). Recipients who were CMV-seropositive at the time of transplantation were 
at increased risk of infection (compared with CMV-seronegative individuals, and irrespective 
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of donor CMV antibody status) on univariate analysis (p=0.03), but this did not hold in the 
final model adjusted for cell phenotyping characteristics.  
 
Although CD8+CD28null frequencies were analysed as a time-dependent variable in the formal 
statistical analysis, a more intuitive representation of the relationship with infection is shown 
in Figure 4.2, which demonstrates the relationship between mean CD8+CD28null frequencies 
over the duration of the study and the risk of infection. Higher mean cell frequencies were 
associated with greater risk of clinically-relevant infection at any time following 
transplantation when considered as a continuous measure (Figure 4.2A), and with reduced 
time to infection with mean values above the lowest tertile (CD8+CD28null frequency>30% of 
total CD8 cells; Figure 4.2B).  
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Figure 4.2 CD8+CD28null cell frequencies and risk of clinically relevant infection 
Relationship between mean CD8+CD28null cell frequencies (average value for all results in an individual 
across the duration of the study and expressed as a proportion of total CD8+ cells), and the risk of 
clinically relevant infection at any time during the duration of the study. Figure 4.2A shows the 
regression line representing the relationship between risk of infection and mean CD8+CD28null cell 
frequencies. Shaded area represents 95% confidence interval around the point estimate. Average 
CD8+CD28null cell frequency of 44% (of total PBMC) used as ‘baseline’ value. Figure 4.2B demonstrates 
relationship between time to first infection and tertiles of mean CD8+CD28null cell frequencies 
(averaged across the duration of the study) 
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Table 4.6  Regression analysis describing relationship between CD8CD28null cell 
frequencies and time to clinically-relevant episodes of infection following 
transplantation. 
 
 
Time to first clinically-relevant infection following kidney transplantation investigated by Cox 
regression adjusted for repeated measures for time-dependent variables; PD=peritoneal 
dialysis; HD=haemodialysis; PRE=pre-emptive transplantation; HLA=human leucocyte 
antigen; Ag=antigen; hsCRP=high sensitivity C-reactive protein  
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4.3.1.4 Higher CD8+CD28null cell frequencies are associated with impaired 
neutrophil migration but not with neutrophil function 
 
Higher CD8+CD28null cell frequencies were associated with impairment of the four neutrophil 
migration parameters of speed, velocity, chemotactic index, and persistence (p<0.02 for all). 
Figure 4.3 (A-D) shows the relationship between increased CD8+CD28null cell frequencies and 
impairment of these 4 parameters of neutrophil migration. Recipient age was not associated 
with these migration parameters (p>0.05 for all).  
 
No association between CD8+CD28null cell frequencies and either bactericidal function 
(phagoburst test) or phagocytic function (phagotest) was evident (p=0.92 and 0.67 
respectively).  Neither was there an association between CD8+CD28null cell frequencies and 
the production of NETS (p=0.72).  
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Figure 4.3 CD8+CD28null cell frequencies and in vitro neutrophil migration 
characteristics 
Figure 4.3 displays the relationship between circulating CD8+CD28null cell frequencies and in vitro 
neutrophil migration characteristics in a subset of 30 patients studied 20±3 months post-
transplantation. Neutrophil migration characteristics were evaluated as (A) average cell speed of the 
distance travelled between frames in any direction over time, (B) average cell velocity in a consistent 
direction toward the chemoattractant, (C) persistence, and (D) chemotactic index (accuracy).  
 
 
4.3.2 Other clinical endpoints  
 
Secondary analyses investigated the relationship between CD8+CD28null frequencies and time 
to biopsy-proven acute rejection (BPAR), and also with renal function (eGFR) and proteinuria 
(UACR) at the end of the study. Cox regression revealed some evidence of an effect, with 
higher cell frequencies associated with lower risk of BPAR (HR: 0.80, 95%CI: 0.62-1.05; 
p=0.09). For the analysis of eGFR and UACR at the end of study follow-up, linear regression 
was used with mean CD8+CD28null frequencies over the duration of the study as the predictor 
variable. No association between cell frequencies and either of these end measures was 
evident (p=0.98 and p=0.99 respectively).  
 
 
157 
 
4.4 DISCUSSION 
 
The increase in human longevity has prompted closer evaluation of the aging immune system, 
and has resulted in the concept of immunosenescence and its clinical sequelae. However, 
immunosenescence is not necessarily only relevant to aging populations, but also for younger 
individuals and those with a variety of chronic conditions. The current study addresses the 
determinants and consequences of immunosenescence in the context of kidney 
transplantation, extending the limited data available hitherto. Specifically, we demonstrate 
the importance of circulating CD8+CD28null frequencies as a valuable marker of 
immunosenescence in this context. By tracking patients serially, we identify the importance 
of CMV latency prior to transplantation, and then CMV infection post-transplantation, as 
major determinants of progressive immunosenescence. We show a temporal association 
between elevated CD8+CD28null frequencies (the immunosenescence phenotype) and the 
subsequent development of clinically relevant episodes of infection following kidney 
transplantation. Finally, we demonstrate dysfunction of the innate immune system 
(specifically abnormal neutrophil migration) as a potential mechanism by which 
immunosenescence predisposes to such infective episodes. 
 
There is no established optimal marker for T-cell immunosenescence, and previous studies in 
the transplant and non-transplant cohorts have used different cell subsets as markers of this 
phenomenon. We performed cluster analysis to define (at least in our cohort) which cell 
subset(s) were associated with, and contributed most to the overarching immunosenescence 
phenotype. Of the previously described markers of immunosenescence (the rationale for 
which are described in the ‘introduction’), it was frequencies of ‘late differentiated’ 
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CD8+CD28null cells which contributed most information. Whilst we cannot attest to the 
generalisability of this specific result, it certainly aligns with data from non-transplant cohorts, 
where the same subset represents a key component of the immune risk profile of elderly 
people [10, 11]. It is also this subset that has received attention in transplantation in regard 
to its potential association with rejection and with tolerance [22, 24]. We therefore contend 
it is an intuitive and reasonable cell subset to study in regard to the drivers towards, and 
consequences of immunosenescence in transplantation. 
 
“Indirect’ effects of CMV, as opposed to the ‘direct’ clinical syndrome(s) of CMV infection and 
disease, are well recognised but ill-understood [31], and the current study suggests that CMV-
driven immunosenescence may represent a pathway towards such effect(s). Cluster analysis 
demonstrated an association between immunosenescence and both antibody and cell-
mediated responses to CMV and its peptides. It is recognised that CMV IE-1 peptides, which 
in vivo are expressed only intracellularly, elicit a particularly strong CD8 response [32], 
probably resulting from frequent ‘abortive reactivation’ and repeated presentation of 
intracellular antigens such as IE-1 [33, 34]. Expansion of cells specific for such ‘inflationary’ 
epitopes results in expansion and accumulation of late-differentiated cells, notably including 
CD8+CD28null cells [35]. Furthermore, when patients in the current study were serially 
evaluated, it was pre-transplant CMV latency (i.e. recipient CMV-seropositivity) and post-
transplant CMV infection that were associated with CD8+CD28null cell expansion. 
Consequently, we observed CD8+CD28null frequencies rise during the first-year post 
transplantation, in particular between 3 and 12 months, and especially (but not exclusively) 
in CMV-seronegative recipients of CMV-seropositive donors. This kinetic is similar to that seen 
in a previous study by Meijer’s [36], although the emphasis there was the lack of improvement 
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in immunosenescence phenotype post-transplantation, and the role of CMV was not 
examined. However the same authors more recently went on to describe the expansion of 
circulating CD8+CD28null cells in 11 kidney transplant recipients experiencing primary CMV 
infection [20], a finding which aligns with the results from the current study.  Whilst we do 
not suggest that immunosenescence is an entirely CMV-driven process, it is clear that CMV is 
an important contributor to the phenotype in this context. We found no association between 
CD8+CD28null cell frequencies and other potential determinants, in particular renal function 
and age, albeit in a cohort with a mean age of 47 years and a (relatively) narrow range in 
comparison with previous studies across age groups. 
 
In the next analysis we demonstrated increased CD8+CD28null frequencies were associated 
with development of clinically relevant episodes of infection following the initial post-
transplant period, with a ‘dose-dependent’ association between this biomarker of 
immunosenescence and outcome. This effect was independent of other clinically relevant 
covariates, including CMV-serostatus, which showed an association with infection on 
univariate analysis, but not in the model adjusted for this biomarker of immunosenescence. 
We acknowledge the described associations only strictly pertain to the time-course of the 
study, and cannot state whether the relationship would hold at later times following 
transplantation. We also accept that episodes of significant infection might have been missed 
if the patients presented elsewhere to our unit. However, in light of the geographical 
architecture and follow-up arrangements within our practice, we suggest that most episodes 
of hospitalisation would be at our parent unit, and it is unlikely that minor ascertainment bias 
would influence the conclusions of the study. Finally, in regard to the clinical outcome data in 
the current study, it was interesting to see a relationship between immunosenescence and 
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reduced risk of biopsy-proven acute rejection. This association did not reach statistical 
significance in the current study, but is worthy of mention in light of the similar results from 
Betjes suggesting immunosenescence may also impact on the allo-immune response [21]. We 
must also highlight the seemingly contrasting results of the current study, and the most recent 
study from the same group, the latter demonstrating no association between CD8+CD28null 
frequencies and post-transplant infection [25]. The 2 studies (which together represent the 
first examinations of the subject) are similar in many regards (year of enrolment; 
immunosuppression; infection frequency; CD8+CD28null frequencies) that simplifies 
comparison. But a major difference is that Dedeoglu and colleagues considered all infections 
(including many mild infections), urinary tract infection (which we excluded with the rationale 
described previously), CMV viraemia and disease (which we consider a major determinant of, 
rather than a consequence of immunosenescence). Patients with severe rejection, who 
received lymphodepletion were excluded, thereby removing one source of bias, but perhaps 
introducing another. We also believe our statistical approach with time-dependent modelling 
is a more robust and powerful way to investigate such clinical series. Ultimately what seems 
clear is that further study is required for this important aspect of transplantation. 
 
It is proposed, and widely accepted, that immunosenescence exerts its deleterious 
consequences as a result of expansion of the circulating CD8 memory compartment, thereby 
restricting the ‘space’ for new memory cells (‘memory cell attrition’), and also by constraining 
the naïve CD8 cell compartment [16, 37-39]. But there are conceptual issues, and also clinical 
discrepancies, which question this paradigm: of the 1011 T cells within the human body, only 
a small fraction circulate within blood [40]; the CMV-associated immune phenotype in blood 
is not mirrored within lymphoid tissue, the major site of the immune response [41]; the 
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memory response to repeated antigenic challenge may be additive rather than fixed [42], and 
is characterised by considerable cross-reactivity to varied antigens and epitopes [43]; clinical 
data from the Leiden Longitudinal Study of unselected individuals aged >85 years 
demonstrated lower (rather than higher) naïve CD8 frequencies were associated with 
improved subsequent survival [44], and it should also be remembered that reduced naïve cell 
frequencies was not associated with the immune risk phenotype of a general aging population 
[5, 9-11].  
 
On that basis, we examined the relationship between T-cell immunosenescence and innate 
immunosenescence, the latter in specific regard to neutrophil function for the first time in 
transplantation. Innate immunosenescence is characterised by defects in neutrophil 
migration and (less consistently) neutrophil cytotoxicity [26, 27]. We found no association 
between CD8+CD28null frequencies and any studied marker of neutrophil degranulation or 
NET formation, but did find associations with all four studied neutrophil migration 
characteristics. This is relevant in light of the association between abnormal neutrophil 
migration in vitro and adverse clinical outcome in other settings [45, 46]. Larger series 
involving repeated neutrophil analysis are now required to expand and refine this pilot data 
from transplantation. The mechanism for impaired neutrophil migration, whilst outside the 
scope of the current study, may involve epigenetic changes secondary to chronic neutrophil 
activation through pattern recognition and cytokine receptors [47, 48], resulting in changes 
to the PI3 kinase pathway which is crucial for directional migration [49, 50]. Finally, 
preliminary data suggesting impaired neutrophil migration may be modifiable [50, 51], sets 
the scene for further investigation in transplantation, where infection is such a key 
determinant of outcome. 
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In summary, we suggest an important role of CMV (one component of the ‘virome’) in shaping 
the underlying immune architecture, and specifically contributing to the phenomenon of 
immunosenescence in the context of transplantation. We identify CD8+CD28null cell 
frequencies as a robust, plausible and straightforward biomarker for this complex phenotype, 
and demonstrate clinical relevance in its association with transplant-associated infection. We 
propose the potential importance of neutrophil dysfunction in this context, and envisage that 
further understanding of these complex relationships will inform and improve clinical care. 
 
4.5 CONCISE METHODS 
4.5.1 Clinical Cohort  
 
One hundred unselected recipients of solitary kidney transplants were enrolled into this 
prospective study during 2009. All patients underwent transplantation and follow-up at 
Queen Elizabeth Hospital Birmingham.  Local ethics committee approval was granted for the 
study (08/H1204/103), which was performed in accordance with the Declaration of Helsinki. 
 
4.5.2 Demographic data and protocol  
 
Baseline donor and recipient information was collected prior to transplantation (Table 4.1): 
donor and recipient age, sex and CMV (cytomegalovirus) status, recipient race, recipient 
cause of renal failure, donor-recipient HLA mismatch (class I and class II), source of transplant 
(live related; live unrelated; deceased donor following brain death [DBD]; deceased donor 
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following cardiac death [DCD]); dialysis modality prior to transplantation (pre-emptive versus 
haemodialysis versus peritoneal dialysis). 
 
Transplantation proceeded provided the cross match between donor and recipient was 
negative by cytotoxicity and flow cytometry. Immunosuppression regimen was identical for 
all participants, and consisted of Basiliximab induction followed by maintenance tacrolimus 
(Prograf; pre-dose level 5-8ng/ml measured by liquid chromatography-tandem mass 
spectrometry), mycophenolate mofetil (Cellcept; 2g daily) and prednisolone (20mg daily; 
reducing to 5mg maintenance by 3 months post transplantation).  
 
4.5.3 Clinical data post-transplantation 
 
Data on delayed graft function, acute rejection, infection, estimated glomerular filtration rate 
(eGFR) and proteinuria evaluation were collected post-operatively and at each clinic review. 
Delayed graft function (DGF) was defined as dialysis requirement during the first post-
operative week; acute rejection was biopsy proven in all cases (BPAR) and classified according 
to the Banff schema; significant infection was defined as requirement for hospitalisation with 
clinical symptoms of infection and either microbiological identification or 
histological/radiological evidence of tissue invasion. We excluded episodes of infection within 
the first 2 weeks post transplantation, and also urinary tract infections at any time, as we 
contend such episodes are more related to the anaesthetic and surgical 
procedure/complications than the overarching competence of the immune system which was 
the focus of this investigation; estimated glomerular filtration rate (eGFR) was calculated 
using the 4 variable MDRD (Modification of Diet in Renal Disease) equation; proteinuria was 
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evaluated by early morning albumin: creatinine measurements on a “spot” urine sample 
(‘UACR’).   
 
4.5.4 Assessment of CMV serostatus, infection, and disease  
 
Pre-transplant CMV serostatus of the recipients and their donors was collected. CMV 
prophylaxis with 100 days of valganciclovir was given to the D+R- group only, with dose 
adjustment for renal function. Serial whole blood samples were taken for CMV DNA PCR in all 
patients at day 0 (prior to transplantation), and then weekly for first month, twice weekly 
during months 2-3, monthly between months 4-12. However, the clinical team remained 
unaware of these results and no changes in clinical management ensued. Additional sampling 
was undertaken at the time of clinical suspicion of CMV disease, which was then diagnosed 
according to international guidelines and was based on one or more of the following in 
association with the finding of CMV viraemia: fever; new onset severe malaise; leucopenia; 
thrombocytopaenia; hepatitis (alanine transaminase or aspartate transaminase levels greater 
than twice the upper limit of normal); tissue invasive disease proven by histology. For our 
laboratory, a copy rate of >500 CMV genome copies/ml of whole blood represents significant 
CMV viraemia.  
 
Patients who were CMV seronegative at the time of transplantation underwent repeat 
serological testing at 12 months post transplantation to identify those who have developed 
asymptomatic infection within the first year, for whom no DNAemia was detected by 
protocolised testing as above.  
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Because the aim of this study was to evaluate the relationship between CMV infection and 
immunosenescence, and then whether the latter predicts episodes of other infections, the 
development of CMV infection was considered a predictor variable in these analyses, rather 
than an infective episode per se. 
 
4.5.5 Immunophenotyping  
 
Multicolour flow cytometry was used to undertake detailed phenotyping of patients’ 
peripheral blood mononuclear cells (PBMCs) prior to transplantation and then 14 days, 3 
months, 6 months, 9 months and 12 months post-transplantation. PBMCs were isolated from 
heparinised blood of the transplant recipient by density gradient centrifugation using Ficoll-
Paque (Fisher, UK) and cryopreserved in fetal calf serum (FCS) containing 10% DMSO. This 
was performed within 6 hours following collection with lithium-heparin anticoagulation. 
PBMC samples were stored in liquid nitrogen until analysis. 
 
The following cell types were defined: CD4+T-lymphocytes (CD3+/CD4+); CD8+T-lymphocytes 
(CD3+/CD8+). CD8+ T-lymphocytes were further characterised into the following subsets: 
Naïve-like: CD8+CD27+CD45RA+; Central memory-like (CM): CD8+CD27+CD45RA-; Effector 
memory-like (EM): CD8+CD27-CD45RA-; Effector memory cells re-expressing RA (‘EMRA’): 
CD8+CD27-CD45RA+. The proportion of CD8+ T-lymphocyte cells lacking CD28 expression 
(‘CD28null’) was evaluated. In addition, frequencies of B-lymphocytes (CD19+) were assessed. 
The following panel was used for this evaluation: CD8 AmCyan (BD Biosciences UK), CD4-
PerCPCy5.5, CD28Cy7, Fixable Viability Dye eFluor® 450, CD3-APC, CD27-eFluor®780 
(eBiosciences UK), CD45RA-AlexaFluor700 (Biolegend), CD19-PE (eBiosciences).  
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Samples were processed in batches of 5-10, with a healthy blood donor PBMC sample 
included with each batch as a quality control. Immediately upon thawing samples were 
washed by dilution with calcium and magnesium-free PBS, pelleted by centrifugation, stained 
at RmT for 30’ in PBS with 2.5% fetal calf serum (Gibco, Paisley, UK), then washed in PBS 
before running on a FacsDiva flow cytometer (Becton Dickinson, Oxford, UK) and analysed 
using Infinicyte software (Cytognos, Salamanca, Spain). Gating was performed manually by a 
single operator within an accredited laboratory, with lymphoid populations defined by 
forward and side scatter. Throughout, the flow cytometry laboratory and personnel were 
blinded to the clinical course of the patients within the study. 
 
4.5.6 Assessment of T-cell mediated immune response to CMV 
 
The frequency of circulating CMV-reactive T cells was determined by antigen stimulation and 
subsequent detection of cytokine production, with the aim to correlate this data with the 
presence of immunosenescence based on cell phenotyping as above. Briefly, fresh PBMCs 
were stimulated with CMV-derived peptides for 16 hours. Peptide pools derived from CMV 
IE-1, pp65 and pp50 proteins were used at a final concentration of 1 µg/ml per peptide (all 
Alta Biosciences, Birmingham, UK). 10µg/ml Brefeldin A (Sigma-Aldrich, Gillingham, UK) was 
added to block cytokine secretion after 1 hour of incubation. As a positive control, cells were 
stimulated with staphylococcus enterotoxin B (SEB) (0.2µg/ml final concentration; Sigma-
Aldrich) and unstimulated cells served as a negative control. Cells were then stained with anti-
CD4 and anti-CD8 antibodies (BD Biosciences, Oxford, UK), fixed using 4% paraformaldehyde, 
and permeabilised with 0.5% Saponin. Intracellular Interferon (IFN)-γ was detected with anti-
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IFN-γ-FITC (BD Biosciences). Analysis was performed on a Beckton-Dickinson LSRII flow 
cytometer with FlowJo software. 
 
4.5.7 Neutrophil function analyses 
 
In vitro neutrophil function assays were performed to quantify the ability of neutrophils to i] 
engulf bacteria (phagocytosis; phagotest), ii] produce reactive oxygen species (phagoburst 
test), iii] to lay Neutrophil Extracellular Traps (NETS) to kill bacteria extracellularly, and iv] to 
evaluate the directed migration of neutrophils.  
 
These investigations were conducted in a subset of 30 patients selected from the wider 
cohort. These patients were ‘hand selected’ based on the results of the cell phenotyping data 
from their 12-month samples, specifically to provide a range of immunosenescence 
characteristics, and in particular a range of CD8+CD28null cell frequencies in light of the results 
of the cluster analysis at month 12 showing this to be the marker which contributed most to 
the measures of immunosenescence (see ‘results’). Because of this lag time between the first 
and last enrolled patients reaching 12 months post-transplantation, these neutrophil function 
analyses were undertaken 20±3 months post-transplantation. To allow correlation between 
neutrophil function results and CD8+CD28null frequencies, the latter were repeated at the time 
of neutrophil function testing. None of these selected patients had experienced clinically 
overt infection or inflammation within the month prior to neutrophil function testing. The 
mean age of these participants was 47±17years (range 20-70yr); 11 of the 30 participants 
were women. 
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4.5.8 Measurement of neutrophil phagocytosis (Phagotest) 
 
The assessment of phagocytosis was performed using the commercial kit Phagotest (BD 
Biosciences, UK) containing the fluorescein-labelled opsonized Escherichia coli (E. coli - FITC). 
100μL of heparinised whole blood were cooled in an ice bath for 10 minutes, followed by 
incubation with 20μL E.coli or control (RPMI) for 10 minutes at 37°C. A negative control was 
represented by the same suspension incubated at 0°C. 100μL of ice cold quenching solution 
was added to stop phagocytosis. After two washing steps, erythrocytes were lysed and 200μL 
of DNA staining solution was added. The samples were analysed within sixty minutes by flow 
cytometry (BD Accuri C6 Flow Cytometer) and the phagocytic index was determined. The 
phagocytic index was calculated as the percentage of the cells having ingested bacteria (FITC 
positive cells), multiplied by the mean fluorescence intensity (MFI) of the FITC positive 
population and divided by 100.  
 
4.5.9 Measurement of neutrophil bactericidal activity (Phagoburst) 
 
Neutrophil oxidative burst was determined quantitatively with the Phagoburst Kit (BD 
Biosciences, UK). 100μL of heparinised whole blood were cooled in an ice bath for 10 minutes, 
followed by incubation with 20μL non-labelled opsonized E. coli, 20μL fMLP (peptide N-
formyl-MetLeuPhe) as low control, 20μL PMA (phorbol 12-myristate 13-acetate) as high 
control and 20μL of wash solution as negative control for 10 minutes at 37°C.  Following the 
addition of 20μL of substrate solution (dihydrorhodamine (DHR) 123), all tubes were 
incubated again for another 10 minutes at 37°C. The erythrocytes were removed using lysing 
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solution and the samples washed and stained with 200μL of DNA staining solution. The 
percentage of cells having produced reactive oxygen metabolites (on phagocytizing E.coli) as 
well as their mean fluorescence intensity (MFI) were analysed by flow cytometry. 
 
4.5.10 Quantification of Neutrophil Extracellular Traps (NETS) production 
 
Peripheral blood neutrophils were isolated within two hours from sample collection. The 
method used has been previously described [52-54]. Briefly, 2% dextran solution was added 
to heparinized peripheral blood, the leukocyte layer was collected, and neutrophils were 
purified by Percoll density gradient centrifugation. Giemsa staining (Diff-Qik; Gentaur Europe) 
and trypan blue staining was used to determine the purity and viability of isolated neutrophils. 
The purity and cell viability was routinely greater than 97%. The neutrophils were 
resuspended at 1-5 x106/ml in RPMI-1640 media (Sigma-Aldrich, UK) containing 2mM L-
glutamine, 100U/ml penicillin and 100μg/ml streptomycin. 
 
The methods used to quantify extracellular DNA in cell-free supernatants have been 
previously described by Hazeldine et al 2014. 1 x 105 neutrophils in assay media were treated 
with 25nM PMA (Sigma-Aldrich) (treated arm), or assay media (untreated arm) for 3 hours at 
37°C in a humidified 5% CO2 chamber. Post-incubation, 1U/mL of micrococcal nuclease 
(MNase; Sigma-Aldrich) and 1μM of the cell impermeable DNA binding dye SYTOX Green (Life 
Technologies, UK) were added to cells in order to digest and stain extracellular DNA, 
respectively. After a 10-minute incubation in the dark at room temperature, cells were 
pelleted, and extracellular DNA content was determined in the cell-free supernatant by 
measuring fluorescence in a BioTek Synergy 2 fluorometric plate reader (NorthStar Scientific 
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Ltd, Leeds, UK), at an excitation wavelength of 485nm and emission at 530nm. Experiments 
were performed in quadruplicate, and background fluorescence values of neutrophils treated 
with assay media alone were subtracted from test samples. 
 
4.5.11 Neutrophil migration assays 
 
Neutrophils were isolated as described above. The isolated neutrophils were resuspended in 
RPMI-1640 medium containing 0.15% bovine albumin. The method used for this assay has 
been previously described by Sapey et al, 2014. 
 
An Insall Chamber (Weber Scientific International Ltd., United Kingdom) was used to assess 
the three parameters of neutrophil migration (speed, velocity, and persistence). Coverslips 
were sterilised by washing once in 0.4M H2SO4, and twice in deionised water followed by 
coating with 400µl of 7.5% culture tested bovine serum albumin (Sigma-Aldrich).  400µl of 
neutrophil solution (suspended at 2 x 106/mL) was pipetted onto the albumin-coated 
coverslips, and left to incubate for thirty minutes. The chemotaxis chamber was prepared by 
washing thrice with 400µl RPMI-1640. After tipping off excess neutrophil solution from the 
coverslip, the slide was inverted onto the chemotaxis chamber. The chemoattractant well was 
slowly filled with 60µl of 100nM IL-8 (R&D systems) and RPMI was used for negative control.  
 
The slides were analysed using Leica DMI6000 Video Capture Microscope. One frame every 
20 seconds for a total of 36 frames (12 minutes) was taken. The data was analysed using image 
J software (Wayne Rasband, National Institutes of Health, Bethesda, MD). All analyses were 
carried out by a single analyst. Four measures of neutrophil migration characteristics were 
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tested: i] chemokinesis (average cell speed of the distance travelled between frames in any 
direction over time); ii] chemotaxis (average cell velocity in a consistent direction toward the 
chemoattractant) was measured in micrometres per minute; iii] accuracy, termed 
‘chemotactic index’, was calculated by the cosine of the angle between the cell’s direction 
and the orientation of the chemoattractant gradient at each time frame forming a vector 
analysis of movement, expressed in a comparative scale (cs) ranging from -1 to 1, where 1 
represents movement directly toward the chemoattractant, and -1 represents movement 
directly away from the chemoattractant source in all frames; iv] persistence represents the 
duration and distance a neutrophil moves in one direction before stopping or turning. It is 
calculated by the cosine of the angle between cellular orientations in consecutive frames, 
expressed with reference to the y direction and expressed as a score between 0 to 1. Cells 
that tend to move in a straight line, or cells that execute slow changes in direction have a high 
persistence value (~1); whereas cells that move randomly and rapidly change direction do not 
(~0); [50].  
 
4.5.12 Statistical analysis 
 
Data are presented as mean ± standard deviation, or as median (interquartile range; IQR). 
Continuously distributed parametric data was compared using Student’s t-test. Multiple 
independent group comparisons were evaluated by ANOVA; repeated measures ANOVA 
compared multiple non-independent datasets (in this case due to repeated results from the 
same patients over time). Categorical data was compared using Chi-square testing. 
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Cluster analysis was performed to segregate patients into groups based on the values of a 
range of potential markers of immune senescence. Two-Step cluster analysis in IBM SPSS 19 
was used, with the number of clusters determined automatically. Demographic factors were 
then compared between the resulting clusters, using Mann-Whitney or Fisher’s Exact test, as 
applicable. 
 
The independent relationship between continuously distributed end-measures and potential 
predictors was evaluated using linear regression analysis. Time to event analysis was 
undertaken using Cox regression. Non-normal distributed data underwent transformation as 
necessary prior to analysis. For all analyses variables showing some effect in the univariate 
analysis (p<0.15) were included in a subsequent multivariable analysis, with a stepwise 
backwards selection procedure to retain only the statistically significant variables (p≤0.05) in 
the final model.  
 
A feature of the data was that there were several measurements for each subject over the 
course of the study. To allow for the non-independence of such repeated data, multilevel 
statistical methods were used for data analysis in the regression models. Two-level models 
were used with individual measurements nested within patients. This was implemented using 
the xtnbreg procedure with the Stata statistical software package. For time to event analyses, 
post-transplant predictor variables, in particular CD8+CD28null cell frequencies, were analysed 
as time-dependent covariates. For analyses of single continuously-distributed endpoints at 
study end (specifically renal function and proteinuria), averaged values (over the course of 
the study) were analysed by linear regression. 
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Chapter 5:  Transitional B lymphocytes 
are associated with protection from 
kidney allograft rejection:  
a prospective study. 
 
 
 
 
This chapter appears as published in the American Journal of Transplantation 
and reflects work undertaken as part of my PhD. 
 Due to the lack of association between CMV and B-cell numbers (including lack of association 
between CD8+CD28null cells), this chapter was prepared as a manuscript for publication and focused 
on the positive findings of the study. 
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5.1 ABSTRACT 
 
Recent cross-sectional studies suggest an important role for transitional B-lymphocytes 
(CD19+CD24hiCD38hi) in promoting transplant tolerance, and protecting from late antibody 
mediated rejection. However prospective studies are lacking. This study enrolled 73 de novo 
transplant recipients, and collected serial clinical, immunological and biochemical information 
over 48±6 months. Cell phenotyping was conducted immediately prior to transplantation, and 
then on 5 occasions during the first-year post-transplantation. When modelled as a time-
dependent covariate, transitional B-cell frequencies (but not total B cells or “regulatory” T 
cells) were associated with protection from acute rejection (any Banff grade; 
HR:0.60;95%CI:0.37-0.95; p=0.03). No association between transitional B-cell proportions and 
either de novo donor-specific or non-donor-specific antibody (dnDSA; dnNDSA) formation 
was evident, although preserved transitional B-cell proportions were associated with reduced 
rejection rates in those patients developing dnDSA. Three episodes of antibody mediated 
rejection (ABMR) occurred, all in the context of non-adherence, and all associated with in 
vitro anti-HLA T-cell responses in an Elispot assay (p=0.008 versus antibody-positive patients 
not experiencing ABMR). This prospective study supports the potential relevance of 
transitional (“regulatory”) B cells as a biomarker and therapeutic intervention in 
transplantation, and highlights relationships between humoral immunity, cellular immunity, 
and nonadherence. 
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5.2 INTRODUCTION 
 
While the immunoregulatory properties of B lymphocytes have been recognised for many 
years (1,2) their importance in human autoimmune and allo-immune disease has developed 
more recently. A subset of IL-10 secreting cells with regulatory properties has been identified 
within the transitional B-cell compartment, characterised by the surface phenotype 
CD19+CD24hiCD38hi, which may protect from autoimmune disease such as systemic lupus and 
multiple sclerosis (3,4). In kidney transplantation, the importance of CD19+CD24hiCD38hi cells 
is highlighted by patients who are “tolerant” to their graft, who display increased frequencies 
of these cells (5-8), although proof as to their direct role in this phenomenon is lacking. 
Following these landmark studies, 2 subsequent case-control, cross-sectional investigations 
(9,10) revealed associations between reduced CD19+CD24hiCD38hi frequencies and transplant 
rejection, albeit mainly in the context of antibody-mediated rejection (ABMR) many years 
following transplantation.  
 
Although these reports highlight the potential importance of these cells in clinical 
transplantation, prospective studies are required to track the evolution of these cells post-
transplantation, and to evaluate the temporal relationship with subsequent rejection 
episodes. In the current study we prospectively followed an incident kidney transplant cohort, 
with sequential, frequent clinical monitoring and immuno-phenotyping to track the temporal 
relationship between these regulatory, transitional B cells and clinical events. This showed 
that patients displaying higher transitional B-cell frequencies experience reduced rejection 
rates, suggesting potential utility of these cells as biomarkers and stratifiers predictive of 
outcome, and for targeting regulatory pathways to improve transplant outcomes. 
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5.3 MATERIALS AND METHODS 
 
Seventy-three unselected recipients of solitary kidney transplants were enrolled into this 
prospective study during 2009 in a single centre. Local ethics committee approval was granted 
for the study (08/H1204/103), which was performed in accordance with the Declaration of 
Helsinki. 
 
5.3.1 Demographic data and protocol  
 
Information collected included (Table 5.1): donor and recipient age, sex and CMV 
(cytomegalovirus) status, recipient cause of renal failure, donor-recipient HLA mismatch, 
source of transplant (live related; live unrelated; deceased donor following brain death [DBD]; 
deceased donor following cardiac death [DCD]).  
 
Transplantation proceeded provided the cross match between donor and recipient was 
negative by cytotoxicity and flow cytometry. Immunosuppression was identical for all 
participants, and consisted of Basiliximab induction followed by maintenance tacrolimus 
(Prograf; pre-dose level 5-8ng/ml), mycophenolate mofetil (Cellcept; 2g daily) and 
prednisolone (20mg daily; reducing to 5mg by 3 months post transplantation). Valganciclovir 
prophylaxis (100 days) was administered to CMV seronegative recipients of seropositive 
donors; co-trimoxazole prophylaxis was administered to all for 12 months, and isoniazid 
prophylaxis for 12 months to those of South-Asian ethnicity or previous tuberculosis.  
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Table 5.1. Patient demographics 
 
 
1 Donation after Brain Death 
2 Donation after Cardiac death 
 
 
5.3.2 Clinical data post-transplantation 
 
Delayed graft function was defined as dialysis requirement during the first post-operative 
week; acute rejection was biopsy proven in all cases (BPAR) and classified according to the 
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Banff schema; significant infection was defined as requirement for hospitalisation with clinical 
symptoms of infection and either microbiological identification or histological/radiological 
evidence of tissue invasion; estimated glomerular filtration rate (eGFR) was calculated using 
the 4 variable MDRD (Modification of Diet in Renal Disease) equation; proteinuria was 
evaluated by early morning albumin: creatinine measurements on a “spot” urine sample.   
 
5.3.3 HLA antibody screening 
 
For evaluation of anti-HLA antibodies, samples were taken prior to transplantation, and then 
weekly for first month, twice weekly during months 2-3, monthly between months 4-12, and 
then three monthly thereafter. Antibody screening was undertaken using mixed screen 
beads; all screen positive samples were tested for HLA specificity using single antigen beads 
(One Lambda). HLA Fusion software was used to obtain raw median fluorescence intensity of 
different alleles, with a positive cut-off defined as MFI ≥ 500 as per manufacturer’s 
instructions.  
 
5.3.4 Cellular Immunophenotyping 
 
Multichannel flow cytometry of patients’ peripheral blood mononuclear cells (PBMCs) was 
undertaken prior to transplantation (within 6 hours before the procedure, and prior to 
immunosuppression dosing) and then 14 days, 3 months, 6 months, 9 months, and 12 months 
post-transplantation. PBMCs were isolated from heparinised blood of the transplant recipient 
by density gradient centrifugation over Ficoll using RPMI-1640 medium (Sigma) and 
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cryopreserved in fetal calf serum (FCS) containing 10% DMSO. This was performed within 6 
hours following collection with lithium-heparin anticoagulation. PBMC samples were stored 
in liquid nitrogen until analysis (interval approximately 10-24 days) 
 
The following flow cytometry panel was used to define: B-lymphocytes (CD19+); transitional 
(“regulatory”) B lymphocytes (CD3+CD19+CD24hiCD38hi); memory B lymphocytes 
(CD19+CD27+); and by way of comparison regulatory T-lymphocytes 
(CD3+CD4+CD25+CD127low) (all antibodies from Biolegend, London, UK).  Samples were 
processed in batches of 5-10, with a healthy blood donor PBMC sample included with each 
batch as a quality control. Immediately upon thawing samples were washed by dilution with 
calcium and magnesium-free PBS, pelleted by centrifugation, stained at RmT for 30’ in PBS 
with 2.5% fetal calf serum (Gibco, Paisley, UK), then washed in PBS before running on a 
FacsDiva flow cytometer (Becton Dickinson, Oxford, UK) and analysed using Infinicyte 
software (Cytognos, Salamanca, Spain). Gating was performed manually by a single operator 
(JG) within an accredited laboratory, with lymphoid populations defined by forward and side 
scatter. The healthy donor control was used to set the gate for transitional B-cell frequency 
evaluation. Throughout, the flow cytometry laboratory and personnel were blinded to the 
clinical course of the patients within the study. 
 
5.3.5 Enzyme Linked Immunosorbent Spot Assay to detect anti-HLA cellular 
response 
 
A γ-interferon ELISPOT assay to evaluate the cellular immune response of transplant 
recipients to non-polymorphic HLA-derived peptides was undertaken as previously described 
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(11-13). The responding cells in this assay are effector-memory CD4+ cells (12,13) which 
recognise cryptic, autologous HLA-derived peptide epitopes, such that inter-patient 
standardisation can be undertaken without using distinct HLA peptides tailored to the donor 
and recipient HLA type. PBMCs were isolated from peripheral blood by Ficoll density gradient 
centrifugation and immune responses to peptides at 11.4μmol/L were assayed in triplicate 
using 4x105 PBMCs per well in a 96-well ELISPOT plate (Mabtech, Nacka Strand, Sweden) and 
cultured for 44 hours at 370C and 5%CO2. Plates were developed according to manufacturer’s 
instructions and the number of spots per well counted using an AID ELISPOT plate reader 
(Strassberg, Germany). A positive response was defined as >7 spots per well in single peptide 
based studies which was >99.8th centile when responses to a wide range of HLA-derived 
peptides are analysed. (This is also the definition of a positive response to tuberculin-derived 
peptides using similar methodology).  
 
5.3.6 Statistical analysis 
 
Data are presented as mean ± standard deviation, or as median (interquartile range; IQR). 
Continuously distributed data was compared using Student’s t-test with multiple comparisons 
evaluated by one-way ANOVA followed by Tukey’s Multiple Comparison Test; categorical data 
was compared using Chi-square and Fisher’s exact testing.  
 
Time to event analyses was undertaken using Weibull regression, an example of a parametric 
survival analysis. This is preferable to the more commonly used Cox regression (semi-
parametric) analysis when exposure variables are absent at early timepoints (14). In the case 
of the current investigation this pertained to de novo anti-HLA antibodies which (by 
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definition) appeared sometime after transplantation. Repeated measures of 
immunophenotyping results and HLA antibody results were modelled as time-dependent 
covariables. The endpoints of UACR and eGFR at the end of follow up were analysed using 
linear regression analysis. Averaged values for the immunophenotyping results were used for 
these analyses, and other time-dependent variables such as biopsy-proven acute rejection 
and the presence of dsHLA antibodies were modelled as categorical (yes/no) variables. Non-
normal distributed data underwent transformation as necessary prior to analysis. For all 
analyses variables showing some effect in the univariate analysis (p<0.15) were included in a 
subsequent multivariable analysis, with a stepwise backwards selection procedure to retain 
only the statistically significant variables (p≤0.05) in the final model. Due to collinearity 
specifically between transitional B-cell frequencies and total numbers, only cell frequencies 
were analysed as a predictor variable to avoid statistical error. 
 
5.4 RESULTS 
5.4.1 Clinical Outcomes 
 
Mean follow up was 48±6 months. 15 patients experienced DGF, and 17 developed (BPAR) at 
a median of 15 days post-transplantation (range 7-450 days). Of these, 3 patients displayed 
biopsy features of microcirculation inflammation (glomerulitis, peritubular capillaritis and 
C4d deposition) in the presence of donor-specific anti HLA antibody. Over the course of 
follow-up there were 3 deaths (all sepsis) and 3 further graft failures (antibody mediated 
rejection n=2; recurrent disease n=1).  
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5.4.2 Transitional B cells and Biopsy-Proven Acute Clinical Rejection 
 
Figure 5.1 shows a representative plot demonstrating transitional B cells as a 
CD19+CD24hiCD38hi population; Figure 5.2 shows the evolution of transitional B-cell 
frequencies (expressed as a percentage of total B cells) over the first year post-
transplantation year. Significant differences in transitional B-cell frequencies were evident 
across time points (ANOVA p<0.001), which represented a decrease from pre-transplant 
levels of 3.66±2.30% to 1.49±1.60% at 3 months post-transplantation (post hoc p<0.001), and 
then a rise to 2.66±1.82% by 6 months post-transplantation (p=0.02 compared with 3 
months), and then stabilisation. 
 
 
 
 
Figure 5.1 Flow cytometry readout of CD24hiCD38hi transitional cell population 
within CD19+ B lymphocytes.  
Lymphocytes were gated according to forward and side scatter, then CD19+ cells were analysis for 
CD24/CD38. 
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Univariate analysis, with transitional B cells modelled as a time-dependent covariate, 
revealed a significant association between transitional B cells and the subsequent 
development of BPAR of any grade, with increased transitional B-cell frequencies protective 
from BPAR (Hazard Ratio [HR]: 0.60; 95% CI: 0.37-0.95; p=0.03).  
 
 
 
Figure 5.2 Evolution of transitional B cells over time.  
Transitional B-cell frequencies expressed as percentage of total CD19+ B-cell population. Bars 
represent standard deviation. Significant differences in transitional B-cell frequencies were evident 
across time points (ANOVA p<0.001). 
 
 
This relationship held in the multiple regression model following adjustment for the variables 
shown in Table 5.2, and indeed was the only predictor of acute rejection in the final model. 
The relationship between transitional B-cell frequencies and BPAR is shown in different ways 
in Figure 5.3. Figure 5.3A represents the regression plot for the relative hazard of BPAR versus 
transitional B-cell frequencies (derived from the statistical analysis and modelling cell 
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frequencies as a time-dependent variable); Figure 5.3B displays time-to-BPAR survival 
estimates based on tertiles of transitional B cells. 
 
 
 
 
Figure 5.3A Risk of BPAR versus transitional B-cell frequency  
 
B-cell frequency expressed as percentage of total CD19+ B-cell population. Regression line represents 
output from Weibull model, with cell frequencies modelled as a time-dependent variable and model 
adjusted for repeated measures. 
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Figure 5.3B Rejection-free survival estimates for tertiles of transitional B cells 
(log rank p=0.02) 
 
cell frequencies averaged over follow-up; Figure 5.3C demonstrates increased transitional B-cell 
frequencies in non-rejectors compared to rejectors when sampled immediately pre-transplant and 14 
days post-transplantation (the latter data applying to patients experiencing BPAR beyond day 14; n=9). 
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Figure 5.3C Transitional B-cell frequencies at baseline and 14 days post-
transplant in the presence and absence of rejection. 
Transitional B-cell frequencies at baseline and Day 14 post-transplantation in patients with and 
without episodes of biopsy-proven acute rejection. For the latter group, acute rejection episodes 
beyond day 14 are considered events. Data shown as median (line), interquartile range (box) and 
range (whiskers). Non-rejectors displayed higher transitional B-cell frequencies than rejectors at both 
timepoints, including comparison with rejectors following exclusion of patients with non-adherence 
(n=3) (p<0.05 for all rejection versus non-rejection analyses). 
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Table 5.2 Association between predictor variables and time to biopsy-proven acute 
rejection 
 
 
Table 5.2 demonstrates association between predictor variables and time to biopsy-proven acute 
rejection (Weibull regression). Multiply-sampled data modelled as time-dependent covariate, and 
model adjusted for repeated measures. 
 
1 Effect shown for each percentage increase in transitional B cells expressed as a proportion of total B 
cells 
 
2 Effect shown per 10-year increase in age 
 
3 Effect shown for each 5% increase in B cells expressed as a proportion of total mononuclear cells 
4 Effect shown for each 5% increase in memory B cells expressed as a proportion of total CD19+ cells 
 
5 Effect shown for each percentage increase in regulatory T cells expressed as a proportion of total 
CD3+CD4+ cells 
 
dnDSA=de novo donor-specific anti HLA antibody detection 
 
dnNDSA=de novo non-donor-specific anti HLA antibody detection 
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No association with time to BPAR was seen with time-dependent measurements for 
frequencies of “regulatory” T cells (expressed as a proportion of total T cells), total B cells 
(expressed as a proportion of total mononuclear cells), or memory B cells (expressed as a 
proportion of total CD19+ cells). Nevertheless, it should be noted that the confidence intervals 
around the point estimates for the effect of these variables was such that an effect could not 
be excluded. 
 
5.4.3 Transitional B cells in patients developing dnDSA and ABMR 
 
Prior to transplantation, only 4 patients displayed anti-HLA donor specific antibodies (DSA) 
above the pre-defined cut off (MFI>500; flow cytometry crossmatch negative as per unit 
protocol described above); none developed BPAR. During follow-up, 10 patients developed 
dnDSA, 23 patients developed dnNDSA, and 9 developed both dnDSA and dnNDSA.  
 
No relationship between time-dependent transitional B-cell frequencies and time to 
appearance of either dnDSA (HR: 1.09; CI: 0.85-1.41; p=0.50) or dnNDSA (HR: 0.88; 95%CI: 
0.70-1.12; p=0.30) was seen. When adjusted for the covariates shown in Table 5.2 (and also 
including BPAR as a predictor variable), HLA-DR mismatch was the sole independent predictor 
of time to dnDSA appearance (HR per mismatch: 2.01; 95%CI: 1.12-3.60; p=0.008); 
independent predictors of time to dnNDSA were prior development of dnDSA (modelled as a 
time-dependent covariate; HR: 13.6; 95%CI: 4.42-41.5; p<0.001) and repeat transplantation 
(HR: 3.73; 95%CI: 1.33-10.5; p=0.01).  
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As described above, of the 10 patients who developed dnDSA, 3 developed graft dysfunctions 
with microvascular inflammation on biopsy, and 7 retained stable function. Although no 
association between the development of dnDSA and rejection of any grade was seen (Table 
5.2), there was a strong association between the development of dnDSA and microvascular 
inflammation (HR: 7.23; 95%CI: 1,37-38.1; p=0.02).  The characteristics of the patients with 
dnDSA who either did or did not experience graft dysfunction (i.e. “antibody mediated 
rejection”; ABMR) differed markedly. All 3 patients with ABMR were nonadherent to 
prescribed medication, whereas none of the 7 rejection-free patients were nonadherent. 
Interestingly, at the time of antibody development all 3 patients developing ABMR displayed 
a positive response in the Elispot test (measuring “indirect” cellular immunity), but none of 
the 7 rejection-free patients displayed such a response (Fisher’s p=0.008). At the end of follow 
up 2 of the 3 patients with ABMR had experienced graft failure, and a marked reduction in 
eGFR (30ml/min) was seen in the other. In contrast all 7 non-rejecting patients displayed 
stable graft function with eGFR 60.1± 17.1ml/min and urine albumin: creatinine ratio 2.0±1.5 
mg/mmol at end of follow-up. 
 
Transitional B-cell frequencies were not associated with development of ABMR in these 3 
nonadherent patients. But following exclusion of these 3 patients, the relationship between 
transitional B-cell frequencies and rejection held for patients with dnDSA (p=0.3 for 
interaction), suggesting that preserved transitional B cells is also associated with protection 
from rejection even in patients with dnDSA. As shown in Table 5.3, up to day 90 post-
transplantation transitional B-cell frequencies were similar in rejection-free patients who did 
and did not develop dnDSA, and in fact were then higher in the former group at later 
timepoints (ANOVA p=0.005; post hoc p<0.05 for timepoints beyond 90 days). 
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Table 5.3 B-cell frequencies in patients with and without  dnDSA and no BPAR 
 
 
Table 5.3 compares transitional B-cell frequencies in patients developing and not developing de novo 
donor-specific anti-HLA antibody without experiencing biopsy-proven acute rejection. ANOVA 
p=0.001; p-values in last column of table refer to post-hoc inter-group comparison. 
 
 
5.4.4 Transitional B cells and other outcomes 
 
No statistically significant relationships between transitional B-cell frequencies (averaged 
over follow-up) and either eGFR (reported as change in ml/min) or UACR (reported as change 
per 1mg/mmol [10mg/g]) at the end of follow-up (in patients alive with graft function at end 
follow-up; n=67) were seen (Effect: -4.3; 95%CI: -9.9, 1.2; p=0.12 and Effect: 0.79; 95%CI: 0.51-
1.22; p=0.22 respectively). Similarly, transitional B-cell frequencies were not associated with 
eGFR at 12 months post transplantation in patients alive with graft function at 12 months 
(n=68; Effect: -4.1; 95%CI: -9.7, 1.5; p=0.14). Repeating these analyses for the entire cohort 
(and including patients who had died or suffered graft failure as displaying eGFR 10ml/min) 
did not influence these results (Effect for eGFR at end follow-up: -4.5; 95%CI: -9.8, 0.8; p=0.09; 
Effect for eGFR at 12 months: -4.4; 95%CI: -10.0, 1.2; p=0.12). Clinically significant infection 
(as defined in “methods”) was diagnosed in 22 patients over follow-up, but no association 
between transitional B-cell frequencies (modelled as time-dependent variable) and time to 
infection was evident (HR: 1.03; 95%CI: 0.83-1.28; p=0.76). It should be noted that due to 
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sample size, these results do not exclude a potential effect of transitional B-cell frequencies 
on these outcomes. Death and graft failure numbers were low, but with no clear difference 
in transitional B-cell frequencies in patients experiencing these events compared to the 
overall cohort (data not shown). 
 
5.5 DISCUSSION 
 
B cells with regulatory properties are of increasing interest in kidney transplantation, in 
particular clinical outcomes and phenotypes associated with transitional B cells characterised 
by surface CD19+CD24hiCD38hi expression (5-10). This study shows that increased frequencies 
of these transitional B cells are associated with protection from episodes of BPAR in 
unselected low/medium immune risk transplant recipients followed longitudinally from the 
time of transplantation. The results of this prospective study, the first to date, are biologically 
plausible and extend the current literature, thereby supporting efforts to further clarify the 
role these cells in clinical transplantation, either as biomarkers of rejection risk, or in potential 
cell-based therapies.  
 
The majority of episodes of BPAR in this study represented cellular rejection, with a minority 
representing ABMR in the context of non-adherence (discussed further below). Although not 
now a common cause of direct and immediate graft failure, cellular rejection remains a potent 
and relevant risk factor for subsequent graft failure (15-17), thereby highlighting the 
relevance of the current findings to contemporary transplantation.  
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Unsurprisingly, no association between transitional B cells and ABMR was seen, as these 
rejection episodes were driven by nonadherence rather than a predisposing immune profile. 
However, the relationship between transitional B cells and rejection held in adherent patients 
who developed dnDSA, suggesting that peripheral cellular regulation may reduce the risk of 
rejection in those patients demonstrating circulating HLA antibodies. This is reminiscent of 
recent work showing absence of immune-related gene expression in peripheral blood of 
“antibody-positive/rejection-negative” kidney transplant recipients (18).  The current finding 
also resonates with the inverse relationship between transitional B-cell frequencies and 
ABMR in recent studies (9,10), perhaps suggesting that the presence of both antibody and 
lack of regulation are required for rejection to occur. It should be noted that these case-
control studies investigated patients undergoing indication biopsies, usually many years post-
transplantation, and as such their designs differ from the current investigation. The results do 
raise the possibility that immunoregulation, and specifically transitional B cells with 
regulatory properties, may explain the reproducible observation that many patients with 
circulating HLA antibody display freedom from rejection and experience clinical stability over 
prolonged follow-up (19-22). 
 
Although not a primary aim of the study, a further interesting finding was the link between 
cellular and humoral allo-immunity in patients developing ABMR. All 3 such patients displayed 
a positive response to HLA peptide in an Elispot assay of indirect cellular immunity, whereas 
none of the patients developing dnDSA but not experiencing BPAR (and who displayed stable 
renal function and negligible proteinuria over follow-up) displayed a positive test at the time 
of antibody formation. This supports the concept that damage as a result of cellular activation 
and infiltration may be more important to graft outcome then the presence of anti-donor 
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antibody per se (18,23,24), thereby extending previous work to the specific situation of 
nonadherence-associated ABMR. We do acknowledge however that this observation, whilst 
interesting, remains preliminary and over-interpretation of this finding based on the low 
numbers of patients with ABMR in the current study should be avoided. 
 
Recent studies have suggested that the development of dnDSA (and then later ABMR) 
following episodes of rejection, are responsible for the link between cellular rejection and 
outcome (15,21,25). This association was not seen in the current study, although this may be 
unsurprising in light of the study size, and the recognition that despite the above association, 
most patients developing dnDSA (generally around 80%) do not have a history of prior BPAR 
(15,21,25). Worthy of note in passing though is that the current study, which carefully 
evaluated dnDSA in a time-dependent fashion, does confirm previous established (26,27) and 
recent (28) data demonstrating that in a low immune-risk population the development of 
dnDSA does not predict acute rejection episodes (although it does predict the development 
of microvascular inflammation). 
 
The prospective, longitudinal design of the current investigation, coupled with time-
dependent statistical analysis in an unselected cohort, represent obvious strengths of the 
study. Although based on a single-centre experience, the results are biologically plausible and 
extend the currently limited understanding of the field. Nevertheless, these data should be 
considered preliminary, and further investigation in separate and larger cohorts with longer 
follow-up duration are required to validate the robustness of the findings, in particular in 
regard to the interplay between cellular immunity, humoral immunity, nonadherence and 
regulation. A major challenge for the future will be inter-laboratory standardisation, a pre-
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requisite for widespread clinical application. Further work is also required to evaluate the 
stability of these cell subsets during storage. Understanding cytokine profiles of transitional 
B cells may refine the predictive utility of immunophenotyping (9), but was beyond the scope 
of this pilot study. However, the findings of the current study set the scene for further clinical 
investigation, contribute to the understanding, and provide a rationale for the use of this 
immune biomarker and potential intervention in clinical transplantation. 
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Chapter 6: GENERAL DISCUSSION 
Indirect Effects of Cytomegalovirus in Kidney Transplantation 
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6.1 Overview of the Thesis  
 
Despite the availability of effective therapy, cytomegalovirus remains the most important 
infection in kidney transplantation. Response to CMV and the presence of large populations 
of CMV-specific T cells that can be easily measured ex vivo provided an ideal model for not 
only studying CMV but also examining the immune response to persistent viruses in solid 
organ transplantation.  
 
In a longitudinal prospective study serial clinical, immunological and biochemical information 
was studied to gain a deeper understanding of the indirect effects of cytomegalovirus in 
kidney transplantation. The findings of the studies are presented in Chapters 2 to 5 of this 
thesis.  
 
In Chapter 2, we show CMV re-infection is clinically relevant. Our preliminary data shows we 
might be able to identify a high-risk subgroup in D-/R+ transplantation by pre-transplant 
assessment of cellular immunity. This may pave the way for a more logical and effective 
prophylactic strategy in these patients. We provide previously undescribed and direct 
evidence of immune hypo- responsiveness to latent CMV. This has implications for how we 
best deal with CMV in this setting, and also wider implications for vaccination programmes. 
In chapter 3, we focus on the mechanism of kidney transplant damage associated with CMV 
infection. In chapter 4, we focus on the role of CMV in causing immunosenescence within the 
kidney transplant cohort. We demonstrate changes to the adaptive and innate immune 
system with resultant effect on post-transplant outcomes. 
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6.2 Summary of the major findings 
6.2.1 CMV re-infection is clinically relevant 
 
In 2008, a study published by Kliem et al demonstrated a greater incidence of CMV infection 
in D+/R+ transplantation. However, this lacked data on CMV disease.  In chapter 2, we highlight 
the differential risk of clinically relevant CMV disease between D+/R+ and D-/R+ 
transplantation. In clinical transplantation, D+/R+ and D-/R+ groups are considered 
“intermediate risk” for CMV infection. As such, CMV prophylaxis is not advised for these two 
serostatus groups in the current British Transplant Society guidelines (with the exception of 
patients treated with T-cell depleting antibody therapy). This study demonstrates the 
increased incidence of CMV disease in non-prophylaxed seropositive recipients of kidneys 
from seropositive donors (D+/R+) compared with seronegative donors (D-/R+). This risk was 
modified by donor-recipient HLA class I mismatch. 
 
These findings have important implications for CMV risk management in transplantation and 
certainly our clinical practice has changed, such that, the D+/R+ group has been re-classified 
as ‘high risk’ with resultant changes in CMV prophylaxis strategy.  
 
6.2.2 Mechanism of viral infection in kidney transplantation 
 
As mentioned above, we observed a modified risk of CMV disease with HLA Class I mismatch. 
In D+/R+ transplantation, a significant relationship was evident between HLA Class I mismatch 
and time to CMV disease. This effect was not evident in the other three serostatus groups. 
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It is possible that donor-recipient HLA mismatch impairs development of cellular immunity to 
CMV within transplanted donor tissue. We utilised HLA-peptide tetramers to investigate the 
underlying mechanism. We have shown, in D+/R+ transplantation, CMV-specific CD8+ T-cell 
immunity does not develop against peptides presented solely by donor-specific HLA alleles.  
 
The relevance of this is that although there is a wealth of data describing mechanisms by 
which latent CMV is proposed to reduce immune responsiveness (↓ HLA presentation, ↓ 
Antigen presentation, ↓ T-cell proliferation, ↓ Production of IL-2, INF-c, PD-1, ↑ Fc receptor 
expression, ↑ Complement inhibitors, ↓ Macrophage migration) there is little evidence to 
directly demonstrate that effect in vivo.  
 
This physiological model of transplantation provides novel insight into antigen presentation 
pathways in viral infection. Absence of directly primed CD8+ T-cell immune responses raises 
questions regarding how infection is ultimately controlled within donor tissue.  
 
6.2.3 Prognostic utility of pre-transplant cellular immunity assays 
 
The pre-implantation histological data from the current study suggests CMV transmission 
peri-transplantation is very common. Early detection of patients at increased risk of 
developing CMV disease could allow targeted CMV prophylaxis/treatment and avoid 
potential toxic side effects of unnecessary exposure to anti-viral drugs.  Assays of cellular 
immunity to CMV are emerging research tools. These in-vitro assays use recipient PBMCs, 
thus CMV peptides are presented by recipient HLA. In our in-vivo model, we have already 
demonstrated that CMV may be harboured within donor tissue and presented by donor HLA 
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on re-activation (section 6.6.2). This has important implications for the prognostic utility of 
these assays in D+R+ (compared with D-R+) transplantation.  
 
This is the first study to look at the prognostic utility of pre-transplant cellular immunity assays 
in predicting CMV infection between D+/R+ and D-/R+ transplantation. We have shown the pre-
transplant CMV-specific CD8+ T-cell is predictive of CMV infection in D-/R+ but not in D+/R+ 
transplantation. This suggests that targeted prophylaxis to such seropositive patients without 
cell mediated immunity may be a clinically effective strategy. However, the same cannot be 
said for the D+/R+ group and our local approach to these patients is now universal prophylaxis. 
 
6.2.4 Mechanism of kidney transplant damage by CMV 
 
Cytomegalovirus infection produces a profound immune system with resultant generation 
and clonal expansion of CMV-specific T cells. In 2003, a cross sectional study published by 
Pawlik [1] demonstrated higher frequencies of CD4+CD28null cells in patients with chronic 
kidney allograft dysfunction. In 2004, Van Leeuwen [2] reported emergence of CD4+CD28null 
cells following primary CMV disease in four kidney transplant patients. These cells 
proliferated to CMV antigens in the four patients studied. These rare and unusual subset of T 
helper cells release cytolytic molecules perforin and Granzyme B and behave like NK cells as 
they express NK cell receptors [3].  The suggestion has arisen that these cells may target and 
damage endothelium in auto-inflammatory diseases. In fact, the few studies reporting 
endothelial damage in autoimmune disease have generally demonstrated T-cell activation in 
the presence of endothelium – usually HUVEC – rather than damage to endothelium by these 
cells [4]. 
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In chapter 3, we confirm CD4+CD27-CD28null cells are atypical and bear markers of potential 
cytotoxicity including perforin and NKG2D. These cells are pathognomonic of prior CMV 
exposure. But the rest of our findings are novel to kidney transplantation. The CD4+CD27-
CD28null cells proliferate in vitro to CMV antigens. We found no evidence that these cells 
mediate an allo-immune response (no in vitro proliferation to HLA antigens). We have 
demonstrated a role for these cells in glomerular endothelial cell damage, an effect which 
may be mediated by NKG2D. We have shown higher CD4+CD27-CD28null cell counts at 12 
months post-transplantation predict a steeper decline in kidney allograft function thereafter. 
This has important implications for the role of CMV in kidney transplantation and strategies 
to ameliorate its damaging effect. 
 
6.2.5 Role of CMV in immunosenescence and transplant outcome 
 
Primary CMV infection produces a profound CD8+ T-cell immune response. These CMV-
specific CD8+ T cells lose expression of the co-stimulatory molecule CD28 (CD8+CD28null). CMV 
establishes lifelong latency following primary infection. Aging and the immunocompromised 
state give rise to low level, repetitive viral re-activation of the latent CMV, with resultant 
clonal expansion of terminally differentiated CD8+CD28null cells. A role for CMV in 
immunosenescence is suggested by the Swedish studies of healthy elderly donors. 
CD8+CD28null phenotype and CMV seropositive status form part of the immune-risk profile 
(IRP) for immunosenescence [5, 6]. This has been shown to be associated with increased risk 
of infection, mortality, and reduced vaccine response in octo- and nonagenarians (the 
Swedish OCTO/NONA immune study) [7, 8]. Recently, this IRP has been demonstrated in 
hexagenerians in the Swedish HEXA immune study [9]. In 2014, Yap reported a 2-fold higher 
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risk (p=0.06) of long-term kidney allograft dysfunction in patients who had increased levels of 
CD8+CD28null cells [10]. It has been argued that CMV contributes materially to 
immunosenescence [11] but there are no studies addressing the potential role of CMV in 
driving immunosenescence. 
  
In chapter 4, we describe the immune-risk profile of the kidney transplant recipients in our 
study. We confirm the importance of circulating CD8+CD28null cell frequencies as an 
informative marker of immunosenescence. The temporal relationship between CMV 
serostatus, primary infection, CMV re-activation and CD8+CD28null cell frequencies provides 
novel insight into the ‘indirect’ effect of CMV in the pathogenesis of CD8+CD28null cells. We 
report a temporal association between elevated CD8+CD28null cell frequencies and 
subsequent development of clinically relevant episodes of infection. Our work suggests CMV 
drives immunosenescence, and that immunosenescence increases risk of infections.  In the 
setting of kidney transplantation, his is the first study to explore mechanism for the increased 
risk of infection by means of in-vitro neutrophil function assays.  
 
6.2.6 CMV infection, B cells and kidney transplant outcomes 
 
In our study, we did not find an association between B-cell numbers and CMV. However, 
retrospective, cross-sectional studies report a protective role for a B-cell subset in kidney 
transplantation [12, 13]. This transitional (regulatory) B-cell subset is defined by the 
phenotype CD19+CD24hiCD38hi. These studies focused on antibody-mediated rejection and 
were conducted as case control studies many years after transplantation. The novelty of our 
study is the ability to track the evolution of these transitional B cells post transplantation and 
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evaluate the temporal relationship between cell counts, rejection, and graft function from 
the time of transplantation. The main findings of the study are summarised below.  
 
6.2.6.1 Transitional B-cell numbers fall following transplantation 
 
A significant fall in transitional B-cell numbers was evident during the first three months 
following transplantation. Although cell numbers subsequently rose, these in general 
represented a fall from the baseline levels. 
 
Our findings are supported by two prospective studies published by Kamburova [14] and 
Svachova [15]. Kamburova reports a decrease in the percentage of transitional B cells in 
fourteen kidney transplant patients receiving standard triple maintenance 
immunosuppression (steroids, tacrolimus, mycophenolate mofetil) [14].  This study did not 
look at clinical transplant outcomes (rejection or graft function).  In a recent study involving 
98 kidney transplant patients, Svachova [15] reports a significant reduction in transitional B-
cell numbers up until the third post-transplant month, with partial repopulation in the first 
year. 
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6.2.6.2 Increased transitional B-cell numbers protect against onset of biopsy-
proven acute rejection (BPAR) 
 
Both univariate and multivariate regression analysis revealed a significant association 
between transitional B-cell frequency and the subsequent development of BPAR, with 
increased transitional B cells protecting against the onset of BPAR. 
 
This is supported by the findings from Svachova’s study [15] where lower numbers of 
transitional B cells at three months post-transplantation were associated with higher risk of 
graft rejection. 
 
6.2.6.3 Pre-transplant transitional B-cell numbers associated with rejection risk 
 
A novel finding from our study is the significant association between pre-transplant 
transitional B-cell numbers and subsequent risk of biopsy-proven acute rejection, with lower 
numbers associated with increased risk of rejection. This is contrary to Svachova’s study in 
which pre-transplant transitional B-cell numbers were not predictive of kidney transplant 
rejection [15]. However, larger prospective studies are required to further clarify the role of 
these cells as biomarkers of rejection risk in clinical transplantation. 
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6.2.6.4 Rejection-free survival optimum in patients with >3% transitional B cells 
 
Our study is the first to use Kaplan-Meier rejection-free survival estimates to quantify risk of 
kidney transplant rejection in relation to specific transitional B-cell frequencies. We have 
shown patients with <1% transitional B cells have the worst rejection free survival and those 
with >3% have the best outcome. This is now supported by findings from Svachova’s study 
[15].  
6.2.6.5 Preserved transitional B cells associated with protection from rejection in 
patients with de-novo Donor Specific Antibody (dnDSA) 
 
This is the first study to look at the association between transitional B-cell frequencies, de-
novo Donor Specific Antibodies and subsequent rejection. Our study suggests preserved 
transitional B-cell frequency is also associated with protection from rejection even in patients 
with dnDSA. This suggests that peripheral regulation may reduce the risk of rejection in 
patients with circulating HLA antibodies. 
 
6.3 Limitations of the study 
 
The studies described in Chapters 2 to 5 were observational in nature and represent single-
centre experience. Nonetheless, associations have been established and supported by 
statistically significant p-values. Although type I statistical errors may exist, the probability 
remains low. Due to the small study size, absences of associations between certain variables 
give rise to the probability of type II statistical error.  
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As freshly-isolated PBMCs were used for a significant proportion of the laboratory work 
undertaken, we are not able to reproduce assay results using the same cell material.   
Future studies with larger cohorts are necessary to validate the conclusions. 
 
6.4 Scope for future work 
 
The studies presented in this thesis add to the current knowledge of T-cell immunity against 
CMV in controlling viral latency and susceptibility to CMV disease. Oxford Immunotec have 
recently developed a T-SPOT.CMV test for measuring T-cell mediated CMV response with 
ELISPOT technology. A clinical trial is necessary to evaluate its therapeutic role in solid organ 
transplantation. Larger studies are necessary to further evaluate CMV cell mediated immunity 
in D+/R+ transplantation. A randomised controlled trial to evaluate the impact of CMV 
prophylaxis on the development and evolution of CMV cell mediated immunity and transplant 
outcomes will take forward the preliminary findings of our small observational study.  
 
6.5 Conclusions 
 
The studies presented in this thesis provide novel insight into the differential risk of CMV 
infection, mechanism of viral infection and subsequent allograft damage following kidney 
transplantation.  The role of CMV in driving immunosenescence with subsequent increases in 
infection is explored. Prognostic utility of cellular immune assays is examined in respect to 
predicting post-transplant CMV infection. The findings from this thesis set the scene for future 
interventional research and therapeutic strategies. 
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7.1 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) 
 
1) Blood samples should be fresh (no more than 6 hours old) with anticoagulant.  
2) Dilute blood 6 in 1 with RPMI1640 and add 10units of sodium heparin per ml of   undiluted 
blood.  
3) Add 15ml of Ficoll-Paque per Accuspin tube and bring to below frit by centrifuging at 1000 
x g for 30 seconds.  
4) Pour in diluted blood (do not exceed 43ml per tube).  
5) Centrifuge for 15min at 1000g. 
6) Carefully remove tubes, as tops can work loose.  
7) Aspirate plasma carefully to within 2cm of PMBCs. 
8) Using a filtered tip carefully transfer PMBC layer to a fresh sterile universal.  
9) Fill tube to 30ml with RPMI1640 and spin at 800 x g for 10min.  
10) Aspirate supernatant and resuspend pellet as above.  
11) Wash pellet twice with RPMI1640.  
12) On final wash resuspend cells in RPMI1640 supplemented with 5% human AB serum.  
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7.2 Protocol Heat Inactivation of AB  
 
1)   Thaw serum rapidly in a water bath at 370C and check all proteins are dissolved by 
shaking when defrosted. 
2) Heat a circulating water bath to 56 0C.  
3) Place the thawed serum bottles in the water bath so that each bottle is completely 
immersed up to the level of the serum. Do not immerse the cap. 
4) Monitor the temperature in the water bath. When the temperature of the water 
bath returns to 56 0C, start timing the process for 30 minutes. Agitate the bottles 
approximately every 5 minutes during the heat inactivation process to prevent 
gelling of the serum proteins and to promote more uniform heating of the serum. 
5) After 30 minutes of heat inactivation at 56 0C, remove the serum bottles from the 
water bath and rapidly cool them in an ice bath. Prolonged treatment of the serum 
at elevated temperatures will cause deterioration of serum components critical for 
growth of cells. 
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7.3 Enzyme-Linked Immunosorbent Spot Assay (ELISPOT).  
7.3.1 Point of Emphasis 
 
o After initial washing of ELISPOT plates (x4 with PBS) do not allow membranes to dry 
out.  
o When developing, wash plates thoroughly with PBS before adding antibody or 
substrate.  
o AB serum should be heat inactivated. Use Heat Inactivation Protocol, Appendix 7.2. 
 
7.3.2 Methods 
 
1)  Prewash plate with x4 washes of PBS. 
2)  Block for at least 30min and no more than 5h with 10% human AB serum.  
3)  Isolate PBMCs using protocol outlined in Appendix 7.1. 
4)  Using haemocytometer determine cell number and adjust to 8 x 106 cells per ml 
     (do not use cells below 6 x 106 cells per ml)  
5)  Add 50µl of cell suspension per well to give 4 x105 cells per well. 
     (NB prewash plate with PBS and block as describe below).  
6) Add 50µl of peptide/antigen stock as described in Appendix 7.4. 
    Incubate cells in a humid atmosphere of 5% CO2 for 48h.  
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7.3.3 Developing ELISPOT Plate  
 
1. Wash plates thoroughly x5 with PBS.  
2. Dilute alkaline phosphatase-conjugated detection mAb 1:200 in filtered (using 0.45µm 
filter) PBS containing 0.5% FCS.  
3. Add 100µl of antibody per well and leave for 2h at room temp.  
4.  Wash plate again x5 with PBS.  
5.  Filter BCIIP/NBT-plus with a 0.45µm filter. 
6. Add 100µl of substrate per well and leave spots to develop (max time 15 min to reduce 
background).  
7. Wash thoroughly x5 in tap water.  
8. Remove underdrain and wash again.  
9. Leave plate to dry in dark for at least 12h.  
 
7.2.2.3 Reading Plates 
 
Read plates using ELISPOT reader on 3 floors of Cancer Studies Building.  
1. Calibrate stage (either recalibrate or use previous settings).  
2. Read plate.  
3. Reset background if necessary.  
4. Check well for debris/false counts.  
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7.4 Dissolving and Diluting Antigens and Peptides for ELIPOT Assay 
7.4.1 Points of Emphasis 
 
o Stock peptides should be stored at -200C in glass vials and repeat freeze thawing 
kept to a minimum.  
o Peptide aliquots can be frozen at 1mg/ml in microfuge tubes for up to six weeks.  
o Once peptides are diluted with complete media they can be kept at 40C for a week. 
Do not Freeze.  
o PPD and antiCD3 both stock solution and dilutions in complete media should be kept 
at 40C.  
 
7.4.2 Method  
 
1) Peptides should be dissolved initial in 1ml of 0. 1mM HCL (conc HCl 16M (1ml to 16ml gives 
1M solution, 100µl to 9.9µl 10-2M and   another 100µl to 9.9µl gives 10-4M or 0.1mM.) 
 
2) Add RPMI1640 supplemented with 1% Pen/Streps 1% glutamine, no serum. These are stock 
solutions that should be stored in glass vials at -200C. Avoid excessive freeze thawing. Peptides 
at 1mg/ml can be aliquoted into 1.5ml microfuge tubes and frozen for up to 6 weeks.  
 
3) Peptide mixes  
Once diluted peptides should be discarded after 1 week. Store at 40C.  
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4) PPD (1mg/ml stock) 50µl to 2450µl complete medium to give final 20µg/ml, and 1µl of 
antiCD3 mab (1mg/ml) to 999µl complete medium per ml, to give 1ng/ml. Make up fresh 
every week from stocks. Store both stocks and dilutions at 40C.  
 
7.5 Protocol for antigen stimulation and intracellular cytokine staining to 
enumerate CMV-reactive T cells 
 
• Isolate PBMCs using Ficoll paque density gradient, washed x2 in RPMI-1640 medium, 
resuspended in RPMI-1640/10% FCS 
• Add 2x105 cells per tube (10 tubes) 
• Unstim, CMV lysate (10µl), mix 1 (30µl), mix 2 (30µl), mix 3 (30µl), SEB (10µl) 
• Make up Unstim, Compensation and SEB tubes to 500µl with media 
• Incubate for 1 hour 
• Make up remaining tubes to 500µl with media 
• Add 0.5ul of BFA to each tube (not compensation) and incubate overnight  
 
Day 2 
• Add MACS buffer (1%PBS, 0.05%BSA, EDTA) and centrifuge (2000rpm, 5 minutes) 
• Pour off supernatant and resuspend cells 
• Surface stain 2.5µl of Ab mix per tube (CD4-PE Texas Red 0.5µl, CD8-PE Cy5 2µl of 1/5 
dilution) 
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• Compensation tubes-2µl CD27-FITC, 0.5µl CD4-PE Texas Red, 2µl of 1/5 dilution CD8-
PE Cy5 
• Incubate 30 minutes in fridge 
• Wash 
• Add 100µl of 4% PFA to each tube, incubate 15 minutes in the dark at room temp 
• Wash 
• Add 100µl of 0.5% saponin to each tube, incubate 5 minutes in the dark at room 
temp 
• Add 4µl IFNg-FITC per tube, incubate 30 minutes in the dark at room temp 
• Wash 
 
 Intracellular Cytokine Stimulation and Staining 
 
Day 1 
• Add 2x105 cells per tube (I have cells at 2x106/ml and add 100µl cells per tube). 
• Unstim, CMV lysate (10µl LyS), mix 1 (IE1 30µl), mix 2 (pp65 30µl), mix 3 (30µl), SEB 
(10µl). 
• Make up Unstim and SEB tube to 500µl with media (RPMI, 10% FCS, 1% P/S, 1% 
Glutamine). 
• Incubate for 1 hour. 
• Make up CMV lysate stimulated, peptide stimulate tubes, etc. to 500µl with media. 
• Add 0.5µl of undiluted BfA to each tube and incubate overnight (do not add to Comp 
tubes). 
• Retain 500µl (1x106 cells) for Comp tube (100µl cells and 400µl media). 
 
 
221 
 
Day 2 
• Prepare Comp tubes (Unstain, FITC, PE, and TC). Do not add antibody to these mixes. 
• Add 4µl MACS buffer and centrifuge (2000rpm, 5 minutes). 
• Pour off supernatant and resuspend cells. 
• Surface stain 4µl of Ab mix per tube (CD4-PE 2µl, and CD8-TC 2µl of 1/5 PBS dilution). 
Add to Unstimulated tubes too. 
• Compensation tubes – 2µl CD27-FITC, 2µl CD4-PE 1:5, and 2µl of 1/5 dilution PBS 
CD8-TC. Do not add to Unstained tube. 
• Incubate 30 minutes in the fridge. 
• Wash with 4ml MACS buffer and resuspend. Spin 2000rpm for 5 minutes. 
• Add 100µl of 4% PFA to each tube including Comp tubes. 
• Vortex and incubate 15 minutes at room temp in the dark. 
• Wash with MACS buffer. Spin 5 minutes at 2000rpm. Por out buffer, resuspend. 
• Add 100µl of 0.5% saponin to each tube including Comp tubes (4% stock diluted to 
0.5% in MACS buffer at room temperature).  
• Mix gently (DO NOT VORTEX) and incubate 5 minutes in the dark at room 
temperature. 
• Add 4µl IFNy-FITC per tube (do not add to Comp tubes). 
• Incubate 30 minutes at room temperature in dark. 
• Wash with 4ml MACS buffer, spin and pour supernatant off. 
• Put in fridge and run samples. 
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7.6 Protocol for HLA: peptide tetramer complexes and staining for flow cytometry 
 
• 2x105 PBMCs incubated with VLE and NLV tetramer at 370C for 30 minutes. 
• Wash cells with PBS containing 2% FCS. 
• Incubate cells with monoclonal antibodies for 30 minutes on ice. 
• Wash cells and fix in PBS containing 2% PFA and 2% FCS. 
 
 Tetramer Staining 
 
• Count cells, need 1x106 per 100µl per tube (50µl per plate). Can use 1-2x105 for 
Comp tubes. 
• Mix 1ml cells with 10mls PBS. 
• Spin at 2000rpm for 5 minutes, pour off supernatant and resuspend. 
• Add 1µl of tetramers to tubes then vortex and incubate at 370C for 15 minutes.  
• Was with MACS buffer. 
• Make up master mixes for tetramers and phenotyping (combined). 
• Add master mixes and antibodies to tubes including Comp tubes. 
• Incubate 20-40 minutes at 40C. 
• Wash with MACS buffer and read on LSR. 
• Use following antibodies for phenotyping: CD4 PerCp-Cy5, CD8 AmCyan, CD3 pacific 
blue, CD57 FITC, CD127 PE, CD45RO ECD (Texas red), CD28 PE-Cy7, CD45RA AF700, 
CD27 APC-Cy7, tetramer APC.   
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7.7 Cell sorting and 5,6-carboxyfluorescein succinimidylester (CFSE) proliferation assays 
 
1. Isolate PBMCs and count.  
2. Divide into a. Cells to be irradiated 1 x 105 per well  
                    b. Compensations tube well for after proliferation 1 x 105 (x10 wells)  
                    c. Cells to be sorted – remaining cells.  
 
a. Cells to be Irradiated   
 
1. Add 4 x 105 cells in Facs tube and antigen pulse.  
                          X2 tubes containing complete media  
                          CMV lysate (as for lysate assay)   
                          PPD and/or HLA peptide mix (as for ELISPOT assay). 
2. Antigen pulse for x3 hours.  
3. Irradiate cells with 10 grays.  
4. Add cells to wells at concentration of 1 x 105  
 
b. Compensation Tubes  
 
1. Add 1 x 105 cells to x 10 well and stimulate with antigen (i.e. PPD or CMV lysate).  
 
c. Cells to be sorted  
 
1. Count remaining cells and resuspend at 2 x 107 cells per ml.  
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2. Add 100µl of stain per 106 cells  
                CD4 PerCP Cy5.5                   5µl 
                CD28 PE-Cy7                          7µl 
                CD8 APC                                 5µl 
                CD27 APC-Cy7                       4µl 
                                                                21      add 79µl MACs Buffer  
3. Sort CD4 positive CD27 negative, CD28 positive, CD28 negative  
 
CD8 positive CD27 negative CD28 positive, CD28 negative 
4. Spin at 800g for 10 minutes and resuspend at 1 x 105 cells per 200µl in PBS.  
5. Dilute CFSE 1µl to 999µl in PBS and add 1µl per 200µl of cells.  
6. Incubate at 370C for 10min.  
7. Quench reaction with 4ml complete media for 5min on ice.  
8. Spin at 800g for 10 minutes. 
9. Resuspend cells in 100µl of media at 40 000 to 100 000 cells per ml.  
 
 
Incubate all for x 5 days and stain.  
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Staining Cells  
 
1. Remove 100µl of supernatant, spin at 800xg for 10 min, then freeze at -800C 
for Luminex assay.  
2. Resuspend cells using pipette and transfer to Facs tube.  
3. Top up to 4ml with MACs buffer spin at 1000g for 5min.  
4. Resuspend cells in 100µl of MACs buffer add stain:  
 
Compensation tubes: 
 
FITC CD4                                                                            12.5µl 
PE CD2                                                                                2.0µl   
Texas Red CD4                                                                  5.0µl               
                          PE-PerCP Cy5.5 CD4                                                         5.0µl       
PE-Cy7 CD28                                                                     7.0µl 
eFluoro®450 CD45RA                                                       4.0µl 
Pacific Orange CD3                                                           6.0µl 
APC CD8                                                                             5.0µl 
APC-Cy7                                                                              4.0µl 
 
Experimental Wells  
 
PE CD2                                                                               2.0µl   
PE-PerCCy5.5CD4                                                             5.0µl       
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PE-Cy7 CD28                                                                       7.0µl 
eFluoro®450 CD45RA                                                         4.0µl 
Pacific Orange CD3                                                             6.0µl 
APC CD8                                                                               5.0µl 
APC-Cy7                                                                               4.0µl 
                                                                                              33µl vs 67µl 
5. Incubate at 40C for 30 minutes.  
6. Top up tube with MACs buffer and spin at 1000g for 5 min.  
7. Aspirate and repeat step 6  
8. Resuspend in 500µl of MACs buffer.  
9. Analyze on Cyan.  
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7.8 Purifying CD4+CD27-CD28+ or CD28null Cells using MACs Columns  
7.8.1 MACs Buffer  
 
100ml x10 PBS, 4ml 0.5M EDTA solution, make up to 1litre and add 5g BSA  
Filter steriliser before use.  
Do not put more than 2 x 108 cells on columns  
 
7.8.2 Isolation of CD4+ Cells  
 
1. Isolate PBMCs wash with MACs buffer and count.  
2. Remove supernatant and resuspend in 40µl of MACs buffer per 1 x 107 cells.  
3. Add 10µl of Biotin Antibody Cocktail per 1 x 107 cells. 
4. Mix well and incubate for 5 min at 4-80C.  
5. Add 30µl MACs buffer per 1 x 107 cells. 
6. Add 20µl of Anti-Biotin Microbeads per 107 cells.  
7. Mix well and incubate for an additional 10 min at 4-80C. 
8. Wash with MACs buffer, completely remove supernatant and resuspend up to 1 x 
108 per 500µl. 
9. Place MACs column on magnetic field and rinse with 3ml of MACs buffer.  
10.  Add cells to column and wash through with 3x3ml MACs buffer.  
 
 
 
 
 
 
228 
 
7.8.3 Isolation of CD4+CD27- Cells  
 
1. Wash cells with MACs buffer and resuspend in 80µl of MACs buffer per 1 x 107 cells.  
2. Add 20µl of CD27 microbeads per 1 x 107 cells.  
3. Mix well and incubate for 15 min at 4-80C. 
4. Wash with MACs buffer and remove supernatant.  
5. Resuspend at 1 x 108 cells per 500µl. 
6. Place MACs column on magnetic field and rinse with 3ml of MACs buffer.  
7.  Add cells to column and wash through with 3x3ml MACs buffer.  
NB. It is the cells passing through the column that need to be collected.  
 
7.8.4 Isolation of CD4+CD27- CD28+ or CD28null Cells  
 
1. Wash cells with MACs buffer and resuspend at 1 x 107 cells per 40µl.  
2. Add 10µl of CD28-PE per 1 x 107 cells. 
3. Mix well and incubate for an additional 15 min at 4-80C. 
4. Wash cells with MACs buffer and remove supernatant. 
5. 80µl of MACs buffer per 1 x 107 cells. 
6. Add 20µl of AntiPE  Microbeads per 1 x 107 cells.  
7. Mix well and incubate for an additional 15 min at 4-80C. 
8. Wash cells with MACs buffer and remove supernatant 
9. Resuspend up to 1 x 108 cells in 500µl of MACs buffer.  
10. Place MACs column on magnetic field and rinse with 3ml of MACs buffer.  
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11.  Add cells to column and wash through with 3x3ml MACs buffer.  
NB. These are the CD4+CD27-CD28null cells.  
12. For CD27+ cells remove from magnet and wash through with 5ml MACs buffer. 
 To further purify the CD28+ cells repeat 9 to 12 with a fresh column. NB. Any cells washed 
through the column will be CD4+CD27-CD28null cells. 
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7.9 Protocol for stimulating CD4+CD28null and CD4+CD28+ cells with CMV peptide, 
HLA peptide 
 
CMV Lysate x2    
Tra34 x2 
Media x2 
Irradiated Cells x2 
PPD x2  
Compensation tubes x5 unstained   
                                     CD4-FITC   2 x105 cells in x5 wells and stimulate with PPD  
                                     CD4-PECP5.5 
                                     CD28-PECy7 
                                     CD27-APC-Cy7    100µl to 100µl 1 x 106 cells  
Irradiated Cells  
X6 tubes of 3 x 105 cells   1.8 x 106 cells  
 
Staining Cells  
Take out 1.8 x 106 cells for irradiating and 2 x 106 cells for compensation tubes  
 2 x 10 5 cells per tube: 8 x 105 
                                     Unstained  
                                     CD4-PECP5.5    0.5 
                                     CD28-PECy7      1µl 
                                     CD27-APC-Cy7    2µl 
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Stains to be added per 1 x 106 cells:  
                                     CD4-PECP5.5    1.3µl 
                                     CD28-PECy7      2.5µl 
                                     CD27-APC-Cy7    5µl 
Pulsing Cells with CFSE 
1. Wash cells and resuspend at 1x 105 cells per 200µl in PBS.  
2. Dilute CFSE 1µl to 1000 in PBS and add 1µl per 200µl of cell suspension.  
3. Incubate for 5min at 370C.  
4. Top up with 5% AB Serum Complete.  
5. Wash and resuspend at 3-5 x 104 cells per 100µl in Complete media.  
6. Add irradiated antigen pulsed cells and incubate.  
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Irradiated cells:  
1. 1.8 x 106 cells divide into x5 tubes  
2. Stimulate with CMV lysate in Complete  
                        Tra34 in Complete  
                        -ve Control (media) in Complete  
                        Irradiated cells (media) Complete  
3. In 1ml for x3 hours  
4. Irradiate at 50 grays  
5. Spin and resuspend in 100µl of Complete media and add to test wells.  
 
Compensation wells:  
1. 1 x 106 cells, resuspend and add to CMV lysate at 2 x 105 cells per 100µl  
2. Seed x5 well as per sheet.  
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7.10 Culturing Immortalised Glomerular Endothelial Cells (iGECs)  
 
1. Seed 24 well plates at 6 x 104 cells per ml (or well).   
2. Incubate for 72h until confluent at 330C. 
3. Replace media and incubate at 370C for 24h to differentiate.  
 
Purifying T cells  
 
1. Isolate PBMCs and incubate in 6 well multi-dishes at 2 x 107 cells per well.  
Do x3 wells control, x3 wells with HLA, x4 wells CMV (current lysate add 10µl per 
well).   
2. Incubate overnight.  
3. Aspirate cells and supplement sup wells with supernatant at 10% (i.e. 150µl) 
 
Isolation of CD4+ Cells  
 
1. Wash isolated cells in MACs buffer.  
2. Remove supernatant and resuspend in 40µl of MACs buffer per 1 x 107 cells.  
3. Add 10µl of Biotin Antibody Cocktail per 1 x 107 cells. 
4. Mix well and incubate for 5 min at 4-80C.  
5. Add 30µl MACs buffer per 1 x 107 cells. 
6. Add 20µl of Anti-Biotin Microbeads per 107 cells.  
7. Mix well and incubate for an additional 10 min at 4-80C. 
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8. Wash with MACs buffer, completely remove supernatant and resuspend up 
to 1 x 108 per 500µl. 
9. Place MACs column on magnetic field and rinse with 3ml of MACs buffer.  
10.  Add cells to column and wash through with 3x3ml MACs buffer.  
 
Isolation of CD4+CD27- Cells  
 
1. Wash cells with MACs buffer and resuspend in 80µl of MACs buffer per 1 x 107 
cells.  
2. Add 20µl of CD27 microbeads per 1 x 107 cells.  
3. Mix well and incubate for 15 min at 4-80C. 
4. Wash with MACs buffer and remove supernatant.  
5. Resuspend at 1 x 108 cells per 500µl. 
6. Place MACs column on magnetic field and rinse with 3ml of MACs buffer.  
7. Add cells to column and wash through with 3x3ml MACs buffer.  
NB. It is the cells passing through the column that need to be collected.  
 
Isolation of CD4+CD27- CD28+ or CD28null Cells  
 
1. Wash cells with MACs buffer and resuspend at 1 x 107 cells per 40µl.  
2. Add 10µl of CD28-PE per 1 x 107 cells. 
3. Mix well and incubate for an additional 10 min at 4-80C. 
4. Wash cells with MACs buffer and remove supernatant. 
5. 80µl of MACs buffer per 1 x 107 cells. 
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6. Add 20µl of AntiPE  Microbeads per 1 x 107 cells.  
7. Mix well and incubate for an additional 15 min at 4-80C. 
8. Wash cells with MACs buffer and remove supernatant 
9. Resuspend up to 1 x 108 cells in 500µl of MACs buffer.  
10. Place MACs column on magnetic field and rinse with 3ml of MACs buffer.  
11.  Add cells to column and wash through with 3x3ml MACs buffer.  
NB. These are the CD4+CD27-CD28null cells.  
12. For CD27+ cells remove from magnet and wash through with 5ml MACs 
buffer. 
  
To further purify the CD28+ cells repeat 9 to 12 with a fresh column.  
NB. Any cells washed through the column will be CD4+CD27-CD28null cells. 
 
24 well plates:  
 
Add same number of T cells to well each well in 500µl of GEC media.  
Add 2µl of TNF stock to give 2ng/ml to one well  
Add 4µl of PR3 stock to give 2µg/ml.  
Add 2µl of camptothecin to give 2µm. 
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Cells Counts   
  
Control  
 
HLA  
 
CMV  
 
PBMCs  
 
 
  
CD4 
 
 
  
CD4CD27neg  
 
 
  
CD4CD27negCD28null  
 
 
  
CD4CD27negCD28pos 
 
 
  
 
 
cells with inserts  
 
Leave cells for 4h and 12h.  
 
Supernatants  
 
1. Remove media from insert and spin, split into x3 150µl.  
2. Resuspend cell pellet in 100µl of PBS and count.  
3. Remove supernatant from bottom layer and other wells, replacing with 1ml PBS.  
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4. Spin media and freeze x3 300µl aliquots (NB make sure label bottom layer).  
 
DAPI Staining 
 
1. Wash cells three times with PBS (1ml per well).  
2. Replace with 1ml ethanol and leave for 10 minutes.  
3. Allow to air dry.  
4. Add 100µl of 1µg/ml DAPI per well (dilute 1µl to 5000µl).  
5. Stain for 2 minutes.  
6. Wash x3 with PBS.  
7. Add 500µl of PBS and view under fluorescence microscope.  
                              
Caspase Staining  
 
1. Save supernatants as describe above.  
2. Wash twice with ice-cold MACs buffer.   
3. Trypsinise Cells with 100µl of Trypsin.  
4. Stop reaction with MACs Buffer. 
5. Spin at 1000xg for 5 min  
6. Resuspend in residual volume and add 100µl of surface antibodies 5µl of CD31 and 
4µl of CD4.  
7. Incubate in dark for 10 min at room temperature  
8. Wash with MACs buffer.  
 
 
238 
 
9. Add 50μL of Reagent A (Fixation Medium) and incubate for 15 minutes in the dark at 
room temperature. 
10. Wash once with 3mL of MACs buffer  
11. Centrifuge for 5 minutes at 800x g, aspirate supernatant, resuspend the cell pellet. 
12. Add 50μL of Reagent B (Permeabilization Medium), add 10µl of Caspase -3 stain or 
2.5µl of Isotype Control incubate for 20 minutes in the dark at 40C.  
13. Wash once with 3mL MACs buffer.  
14.  Centrifuge for 5 minutes at 800 x g and aspirate the supernatant. 
15.  Resuspend in 250µl MACs buffer.  
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7.11 Fractalkine  
 
1. Dilute capture antibody to 4.0µl per ml.  
Dilute 1µl to 179µl  
1 plate 100µl to 17900µl (17.9ml) 
2. Incubate 100µl per well overnight at 40C. 
3. Wash with 3 x 400µl PBS-Tween  
4. Block plate for 1h with 1% BSA  
5. Wash x3 with PBS-Tween  
6. Standards: 20ng/ml stock dilute 250µl to 250µl in 1% BSA  
10, 5, 2.5,1.25, 0.6 and 0.3ng/ml  
Add 100µl of supernatant and incubate at room temperature for 2 hour  
7. Wash x3 PBS Tween  
8. Dilute detection antibody 1: 179 i.e. 50µl to 8,950µl  
                                         To do x1 full plate dilute 100µl to 17.9ml  
9. Incubate for 2h at room temperature.  
10. Wash x 3 with PBS-Tween.  
11.  Dilute HRP dilute 1: 100 (100µl to 10ml)  
12. Incubate x20 minutes.  
13. Wash x3 PBS  
14. Develop as for vWF. 
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7.12 vWF ELISA  
 
Solutions 
 
Carbonate Buffer Na2CO3 0.4g (19mM final concentration) 
                              NaHCO3 0.74g (28mM final concentration) add 250ml 
PBS tween -1 litre PBs to 1ml of Tween20 
NB use charged flat bottomed plates.  
 
Method  
 
1. Dilute polyclonal Rb anti-human vWF (DAKO A0082) 1:500 in carbonate buffer. Add 
100µl to each well (samples in doublet + column 1 and 2 for standards) of a 
medium/high bind ELISA plate. 
2. Cover (or use humid box) and incubate overnight in the fridge/cold room 
(day2) 
 
3. Wash 3x in PBS+0.05%tween20 
 
4.  Block plate with 5% BSA for minimum of 1h (can leave as long as you like) 
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5.    Make up standards – stock 100IU/dL. Use a top dilution of 1.25IU/dL in PBS and serial 
dilute down columns 1 and 2. Leave row H (bottom row) with just PBS and no standard to act 
as a blank (see example layout below).   
NB Use supernatant samples neat (non-diluted) – NB serum and plasma will need to be 
diluted should you ever use these. 
6.    Wash plate in PBS-tween 
7.    Add samples and standards and incubate for 1 hour at room temperature 
8.    Wash in PBS-tween 
9.    Dilute secondary antibody, Rb anti-human vWF-HRP (DAKO P0226) 1:500 in PBS-tween 
and add 100µl per well. 
10.   Incubate at room temp for 1 hour. 
11.   Prepare OPD solution (1silver+1gold tablet in 20ml ddH2O) 
12.   Wash plate in PBS tween 
13.   Add 100µl of OPD to each well and read on kinetic plate reader at 0, 5, 10, 15, 20, 25, 30, 
45min and 1hour at 450nm. Use the reading at which the standard curve is at its most linear 
for all future experiments. 
 Using plate reader:  
Log on as normal  
Gen S Software  
Calculate samples using Prism (spread sheet set up).  
7.13 Modified Protocol for B Regs 
 
1. Coat wells with 50µl of 2µg/ml antiCD3 for 1h. (Add 2µl of 1mg/ml antiCD3 per 1ml 
media) 1ml will do 5 patients (20wells), incubate for 1h at 370C.  
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2. Add 150µl of PBMCs, gives 2.5 x105 cells per well, at least x8 per patient. (Gives a 
final [c] of antiCD3 of 0.5µg/ml).  
3. Incubate for 72h. 
4. Stimulate for last 6h with PMA (50ng/ml) and Ionomycin (500ng/ml).  
PMA 1mg/ml stock: add10µl to 490µl to give 500µg/ml stock.  
                                add 15µl to1485µl to give 5µg/ml  
                                add 2µl per well.  
Ionomycin 1mg/ml stock: add 10µl to 490µl to give 500µg/ml stock  
                                        add 150µl to 1350µl to give 50µg/ml  
                                        add 2µl per well  
BFA stock 1mg/ml add 100µl to 900µl of media and add 2µl per well. (Treat x2 
compensation wells to check staining).  
5. Add 6µl containing all 3 per well.  
6. Defrost x2 samples of transplantation PBMS and seed a 1 x107 cells per ml in Facs 
tubes. (Do isotype on x1 and use spare cells for comp tubes)  
7. Stimulate with PMA for 4h. Process as for 72h stimulate  
8. Transfer cells to Facs tubes: x2 tubes per patient, wash with ice cold PBS and adjust 
[c] to 1 x 107 cells per ml. (Any spare use as for Isotype control)  
9. Stain with live dead stain.  
10. Wash and resuspend in MACs buffer.  
11. Surface stain with  
Stain  [C] per 1 x 106 (µl) For 5 samples (µl) For 1 x 107 
CD24FITC  
2 10 20 
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CD19PE  
1 5 10 
CD38 PE-Cy7  
1 5 10 
Volume MACs  
96 1444 1960 
for 30 minutes at -200C.  
Compensation Tubes CD4 use 1 well per tubes (spare tubes for unstained) 
 
Stain  [C] per 2 x 105 cells (µl) 
CD4 FITC  
2 
CD3 PE  
2 
CD4 PE-Cy7 
2 
CD3 APC  
2 
  
Stains for Experiment 
Stain  [C] per 2 x 105 cells (µl) 
CD24 FITC  
1 
CD19PE 
1 
CD38PE-Cy7 
1 
IL-10 APC* 
(stain PMA treated wells)  
1 
 
      (Do x1 stimulated well with isotype control) 
12. Wash with MACs buffer  
13.  Add 50µl of Reagent A (Fixation Medium) and incubate for 15 min in dark.  
14.  Wash with MACs buffer (500µl 1 x 107 cells).  
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15.  Add 2µl of IL-10 stain to one tube and isotype control to one tube per patient in 
50µl of Reagent B (Permeabilization Media), leave for 30 min. (x dilute to 500µl stain 
x 250µl of stain 20µl  
16. Wash with MACs buffer. 
17. Resuspend in 200µl MACs buffer and read.                         
                                 
7.14 Chemotaxis Assay: Insall Chamber 
 
1. Isolate neutrophils using Percoll gradient. 
2. Suspend neutrophils at 2x106/ml in RPMI-1640, and add 0.15% by volume of 
7.5% Bovine Serum Albumin (Sigma) 
3. Sterilize coverslips: Wash 1x in 0.4M H2SO4, and 2x in deionized water. Place 
in covered filter paper lined petri dish. 
4. Remove one coverslip to a second petri dish. Pipette 400µl albumin onto 
coverslip surface and tilt coverslip to cover the whole surface in solution. Tip 
off excess albumin and leave to dry in a covered petri dish for ~30seconds. 
5. Pipette 400µl of neutrophil solution onto albumin-coated coverslip. Incubate 
for 30 minutes. 
6. Prepare chemotaxis chamber by washing 3x with 400µl RPMI-1640. After 
final wash, fill the wells with RPMI and leave. 
7. Lift coverslip out of petri dish and tip off excess neutrophil solution. Invert 
the slide onto the chemotaxis chamber leaving loading bays uncovered, as 
shown below:  
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8. Mop up excess RPMI with filter paper. Draw up remaining RPMI from 
chemoattractant wells using a 200µl pipette. 
9. Slowly fill chemoattractant well with 70µl of chemoattractant/RPMI, 
ensuring there are no bubbles. 
10. Analyze slide using microscope. Take one frame every 20 seconds for a total 
of 36 frames (12 minutes). 
Materials 
 
• 7.5% Bovine Serum Albumin: Sigma A8412 
• Coverslips: IBR Stores:  IBR-COVER1.  Micro Cover glass 22x22mm 
• Inverted forceps: Sigma Z168769 
• fMLP: Sigma F3506 
• IL8: R&D Systems 208-IL 
Microscope Booking: Technology Hub Leica DMI6000 Video Capture Microscope 
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7.15 Buffers, Media, Solutions and Reagents  
 
(Sigma- Aldrich, Dorset, UK)  
 
Tissue Culture Medium (Complete Medium)  
 
Roswell Park Memorial institute (RPMI) 1640 (Sigma, Poole, UK)           50ml  
L-glutamine (Sigma, Poole, UK)                                                               2mM  
Penicillin (Sigma, Poole, UK)                                                                     100IU/ml  
Streptomycin (Sigma, Poole, UK)                                                               100IU/ml  
Foetal calf serum (PAA labs, Somerset, UK)                                                  5% v/v  
Ficoll Plaque (Sigma- Aldrich, Dorset, UK) 
 
RPMI-1640 (Sigma, Poole, UK) 
 
Phosphate Buffered Saline (PBS)  
 
PBS tablet (Oxoid)                                                                                         1 tablet  
Sterile distilled water                                                                                     100ml    
Magnetic Activated Cell Sorting (MACs) Buffer  
 
Sterile PBS (pH 7.2)                                                                                      500ml   
Bovine Serum Albumin                                                                                  0.50% 
EDTA                                                                                                              2mM 
Lipopolysaccharide (LPS) (Sigma- Aldrich, Dorset, UK)                           100ng/ml 
Brefeldin A (eBioscience, ID 00-4506-51)                                                    1:1000 
 
